form10k.htm
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K
(Mark
One)
[X]
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For
the fiscal year ended December 31, 2008
OR
[ ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For
the transition period from ____________ to ___________
Commission
File Number 1-12031
UNIVERSAL DISPLAY
CORPORATION
(Exact
name of registrant as specified in its charter)
Pennsylvania
|
|
23-2372688
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification No.)
|
|
|
|
375
Phillips Boulevard, Ewing, New Jersey
|
|
08618
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area
code: (609)
671-0980
Securities
registered pursuant to Section 12(b) of the
Act:
Title of Each Class
|
|
Name of Each Exchange on Which
Registered
|
Common
Stock, $0.01 par value
|
|
The
NASDAQ Stock Market LLC
|
Securities
registered pursuant to Section 12(g) of the Act: None
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in
Rule 405 of the Securities Act. Yes
No X
Indicate
by check mark if the registrant is not required to file reports pursuant to
Section 13 or Section 15(d) of the Act. Yes
No X
Indicate
by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X
No
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the best
of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K.
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer
Accelerated
filer X
Non-accelerated
filer
(Do not check if a smaller reporting
company) Smaller
reporting company
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes
No X
The
aggregate market value of the voting and non-voting common equity held by
non-affiliates of the registrant computed by reference to the closing sale price
of the registrant’s common stock on the NASDAQ Global Market as of June 30,
2008, was $378,647,340. Solely for purposes of this calculation, all
executive officers and directors of the registrant and all beneficial owners of
more than 10% of the registrant’s common stock (and their affiliates) were
considered affiliates.
As of
March 9, 2009, the registrant had outstanding 36,308,821 shares of common
stock.
DOCUMENTS
INCORPORATED BY REFERENCE
Portions
of the registrant’s Proxy Statement for the 2009 Annual Meeting of Shareholders,
which is to be filed with the Securities and Exchange Commission no later than
April 30, 2009, are incorporated by reference into Part III of this
report.
TABLE
OF CONTENTS
PART
I
ITEM
1.
|
BUSINESS……………………………………………...…………………………………..............…...…..
|
2
|
ITEM
1A.
|
RISK
FACTORS…………………………...………………..…………...………………………………….
|
14
|
ITEM
1B.
|
UNRESOLVED
STAFF
COMMENTS…………...……..……………………………...……..…................
|
22
|
ITEM
2.
|
PROPERTIES
………………….………………………………………...…………………………………
|
22
|
ITEM
3.
|
LEGAL
PROCEEDINGS ….……………………………………………………..………………………...
|
23
|
ITEM
4.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY HOLDERS……………....………………...
|
23
|
PART
II
ITEM
5.
|
MARKET
FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
PURCHASES OF EQUITY SECURITIES…………………………………………………
|
25
|
ITEM
6.
|
SELECTED
FINANCIAL DATA ………...…………………………………………………………..........
|
28
|
ITEM
7.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS …………...……………………………………………………………………………..
|
28
|
ITEM
7A.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK…………………...
|
35
|
ITEM
8
|
FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA …........………………………………..
|
36
|
ITEM
9.
|
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE………………………………………………………………………..............
|
36
|
ITEM
9A.
|
CONTROLS
AND PROCEDURES ……………….……………………………………………………….
|
36
|
ITEM
9B
|
OTHER
INFORMATION……………….…………………………………………………………………..
|
36
|
PART
III
ITEM
10.
|
DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE………………………...
|
37
|
ITEM
11.
|
EXECUTIVE
COMPENSATION ………...………………………………………………………..............
|
37
|
ITEM
12.
|
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
……..………………………….................................................
|
37
|
ITEM
13.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
………………………………………………………………………………………….
|
37
|
ITEM
14.
|
PRINCIPAL
ACCOUNTING FEES AND SERVICES
………….……………….....................................
|
37
|
PART
IV
ITEM
15.
|
EXHIBITS,
FINANCIAL STATEMENT SCHEDULES
….................................................................
|
37
|
CAUTIONARY
STATEMENT
CONCERNING
FORWARD-LOOKING STATEMENTS
This
report and the documents incorporated by reference in this report contain some
“forward-looking statements.” Forward-looking statements concern possible or
assumed future events, results and business outcomes. These statements often
include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,”
“estimate,” “seek,” “will,” “may” or similar expressions. These statements are
based on assumptions that we have made in light of our experience in the
industry, as well as our perceptions of historical trends, current conditions,
expected future developments and other factors we believe are appropriate under
the circumstances.
As you
read and consider this report, you should not place undue reliance on any
forward-looking statements. You should understand that these statements involve
substantial risk and uncertainty and are not guarantees of future performance or
results. They depend on many factors that are discussed further under Item 1A
below (Risk Factors), including:
·
|
the
outcomes of our ongoing and future research and development activities,
and those of others, relating to organic light emitting diode (OLED)
technologies and materials;
|
·
|
our
ability to access future OLED technology developments of our academic and
commercial research partners;
|
·
|
the
potential commercial applications of and future demand for our OLED
technologies and materials, and of OLED products in
general;
|
·
|
our
ability to form and continue strategic relationships with manufacturers of
OLED products;
|
·
|
successful
commercialization of products incorporating our OLED technologies and
materials by OLED manufacturers, and their continued willingness to
utilize our OLED technologies and
materials;
|
·
|
the
comparative advantages and disadvantages of our OLED technologies and
materials versus competing technologies and materials currently on the
market;
|
·
|
the
nature and potential advantages of any competing technologies that may be
developed in the future;
|
·
|
our
ability to compete against third parties with resources greater than
ours;
|
·
|
our
ability to maintain and improve our competitive position following the
expiration of our fundamental OLED
patents;
|
·
|
the
adequacy of protections afforded to us by the patents that we own or
license and the cost to us of maintaining and enforcing those
patents;
|
·
|
our
ability to obtain, expand and maintain patent protection in the future,
and to protect our unpatentable intellectual
property;
|
·
|
our
exposure to and ability to withstand third-party claims and challenges to
our patents and other intellectual property
rights;
|
·
|
the
payments that we expect to receive under our existing contracts with OLED
manufacturers and the terms of contracts that we expect to enter into with
OLED manufacturers in the future;
|
·
|
our
future capital requirements and our ability to obtain additional financing
if and when needed;
|
·
|
our
future OLED technology licensing and OLED material revenues and results of
operations; and
|
·
|
general
economic and market conditions.
|
Changes
or developments in any of these areas could affect our financial results or
results of operations, and could cause actual results to differ materially from
those contemplated by any forward-looking statements.
All
forward-looking statements speak only as of the date of this report or the
documents incorporated by reference, as the case may be. We do not undertake any
duty to update any of these forward-looking statements to reflect events or
circumstances after the date of this report, or to reflect the occurrence of
unanticipated events.
PART
I
Our
Company
We are a
leader in the research, development and commercialization of organic light
emitting diode, or OLED, technologies and materials. OLEDs are thin, lightweight
and power-efficient solid-state devices that emit light, making them highly
suitable for use in full-color displays and as lighting products. We believe
that OLED displays have begun to capture a share of the growing flat panel
display market because they offer potential advantages over competing display
technologies with respect to brightness, power efficiency, viewing angle, video
response time and manufacturing cost. We also believe that OLED lighting
products have the potential to replace many existing light sources in the future
because of their high efficiency, excellent color rendering index, low heat
generation and novel form factors. Our technology leadership and intellectual
property position should enable us to share in the revenues from OLED displays
and lighting products as they enter mainstream consumer markets.
Our
primary business strategy is to further develop and license our proprietary OLED
technologies to manufacturers of products for display applications, such as cell
phones, MP3 players, laptop computers and televisions, and specialty and general
lighting products. In support of this objective, we also develop new OLED
materials and sell materials to those product manufacturers. Through our
internal research and development efforts and our relationships with world-class
partners such as Princeton University, the University of Southern California,
the University of Michigan, Motorola, Inc. and PPG Industries, Inc., we have
established a significant portfolio of proprietary OLED technologies and
materials. We currently own, exclusively license or have the sole right to
sublicense more than 940 patents issued and pending worldwide.
In 2008,
we continued selling our proprietary OLED materials to customers for evaluation
and use in commercial OLED products. A substantial portion of our
OLED material sales in 2008 were to Samsung SDI Co., Ltd. of South Korea, whose
OLED business was transferred to Samsung Mobile Display Co., Ltd. (Samsung SMD)
in September 2008. We also sold commercial OLED chemicals in 2008 to
Chi Mei EL Corporation of Taiwan and Tohoku Pioneer Corporation of Japan, and in
November 2008 we renewed our commercial supply agreement with LG Display Co.,
Ltd. of South Korea.
We
received royalties under our patent license agreement with Samsung SMD on
account of its sales of active matrix OLED display products throughout
2008. In August 2008, we entered into our first patent license
agreement for OLED lighting products with Konica Minolta Holdings, Inc. and its
subsidiary. We also entered into license and material supply
agreements with Kyocera Corporation in July 2008, although we are waiting for
Kyocera to notify us that these agreements are to become
effective. We continue to work with many other companies who are
evaluating our OLED technologies and materials for possible use in commercial
OLED display and lighting products, including Sony Corporation and Seiko Epson
Corporation.
Market
Overview
The
Flat Panel Display Market
Flat
panel displays are essential for a wide variety of portable consumer electronics
products, such as cell phones, MP3 players, digital cameras and laptop
computers. Due to their narrow profile and light weight, flat panel
displays have also become the display of choice for larger product applications,
such as desktop computer monitors and televisions.
Liquid
crystal displays, or LCDs, currently dominate the flat panel display
market. However, we believe that OLED displays are an attractive
alternative to LCDs because they offer a number of potential advantages,
including:
·
|
a
thinner profile and lighter weight;
|
·
|
higher
brightness and contrast ratios, leading to sharper picture images and
graphics;
|
·
|
faster
response times for video;
|
·
|
higher
operating efficiencies, thereby reducing energy consumption;
and
|
·
|
lower
cost manufacturing methods and
materials.
|
Based on
these characteristics, product manufacturers are starting to adopt small-area
OLED displays for use in portable electronic devices, such as cell phones and
MP3 players. These manufacturers are also working to develop OLED displays for
use in larger applications, such as computer monitors and
televisions. We believe that if these efforts are successful, they
could result in sizeable markets for OLED displays.
In
addition, due to the inherent transparency of organic materials and through the
use of transparent electrode technology, OLEDs eventually may enable the
production of transparent displays for use in products such as automotive
windshields and windows with embedded displays. Organic materials also make
technically possible the development of flexible displays for use in an entirely
new set of product applications, such as display devices that can be conformed
to certain shapes or even rolled up for storage.
Traditional
incandescent light bulbs are inefficient because they convert only about 5% of
the energy they consume into visible light, with the rest emerging as
heat. Fluorescent lamps use excited gases, or plasmas, to achieve a
higher energy conversion efficiency of about 20%. However, the color
rendering index, or CRI, of most fluorescent lamps – how good their color is
compared to an ideal light source – is inferior to that of an incandescent
bulb. Fluorescent lamps also pose environmental concerns because they
contain mercury.
Solid-state
lighting relies on the direct conversion of electricity to visible white light
using semiconductor materials. By avoiding the heat and
plasma-producing processes of incandescent bulbs and fluorescent lamps,
solid-state lighting products can have substantially higher energy conversion
efficiencies, which in theory could approach 100%.
There are
currently two basic types of solid-state lighting devices: inorganic light
emitting diodes, or LEDs, and OLEDs. Current LEDs are very small in
size (about one square millimeter) and are extremely bright. Having
been developed about 25 years before OLEDs, they are already employed in various
specialty lighting products, such as traffic lights, billboards, replacements
for neon lighting and as border or accent lighting. However, their
intense brightness and high operating temperatures may make them less desirable
for general illumination and diffuse lighting applications.
OLEDs, on
the other hand, are larger in size and can be viewed directly, without using
diffusers that are required to temper the intense brightness of
LEDs. OLEDs can be built on any suitable surface, including glass,
plastic or metal foil, and could be cost-effective to manufacture in high
volume. Given these characteristics, product manufacturers are
working to develop OLEDs for diffuse specialty lighting applications and
ultimately general illumination. If these efforts are successful, we
believe that OLED lighting products could begin to be used for applications
currently addressed by incandescent bulbs and fluorescent lamps.
Our
Competitive Strengths
We
believe our position as one of the leading technology developers in the OLED
industry is the direct result of our technological innovation. We have built an
extensive intellectual property portfolio around our OLED technologies and
materials, and are working diligently to enable our manufacturing partners to
adopt our OLED technologies and materials for commercial usage. Our key
competitive strengths include:
Technology Leadership. We are
a recognized technology leader in the OLED industry. We and our research
partners pioneered the development of our UniversalPHOLED™ phosphorescent OLED
technologies, which can be used to produce OLEDs that are up to four times as
efficient as traditional fluorescent OLEDs and significantly more efficient than
current backlit LCDs. We believe that our PHOLED technologies are well-suited
for industry usage in the commercial production of OLED displays and lighting
products. Through our relationships with companies such as PPG Industries and
our academic partners, we have also developed other important OLED technologies,
as well as novel OLED materials that we believe will facilitate the adoption of
our various OLED technologies by product manufacturers.
Relationships with Leading Product
Manufacturers. We have established relationships with well-known
manufacturers that are using, or are evaluating, our OLED technologies and
materials for use in commercial products. In
2008,
Samsung SMD, Chi Mei EL and Tohoku Pioneer purchased our proprietary OLED
materials for use in commercial OLED display products, and we renewed our
commercial material supply agreement with LG Display. We also entered
into a license agreement with Konica Minolta for its manufacture of OLED
lighting products, and license and material supply agreements with Kyocera for
its manufacture of active matrix OLED display products. In 2005, we
entered into a license agreement with Samsung SMD for its manufacture of active
matrix OLED display products, and in 2002 we entered into a cross-license
agreement with DuPont Displays, Inc. for its manufacture of solution-processed
OLED display products. We also licensed one of our ink-jet printing patents and
certain related patent filings to Seiko Epson in 2006. We continue to work with
many product manufacturers who are evaluating our OLED technologies and
materials for use in commercial OLED displays and lighting products, including
Sony and Seiko Epson.
Broad Portfolio of Intellectual
Property. We believe that our extensive portfolio of patents, trade
secrets and know-how provides us with a competitive advantage in the OLED
industry. Through our internal development efforts and our relationships with
world-class partners such as Princeton University, the University of Southern
California, the University of Michigan, Motorola and PPG Industries, we own,
exclusively license or have the sole right to sublicense more than 940 patents
issued and pending worldwide. We also continue to accumulate valuable trade
secret information and technical know-how relating to our OLED technologies and
materials.
Focus on Licensing Our OLED
Technologies. We are focused on licensing our proprietary OLED
technologies to product manufacturers on a non-exclusive basis. Our current
business model does not involve the direct manufacture or sale of OLED display
or lighting products. Instead, we seek license fees and royalties from OLED
product manufacturers based on their sales of licensed products. We believe this
business model allows us to concentrate on our core strengths of technology
development and innovation, while at the same time providing significant
operating leverage. We also believe that this approach may reduce potential
competitive conflicts between us and our customers.
Leading Supplier of PHOLED Emitter
Materials. We are the leading supplier of phosphorescent emitter
materials to OLED product manufacturers. PPG Industries currently manufactures
our proprietary emitter materials for us, which we then qualify and resell to
OLED product manufacturers. We record revenues based on our sales of
these materials to OLED product manufacturers. This allows us to
maintain close technical and business relationships with the OLED product
manufacturers purchasing our proprietary materials, which in turn further
supports our technology licensing business.
Established U.S. Government
Contracts to Fund Research and Development. In 2008, we started or
continued working under approximately 14 research and development contracts with
U.S. government agencies, such as the U.S. Department of the Army and the U.S.
Department of Energy. Under these contracts, the U.S. Government funds a portion
of our efforts to develop next-generation OLED technologies for applications
such as flexible displays and solid-state lighting. This enables us to
supplement our internal research and development budget with additional
funding.
Experienced Management and
Scientific Advisory Team. Our management team has significant experience
in developing business models focused on licensing disruptive technologies in
high growth industries. In addition, our management team has assembled a
Scientific Advisory Board that includes some of the leading researchers in the
OLED industry, such as Professor Stephen R. Forrest of the University of
Michigan (formerly of Princeton University) and Professor Mark E. Thompson of
the University of Southern California.
Our
Business Strategy
Our
current business strategy is to both promote and continue to expand our
portfolio of OLED technologies and materials for widespread use in OLED displays
and lighting products, and to generate revenues by licensing our OLED
technologies and selling our proprietary OLED materials. We presently are
focused on the following steps to implement our business strategy:
Target Leading Product
Manufacturers. We are targeting leading manufacturers of flat panel
displays and lighting products as potential commercial licensees of our OLED
technologies and purchasers of our OLED materials. For example, in April 2005 we
entered into a patent license agreement with Samsung SMD for its manufacture and
sale of active-matrix OLED display products, and in August 2008 we entered into
a license agreement with Konica Minolta for its manufacture and sale of OLED
lighting products. In 2008, we also sold our proprietary phosphorescent OLED
materials to Samsung SMD, Chi Mei EL and Tohoku Pioneer for use in commercial
OLED display products. We also provide technical assistance and support to
several manufacturers of displays and lighting products who are evaluating our
OLED technologies and materials, or utilizing them in product development and/or
for pre-commercial product manufacturing. We concentrate on
working
closely with these manufacturers because we believe that the successful
incorporation of our technologies and materials into commercial products is
critical to their widespread adoption.
Enhance Our Existing Portfolio of
PHOLED Technologies and Materials. We believe that a strong portfolio of
proprietary OLED technologies and materials is critical to our success.
Consequently, we are continually seeking to expand this portfolio through our
internal development efforts, our collaborative relationships with academic and
other research partners, and other strategic opportunities. One of our primary
goals is to develop new and improved PHOLED technologies and materials with
increased efficiencies, enhanced color gamut and extended lifetimes, which are
compatible with different manufacturing methods, so that they can be used by
various manufacturers in a broad array of OLED products.
Business
and Geographic Markets
We derive
revenue from the following:
·
|
technology
research and development, including government contract work and
collaborative R&D with third
parties;
|
·
|
intellectual
property and technology licensing;
|
·
|
sales
of OLED materials for evaluation, development and commercial
manufacturing; and
|
·
|
technical
assistance and support provided to third parties for commercialization of
their OLED products.
|
Most
manufacturers of flat panel displays and lighting products who are or might
potentially be interested in our OLED technologies and materials are currently
located in foreign countries, particularly the Asia-Pacific
region. Consequently, we receive a substantial portion of our
revenues from external customers that are domiciled outside of the United
States, and our business is heavily dependent on our relationships with these
customers. In particular, one customer located in the Asia-Pacific
region, Samsung SMD, accounted for approximately 42% of our consolidated
revenues for 2008. Substantially all revenue derived from these customers is
denominated in U.S. dollars.
For more
information on our revenues, costs and expenses associated with our business, as
well as a breakdown of revenues from domestic and foreign sources, please see
our audited Consolidated Financial Statements and the notes thereto, as well as
“Management’s Discussion and Analysis of Financial Condition and Results of
Operations,” included elsewhere in this report.
Our
Phosphorescent OLED Technologies
Phosphorescent
OLEDs utilize specialized materials and device structures that allow OLEDs to
emit light through a process known as phosphorescence. Conversely, traditional
fluorescent OLEDs emit light through an inherently less efficient process.
Theory and experiment show that phosphorescent OLEDs exhibit device efficiencies
up to four times higher than those exhibited by fluorescent OLEDs.
Phosphorescence substantially reduces the power requirements of an OLED and is
potentially useful for hand-held devices, such as mobile phones, where battery
power is often a limiting factor. Phosphorescence is also important for
large-area displays such as televisions, where higher device efficiency and
lower heat generation may enable longer product lifetimes and increased energy
efficiency.
We have a
strong intellectual property portfolio surrounding our existing PHOLED
phosphorescent OLED technologies and materials. We also conduct work
to develop new and improved PHOLED technologies and materials, and to enhance
our intellectual property position. In 2008, we announced further
advances in the development of our proprietary PHOLED materials and device
architectures. We also continued our commercial supply relationships
with companies such
as
Samsung SMD to use our PHOLED materials for their manufacture of OLED
displays. In addition, we continued to work closely with customers
evaluating and qualifying our proprietary PHOLED materials for commercial usage,
and with other material suppliers to match our PHOLED emitters with their
phosphorescent hosts and other OLED materials.
Our
Additional Proprietary OLED Technologies
Our
research, development and commercialization efforts also encompass a number of
other OLED device and manufacturing technologies, including the
following:
TOLED™ Transparent OLEDs. We have
developed a technology for the fabrication of OLEDs that have transparent
cathodes. Conventional OLEDs use a reflective metal cathode and a transparent
anode. In contrast, TOLEDs use a transparent cathode and either a transparent,
reflective or opaque metal anode. TOLEDs utilizing transparent cathodes and
reflective metal anodes are known as “top-emission” OLEDs. In a “top-emission”
active-matrix OLED, light is emitted without having to travel through much of
the device electronics where a significant portion of the usable light is lost.
This results in OLED displays having image qualities and lifetimes superior to
those of conventional active-matrix OLEDs. TOLEDs utilizing transparent cathodes
and transparent anodes may also be useful in novel flat panel display
applications requiring semi-transparency or transparency, such as graphical
displays in automotive windshields.
FOLED™ Flexible OLEDs. We are
working on a number of technologies required for the fabrication of OLEDs on
flexible substrates. Most OLED and other flat panel displays are built on rigid
substrates such as glass. In contrast, FOLEDs are OLEDs built on non-rigid
substrates such as plastic or metal foil. This enhances durability and enables
conformation to certain shapes or repeated bending or flexing. Eventually,
FOLEDs may be capable of being rolled into a cylinder, similar to a window
shade. These features create the possibility of new flat panel display product
applications that do not exist today, such as a portable, roll-up Internet
connectivity and communications device. Manufacturers also may be able to
produce FOLEDs using more efficient continuous, or roll-to-roll, processing
methods. We currently are conducting research and development on FOLED
technologies internally, under several of our U.S. government programs and in
connection with the government-sponsored Flexible Display Center at Arizona
State University.
OVPD™ Organic Vapor Phase
Deposition. The standard approach for manufacturing a small molecule
OLED, including a PHOLED, is based on a vacuum thermal evaporation, or VTE,
process. With a VTE process, the thin layers of organic material in an OLED are
deposited in a high-vacuum environment. An alternate approach for manufacturing
a small molecule OLED is based on OVPD. In contrast to the VTE process, the OVPD
process utilizes a carrier gas stream in a hot walled reactor in a low pressure
environment to deposit the layers of organic material in an OLED. The OVPD
process may offer advantages over the VTE process through more efficient
materials utilization and enhanced deposition control. We have partnered with
Aixtron AG, a leading manufacturer of metal-organic chemical vapor deposition
equipment, to develop and qualify equipment for the fabrication of OLED displays
utilizing the OVPD process.
UniversalP2OLED™ Printable Phosphorescent
OLEDs. OLEDs can be manufactured using other processes as well. Another
method involves preparing solutions of the various organic materials in an OLED
that can be solution-processed by techniques such as spin coating or inkjet
printing onto the substrate. Solution-processing methods, and inkjet printing in
particular, have the potential to be lower cost approaches to OLED manufacturing
and scalable to large area displays. Over the past several years, we have worked
on P2OLEDs
under Joint Development Agreements with Seiko Epson, and we have collaborated
with other material manufacturers to develop and evaluate novel P2OLED
materials. In May 2008, we announced continued advances in P2OLED
material systems for ink-jet printing.
OVJP™ Organic Vapor Jet Printing.
Our groundbreaking OVJP technology is another direct printing method for the
manufacture of OLEDs. As a direct printing technique, OVJP technology has the
potential to offer high deposition rates for any size or shaped OLED. In
addition, OVJP technology avoids the OLED material wastage associated with use
of a shadow mask (i.e.,
the waste of material that deposits on the shadow mask itself when fabricating
an OLED). By comparison to inkjet printing, an OVJP process does not use
solvents and therefore the OLED materials utilized are not limited by their
viscosity or solvent solubility. We are working on developing our proprietary
OVJP technology in collaboration with Professor Forrest of the University of
Michigan under a U.S. Department of Energy (DOE) Solid State Lighting program.
We have installed a prototype OVJP tool at our Ewing, New Jersey facility and
are using this tool to build prototype white PHOLED lighting
panels.
Our
Strategic Relationships with Product Manufacturers
We have
established evaluation, technology development, licensing and material supply
relationships with numerous manufacturers of displays and lighting products. As
of December 31, 2008, we had entered into 36 such relationships, four of
which were newly established in 2008. These relationships generally are directed
towards tailoring our proprietary OLED technologies and materials for use by
each individual manufacturer. Our ultimate objective is to license our OLED
technologies and sell our OLED materials to these manufacturers for their
commercial production of OLED products. Our key relationships with product
manufacturers in 2008 included the following:
Samsung SMD. In April 2005,
we entered into an OLED Patent License Agreement with Samsung SMD. Under this
agreement, we granted Samsung SMD license rights to make and sell active-matrix
OLED displays on glass. Throughout 2008, we supplied several of our proprietary
PHOLED materials to Samsung SMD for use in the manufacture of these OLED
displays. We also continue to supply other of our proprietary PHOLED
materials to Samsung SMD for evaluation and development activities under a
separate agreement that has been in place since July 2001.
Chi Mei EL. In April 2007, we
entered into an agreement to supply our proprietary PHOLED materials and
technologies to Chi Mei EL for use in its manufacture of commercial AMOLED
display products. The agreement ran through the end of 2008, and we
are in the process of negotiating an extension of the agreement. We
recognize commercial chemical sales and license fee revenues from our supply of
material to Chi Mei EL.
LG Display. In May 2007, we
entered into an agreement to supply LG Display with our proprietary PHOLED
materials for use in AMOLED display products. In November 2008, this
agreement was extended through June 2009. The agreement allow us to
recognize commercial chemical sales and license fee revenues from our supply of
materials to LG Display. In May 2008, we also demonstrated with LG
Display a flexible, full-color, active matrix OLED display
prototype.
Sony. We have been supporting
Sony in its development of active-matrix OLED display products under various
agreements since February 2001. We are currently operating under an evaluation
agreement with Sony that has been in place since February 2005. That agreement
enables us to sell our proprietary PHOLED materials to Sony for
evaluation.
Seiko Epson. We have been
conducting joint development work with Seiko Epson under various agreements
since December 2004. This work relates to the application of our proprietary
PHOLED technologies and materials to ink-jet printing processes used by Seiko
Epson. In May 2008, we announced continued advances in P2OLED
device results for ink-jet printing in collaboration with Seiko Epson. We also
supply our proprietary PHOLED materials to Seiko Epson for evaluation and for
use under our development program, and in July 2006 we licensed one of our
ink-jet printing patents and certain related patent filings to Seiko
Epson.
Konica Minolta. In August
2008, we entered into a technology license agreement with Konica Minolta for its
manufacture and sale of OLED lighting products. We have also entered
into separate agreements with Konica Minolta under which Konica Minolta
continues to purchase our red and green PHOLED materials for
evaluation.
Kyocera. In July 2008, we
entered into license and material supply agreements with Kyocera for its
manufacture and sale of OLED displays. These agreements were to
become effective upon notice from Kyocera given on or before December 31,
2008. We recently agreed with Kyocera to extend this date for one
additional year.
Tohoku Pioneer. In August
2003, we began supplying our proprietary red PHOLED material to Tohoku Pioneer,
a subsidiary of Pioneer Corporation, for the commercial production of a
passive-matrix OLED display product. Tohoku Pioneer continued purchasing this
material from us in 2008.
DuPont Displays. In December
2005, we completed work under a Joint Development Agreement with DuPont Displays
for the development of novel phosphorescent materials and device structures for
solution-processed OLEDs. In December 2002, we entered into a Cross-License
Agreement with DuPont Displays for its manufacture of solution-processed OLED
display products. As of December 31, 2008, we had not received any
royalties from DuPont under that agreement.
Our
OLED Materials Supply Business
In
support of our OLED licensing business, we supply our proprietary OLED materials
to display manufacturers and others. We device-qualify our materials before
shipment in order to ensure the materials meet required
specifications. We
believe
that our inventory-carrying practices, along with the terms under which we sell
our OLED materials (including payment terms) are typical for the markets in
which we operate.
PPG
Industries
We have
maintained a close working relationship with PPG Industries since October
2000. Under our original agreements, PPG Industries conducted OLED
materials development work for us and supplied us with our proprietary OLED
materials. Our relationship with PPG Industries on the development of
OLED materials changed in 2006, at which time we assumed sole responsibility
over OLED materials development activities. In connection with that
change, we hired four chemists from the PPG Industries’ OLED materials
development team to work for us in our newly constructed synthetic chemistry
laboratories.
Our new
OLED Materials Supply and Service Agreement with PPG Industries went into effect
in January 2006. Under that agreement, PPG Industries remains
responsible, under our direction, for manufacturing scale-up of our proprietary
OLED materials, and for supplying us with those materials for research and
development, and for resale to our customers, both for their evaluation and for
use in commercial OLED products. Through our collaboration with PPG Industries,
key raw materials are sourced from multiple suppliers to ensure that we are able
to meet the needs of our customers on a timely basis. In January
2008, we extended the term of the OLED Materials Supply and Service Agreement
through December 2011.
Our
OLED Material Customers
Throughout
2008, we continued supplying our proprietary PHOLED materials to Samsung SMD for
use in its commercial AMOLED display products. Samsung SMD is currently the
largest manufacturer of AMOLED displays for handset and other personal
electronic devices. Samsung SMD’s customers for these products have included
many well-known consumer electronics companies throughout the
world.
In 2008,
we continued supplying our proprietary PHOLED materials to Chi Mei EL for use in
its commercial AMOLED display products, and to Tohoku Pioneer for use in its
commercial passive-matrix OLED display products. In November 2008, we
also renewed our commercial supply agreement with LG Display. During the year,
we supplied our proprietary OLED materials to various other product
manufacturers for evaluation and for purposes of development, manufacturing
qualification and product testing.
Collaborations
with other OLED Material Manufacturers
We
continued our non-exclusive collaborative relationships with other manufacturers
of OLED materials during 2008. These included relationships with Nippon Steel
Chemical Company (NSCC) and Idemitsu Kosan Co., Ltd., both of which are focused
on matching our proprietary PHOLED emitters with the host and other OLED
materials of these companies. In March 2008, we announced a
relationship with LG Chem, Ltd. focused on combining our PHOLED materials and
technology with LG Chem’s complementary OLED materials. In December
2008, we announced a strategic business relationship with SFC Co., Ltd. for the
development of PHOLED material systems. We believe that collaborative
relationships such as these are important for ensuring success of the OLED
industry and broader adoption of our PHOLED and other OLED
technologies.
Research
and Development
Our
research and development activities are focused on the advancement of our OLED
technologies and materials for displays, lighting and other applications. We
conduct this research and development both internally and through various
relationships with our commercial business partners and academic institutions.
In the years 2008, 2007 and 2006, we incurred $22,257,634, $20,909,262 and
$19,562,004, respectively, on both internal and third-party sponsored research
and development activities with respect to our various OLED technologies and
materials.
Internal
Development Efforts
We
conduct a substantial portion of our OLED development activities at our
state-of-the-art development and testing facility in Ewing, New Jersey. At this
40,200 square-foot facility, we perform technology development, including device
and
process
optimization, prototype fabrication, manufacturing scale-up studies, process and
product testing, characterization and reliability studies, and technology
transfer with our business partners.
Our Ewing
facility houses six OLED deposition systems, including a full-color flexible
OLED system, a system for fabricating solution-processible OLEDs, an OVPD
organic vapor phase deposition system and an OVJP organic vapor jet printing
system. In addition, the facility contains equipment for substrate patterning,
organic material deposition, display packaging, module assembly and extensive
testing in Class 100 and 100,000 clean rooms and opto-electronic test
laboratories.
In 2006,
we opened state-of-the-art synthetic chemistry laboratories at our Ewing
facility. In these laboratories, our scientists conduct OLED materials research
and make small quantities of new materials that we then test in OLED devices.
Prior to opening these laboratories, we conducted this materials research in
laboratory space that we leased in Princeton, New Jersey.
As of
December 31, 2008, we employed a team of 51 research scientists, engineers and
laboratory technicians at our Ewing facility. This team includes chemists,
physicists, engineers with electrical, chemical and mechanical backgrounds, and
highly-trained experimentalists. Fifteen members of our R&D team were
newly-hired in 2008.
University
Sponsored Research
We have
long-standing relationships with Princeton University and the University of
Southern California (USC), dating back to 1994, for the conduct of research
relating to our OLED and other organic thin-film technologies and materials for
applications such as displays and lighting. This research has been performed at
Princeton University under the direction of Dr. Forrest and at USC under the
direction of Dr. Thompson. In 2006, Dr. Forrest transferred to the University of
Michigan, where we continue to fund his research.
We funded
research at Princeton University under a Research Agreement executed with the
Trustees of Princeton University in August 1997. The 1997 Research
Agreement was allowed to expire in July 2007, after Dr. Forrest had transferred
to the University of Michigan. We have exclusive license rights to all OLED and
other thin-film organic electronic patents (other than for organic photovoltaic
solar cells) arising out of research conducted under that
agreement.
In
connection with Dr. Forrest’s transfer to the University of Michigan, in May
2006 we entered into a new Sponsored Research Agreement with USC under which we
are funding organic electronics research being conducted by Drs. Forrest and
Thompson. Work by Dr. Forrest is being funded through a subcontract between USC
and the University of Michigan. We reimburse the universities for actual costs
incurred for sponsored research conducted under this agreement, up to a maximum
of $4,936,296 over the three-year agreement term. As with the 1997 Research
Agreement, we have exclusive license rights to all OLED and thin-film organic
electronic patents (other than for organic photovoltaic solar cells) arising out
of this research. This arrangement runs through April 2009, and we
are currently negotiating a further extension with the
universities.
In
October 2005, we entered into a separate Sponsored Research Agreement with
Princeton University to fund research under the direction of Dr. Sigurd Wagner
on thin-film encapsulation and fabrication of OLED devices. In December 2008, we
extended this agreement through December 2009. Like our other relationships with
Princeton University, we have exclusive license rights to all patents arising
out of the research.
In
December 2004, we entered into a Sponsored Research Agreement with the Yuen
Tjing Ling Industrial Research Institute of National Taiwan University (TLIRI).
Under that agreement, we funded a research program under the direction of Dr.
Ken-Tsung Wong relating to new OLED materials. We have exclusive rights to all
intellectual property developed under that program. The program ran through
February 2009.
In April
2004, we entered into a Contract Research Agreement with the Chitose Institute
of Science and Technology of Japan (CIST). Under that agreement, we funded a
research program headed by Dr. Chihaya Adachi relating to high-efficiency OLED
materials and devices. We were granted exclusive rights to all intellectual
property developed under this program. This relationship with CIST ended in
March 2006 when Dr. Adachi transferred to Kyushu University. However,
we have continued our relationship with Dr. Adachi under a separate consulting
arrangement that currently runs through March 2010.
In March
2006, we entered into a Research Agreement with Kyung Hee University to sponsor
a research program on flexible, amorphous silicon TFT backplane
technology. The program was directed by Dr. Jin Jang and continued
for one year. In August 2007, we entered into a second Research
Agreement with Kyung Hee University to sponsor further research in this
area. This research was also directed by Dr. Jang, and the program
ran through August 2008. We are in the process of
extending our relationship with Kyung Hee University and Dr.
Jang.
Aixtron
In July
2000, we entered into a Development and License Agreement with Aixtron AG of
Aachen, Germany to jointly develop and commercialize equipment for the
manufacture of OLEDs using the OVPD process. Under the Development and License
Agreement, we granted Aixtron an exclusive license to produce and sell its
equipment for the manufacture of OLEDs and other devices using our proprietary
OVPD process. Aixtron is required to pay us royalties on its sales of this
equipment. Purchasers of the equipment also must obtain rights to use our
proprietary OVPD process to manufacture OLEDs and other devices using the
equipment, which they may do through us or Aixtron. If these rights are granted
through Aixtron, Aixtron is required to make additional payments to us under our
agreement.
Aixtron
has reported to us the delivery of six OVPD systems since July
2002. These include two second-generation systems, one of which was
sold to the Fraunhofer Institute for Photonic Microsystems (IPMS) in Dresden,
Germany in November 2007, and the other of which was sold to RiTdisplay
Corporation of Taiwan in April 2003. We record royalty income from Aixtron’s
sales of these various systems in the quarter in which Aixtron notifies us of
the sale and the related royalties are due.
U.S.
Government-Funded Research
We have
entered into several U.S. government contracts and subcontracts to fund a
portion of our efforts to develop next-generation OLED technologies and
materials for applications such as flexible displays and energy-efficient
solid-state lighting. These include, among others, Small Business Innovation
Research (SBIR) Phase I program contracts for the demonstration of technical
merit and feasibility and SBIR Phase II program contracts for continued research
and development and the fabrication of prototypes. On contracts for which we are
the prime contractor, we subcontract portions of the work to various entities
and institutions, including Princeton University, the University of Southern
California, the University of Michigan, L-3 Communications Corporation — Display
Systems (L-3DS), Armstrong World Industries, Inc. and LG Display. All of our
government contracts and subcontracts are subject to termination at the election
of the contracting governmental agency. Our government contracts include, among
others, the following:
·
|
OLED Displays on Flexible
Metal Foil Substrates. We continued our work during 2008 to develop
and deliver next-generation prototype OLED displays on flexible metal foil
substrates for the U.S. Army Communications-Electronics Research
Development and Engineering Center (CERDEC), the U.S. Army Research
Laboratory (ARL) and the U.S. Air Force Research Laboratory. For 2008, we
recognized $1,065,898 in revenue for the program under several government
contracts. In December 2008, we delivered to these agencies several
full-color, active matrix OLED display prototypes on flexible metal foil
that were developed under the program. Our contractual commitments to
conduct further work under this program currently run until November
2009.
|
·
|
Infrared OLED Displays for
Night-Vision Applications. In 2008, we completed work under an SBIR
Phase II program contract from CERDEC for the development of a flexible
OLED display containing infrared-emitting OLED pixels that would be
visible through night vision goggles. We delivered a prototype
infrared-emitting OLED display to CERDEC in April 2008. For 2008, we
recognized $115,387 in revenue under this
program.
|
·
|
Novel Encapsulation Technology
for Flexible OLEDs. In 2008, we continued our work under an SBIR
Phase II program contract from ARL to develop innovative encapsulation
technology for flexible OLEDs. Using technology pioneered at
Princeton University, we have demonstrated the feasibility of a novel
encapsulation process based on plasma-enhanced chemical vapor deposition
(PECVD), which is an important element on the development roadmap for
flexible OLED displays. We recognized $218,547 in revenue from
ARL for 2008 under this contract. The program is currently
scheduled to run through September
2009.
|
·
|
OLEDs for High-Efficiency
White Lighting. Our work on behalf of the U.S. Department of Energy
(DOE) to develop technical approaches for using our proprietary PHOLED and
other OLED technologies for high-efficiency white lighting applications
continued in 2008. For the year, the DOE recognized $1,076,363 in revenue
for this work under three SBIR Phase II program contracts and three SBIR
Phase I program contracts. We also received funding from the
DOE under a Solid State Lighting (SSL) program contract to develop a
ceiling-based white OLED lighting system in conjunction with Armstrong
World Industries. Two of the SBIR Phase I programs were
completed in March 2008, and our other DOE programs are currently
scheduled for completion between March 2009 and August
2010.
|
·
|
OVJP Technology for Lighting
Applications. In 2008, we continued our work on behalf of the DOE
to develop our proprietary OVJP organic vapor jet printing technology for
the printing of striped OLEDs for lighting applications. Revenue
recognized under this DOE Solid State Lighting program totaled $313,918 in
2008. The program ran through December 2008. At the conclusion
of the program, we delivered to the DOE prototype OLED devices fabricated
using our OVJP process. The OLED materials in these devices
were deposited in red, green and blue stripes, and the resulting devices
generated white light.
|
The
Army Flexible Display Center
We have
been a charter member of The Army Flexible Display Center (FDC) since its
establishment at Arizona State University in December 2004. The FDC is being
supported through a $51.5 million Cooperative Agreement between Arizona State
University and the U.S. Army Research Laboratory. This agreement was
recently renewed to provide an additional $50 million in funding to the FDC over
the next five years. The goal of the FDC is to develop flexible, low power,
light-weight, information displays for future usage by soldiers and for other
military and commercial applications. We believe our involvement with the FDC
enhances our flexible OLED display technology development efforts.
The
FlexTech Alliance
We are a
member of the FlexTech Alliance, Inc. (formerly the United States Display
Consortium), a cooperative industry and governmental effort aimed at developing
an infrastructure to support North American flat panel display manufacturing.
The role of the FlexTech Alliance is to provide a common platform for flat panel
display manufacturers, developers, users and the manufacturing equipment and
supplier base. It has more than 100 members, as well as support from ARL. We are
one of 11 members with representation on the Governing Board of the FlexTech
Alliance, and we actively participate on its Technical Council. Our President,
Steven Abramson, previously served as Vice-Chairman of the Governing
Board.
OLED
Association
We are a
charter member of the newly-established OLED Association
(OLED-A). OLED-A is a trade association whose mission involves
serving as an OLED information resource, driving OLED technology development,
and promoting interest in OLED products. We are one of 10 members of
OLED-A, and we actively participate on its marketing and technology
committees. Janice Mahon, our Vice President of Technology
Commercialization, is chairperson of the OLED-A marketing
committee.
Intellectual
Property
Along
with our personnel, our primary and most fundamental assets are patents and
other intellectual property. This includes numerous U.S. and foreign patents and
patent applications that we own, exclusively license or have the sole right to
sublicense. It also includes a substantial body of trade secrets and technical
know-how that we have accumulated over time.
Our
Patents
Our
research and development activities, conducted both internally and through
collaborative programs with our partners, have resulted in the filing of a
substantial number of patent applications relating to our OLED technologies and
materials. As of December 31, 2008, we owned, through assignment to us alone or
jointly with others, 122 issued and pending patents in the U.S., together with
numerous counterparts filed in various foreign countries. These patents will
start expiring in the U.S. in 2020.
Patents We License from Princeton University, the University of
Southern California and the University of Michigan
We
exclusively license the bulk of our patent rights, including our key PHOLED
technology patents, under an Amended License Agreement we executed with the
Trustees of Princeton University and USC in October 1997. Based on Dr. Forrest’s
transfer to the University of Michigan, in January 2006 the University of
Michigan was added as a party to this agreement. As of December 31,
2008, the patent rights we license from these universities included 214 issued
and pending patents in the U.S., together with numerous counterparts filed in
various foreign countries. These patents will start expiring in the U.S. in
2014, but our key PHOLED technology patents licensed from these universities
will not start expiring in the U.S. until 2017.
Under the
Amended License Agreement, Princeton University, USC and the University of
Michigan granted us worldwide, exclusive license rights to specified patents and
patent applications relating to OLED technologies and materials. Our license
rights also extend to any patent rights arising out of the research conducted by
Princeton University, USC or the University of Michigan under our various
research agreements with these entities. We are free to sublicense to third
parties all or any portion of our patent rights under the Amended License
Agreement. The term of the Amended License Agreement is perpetual, though it is
subject to termination for an uncured material breach or default by us, or if we
become bankrupt or insolvent.
Princeton
University is primarily responsible for the filing, prosecution and maintenance
of all patent rights licensed to us under the Amended License Agreement pursuant
to an Interinstitutional Agreement between Princeton University, USC and the
University of Michigan. However, we manage this process and have the right to
instruct patent counsel on specific matters to be covered in any patent
applications filed by Princeton University. We are required to bear all costs
associated with the filing, prosecution and maintenance of these patent
rights.
We are
required under the Amended License Agreement to pay Princeton University
royalties for licensed products sold by us or our sublicensees. These royalties
amount to 3% of the net sales price for licensed products sold by us and 3% of
the revenues we receive for licensed products sold by our sublicensees. These
royalty rates are subject to renegotiation for products not reasonably
conceivable as arising out of the research agreements if Princeton University
reasonably determines that the royalty rates payable with respect to these
products are not fair and competitive. Princeton University shares portions of
these royalties with USC and the University of Michigan under their
Interinstitutional Agreement.
We have a
minimum royalty obligation of $100,000 per year during the term of the Amended
License Agreement. Royalties under the Amended License Agreement with Princeton
University were $223,901 for 2008. We also are required under the Amended
License Agreement to use commercially reasonable efforts to bring the licensed
OLED technology to market. However, this requirement is deemed satisfied if we
invest a minimum of $800,000 per year in research, development,
commercialization or patenting efforts respecting the patent rights licensed to
us under the Amended License Agreement.
Patents
We License from Motorola
In
September 2000, we entered into a License Agreement with Motorola whereby
Motorola granted us perpetual license rights to what are now 74 issued U.S.
patents relating to Motorola’s OLED technologies, together with numerous foreign
counterparts in various countries. These patents will start expiring in the U.S.
in 2012. We have the right to freely sublicense these patents to third parties
and, with limited exceptions, Motorola has agreed not to license these patents
to others in the OLED industry. Motorola remains responsible for the
prosecution and maintenance of all patent rights licensed to us under the
License Agreement, including all associated costs. Motorola is obligated to keep
us informed as to the status of these activities.
We are
required under the License Agreement to pay Motorola annual royalties on gross
revenues received by us on account of our sales of OLED products or components,
or from our OLED technology licensees, whether or not these revenues relate
specifically to inventions claimed in the patent rights licensed from Motorola.
We have the option to pay these royalties to Motorola in either all cash or 50%
cash and 50% shares of our common stock.
The
royalty due to Motorola for the year ended December 31, 2008 was
$163,916. We satisfied this royalty obligation by issuing 12,015
shares of our common stock to Motorola on March 2, 2009, and by paying Motorola
$81,962 in cash on March 5, 2009. The number of shares of common stock used to
pay the stock portion of the royalty was equal to approximately 50% of the total
royalty due divided by the average daily closing price per share of our common
stock on the NASDAQ Global Market over the 10 trading days ended two business
days prior to the date of payment.
Intellectual
Property Developed under Our Government Contracts
We and
our subcontractors have developed and may continue to develop patentable OLED
technology inventions under our various U.S. government contracts and
subcontracts. Under these arrangements, we or our subcontractors generally can
elect to take title to any patents on these inventions, and to control the
manner in which these patents are licensed to third parties. However, the U.S.
government reserves rights to these inventions and associated technical data
that could restrict our ability to market them to the government for military
and other applications, or to third parties for commercial applications. In
addition, if the U.S. government determines that we or our subcontractors have
not taken effective steps to achieve practical application of these inventions
in any field of use in a reasonable time, the government may require that we or
our subcontractors license these inventions to third parties in that field of
use.
Trade
Secrets and Technical Know-How
We have
accumulated, and continue to accumulate, a substantial amount of trade secret
information and technical know-how relating to OLED technologies and materials.
Where practicable, we share portions of this information and know-how with
display manufacturers and other business partners on a confidential basis. We
also employ various methods to protect this information and know-how from
unauthorized use or disclosure, although no such methods can afford complete
protection. Moreover, because we derive some of this information and know-how
from academic institutions such as Princeton University, USC and the University
of Michigan, there is an increased potential for public disclosure.
Competition
The
industry in which we operate is highly competitive. We compete against
alternative flat panel display technologies, in particular LCDs, as well as
other OLED technologies. We also compete in the lighting market
against incumbent technologies, such as incandescent bulbs and fluorescent
lamps, and emerging technologies, such as inorganic LEDs.
Flat
Panel Display Industry Competitors
Numerous
domestic and foreign companies have developed or are developing LCD, plasma and
other flat panel display technologies that compete with our OLED display
technologies. We believe that OLED display technologies ultimately can compete
with LCDs and other display technologies for many product applications on the
basis of lower power consumption, better contrast ratios, faster video rates and
lower manufacturing cost. However, other companies may succeed in continuing to
improve these competing display technologies, or in developing new display
technologies, that are superior to OLED display technologies in various
respects. We cannot predict the timing or extent to which such improvements or
developments may occur.
Lighting
Industry Competitors
Traditional
incandescent bulbs and fluorescent lamps are well-entrenched products in the
lighting industry. In addition, compact fluorescent lamps and
solid-state LEDs have recently been introduced into the market and would compete
with OLED lighting products. Having attributes different than fluorescent lamps
and LEDs, OLEDs may compete directly with these products for certain lighting
applications. However, manufacturers of LEDs and compact fluorescent lamps may
succeed in more broadly adapting their products to various lighting
applications, or others may develop competing solid-state lighting technologies
that are superior to OLEDs. Again, we cannot predict whether or when this might
occur.
OLED
Technology and Materials Competitors
Eastman
Kodak Company has licensed its competing fluorescent OLED technology and other
patents to a number of display manufacturers, several of whom are presently
manufacturing OLED products. Cambridge Display Technology, Ltd., which was
acquired by Sumitomo Chemical Company in 2007, also has licensed its competing
polymer OLED technology and sells its polymer OLED materials to display
manufacturers. Many display manufacturers themselves are engaged in research,
development and commercialization activities with respect to OLED technologies
and materials. In addition, other material manufacturers, such as Idemitsu Kosan
Co., Ltd., Merck KGaA and BASF Corporation, are selling or sampling OLED
materials to the same customers to which we sell our proprietary PHOLED
materials.
Our existing business relationships
with Samsung SMD and other product manufacturers suggest that our OLED
technologies and materials, particularly our PHOLED technologies and materials,
may achieve some level of market penetration in the flat panel display and
lighting industries. However, our competitors may succeed in improving their
competing OLED technologies and materials so as to render them superior to ours.
We cannot be sure of the extent to which product manufacturers ultimately will
adopt our OLED technologies and materials for the production of commercial flat
panel displays and lighting products.
Employees
As of
December 31, 2008, we had 78 full-time employees and two part-time employees,
none of whom are unionized. We believe that relations with our employees are
good.
Our
Company History
Our
corporation was organized under the laws of the Commonwealth of Pennsylvania in
April 1985. Our business was commenced in June 1994 by a company then known as
Universal Display Corporation, which had been incorporated under the laws of the
State of New Jersey. On June 22, 1995, a wholly-owned subsidiary of ours
merged into this New Jersey corporation. The surviving corporation in this
merger became a wholly-owned subsidiary of ours and changed its name to UDC,
Inc. Simultaneously with the consummation of this merger, we changed our name to
Universal Display Corporation. UDC, Inc. now functions as an operating
subsidiary of ours and has overlapping officers and directors. In
January 2008, we also formed a second wholly-owned subsidiary, Universal Display
Corporation Hong Kong, Ltd.
Our
Compliance with Environmental Protection Laws
We are
not aware of any material effects that compliance with Federal, State or local
environmental protection laws or regulations will have on our business. We have
not expended material amounts to comply with any environmental protection laws
or regulations and do not anticipate having to do so in the foreseeable
future.
Our
Internet Site
Our Internet address is
www.universaldisplay.com. We make available through our Internet website, free
of charge, our annual reports on Form 10-K, quarterly reports on
Form 10-Q, current reports on Form 8-K and amendments to those reports
filed or furnished pursuant to Section 13(a) or 15(d) of the
Exchange Act as soon as reasonably practicable after we file such material with
the Securities and Exchange Commission (the “SEC”). In addition, we have made
available on our Internet website under the heading “Corporate Governance” the
charter for the Audit Committee of our Board of Directors, as well as our Code
of Ethics and Code of Conduct for Employees, and our Code of Conduct for
Directors. We intend to make available on our website any future amendments or
waivers to our Code of Ethics and Code of Conduct for Employees, and our Code of
Conduct for Directors within four business days after any such amendments or
waivers. The information on our Internet site is not part of this
report.
The
following factors, as well as other factors affecting our operating results and
financial condition, could cause our actual future results and financial
condition to differ materially from those projected.
If
our OLED technologies and materials are not feasible for broad-based product
applications, we may never generate revenues sufficient to support ongoing
operations.
Our main
business strategy is to license our OLED technologies and sell our OLED
materials to manufacturers for incorporation into the flat panel display and
lighting products that they sell. Consequently, our success depends on the
ability and willingness of these manufacturers to develop, manufacture and sell
commercial products integrating our technologies and materials.
Before
product manufacturers will agree to utilize our OLED technologies and materials
for wide-scale commercial production, they will likely require us to demonstrate
to their satisfaction that our OLED technologies and materials are feasible for
broad-based product applications. This, in turn, may require additional advances
in our technologies and
materials,
as well as those of others, for applications in a number of areas, including,
without limitation, advances with respect to the development of:
·
|
OLED
materials with sufficient lifetimes, brightness and color coordinates for
full-color OLED displays and general lighting
products;
|
·
|
more
robust OLED materials for use in large-scale, more demanding manufacturing
environments; and
|
·
|
scalable
and cost-effective methods and technologies for the fabrication of OLED
products.
|
We cannot
be certain that these advances will ever occur, and hence our OLED technologies
and materials may never be feasible for broad-based product
applications.
Even
if our OLED technologies are technically feasible, they may not be adopted by
product manufacturers.
The
potential size, timing and viability of market opportunities targeted by us are
uncertain at this time. Market acceptance of our OLED technologies will depend,
in part, upon these technologies providing benefits comparable or superior to
current display and lighting technologies at an advantageous cost to
manufacturers, and the adoption of products incorporating these technologies by
consumers. Many potential licensees of our OLED technologies manufacture flat
panel displays and lighting products utilizing competing technologies, and may,
therefore, be reluctant to redesign their products or manufacturing processes to
incorporate our OLED technologies.
During
the entire product development process for a new product, we face the risk that
our technology will fail to meet the manufacturer’s technical, performance or
cost requirements or will be replaced by a competing product or alternative
technology. For example, we are aware that some of our licensees and prospective
licensees have entered into arrangements with our competitors regarding the
development of competing technologies. Even if we offer technologies that are
satisfactory to a product manufacturer, the manufacturer may choose to delay or
terminate its product development efforts for reasons unrelated to our
technologies.
Mass
production of OLED products will require the availability of suitable
manufacturing equipment, components and materials, many of which are available
only from a limited number of suppliers. In addition, there may be a number of
other technologies that manufacturers need to utilize to be used in conjunction
with our OLED technologies in order to bring OLED products containing them to
the market. Thus, even if our OLED technologies are a viable alternative to
competing approaches, if product manufacturers are unable to obtain access to
this equipment and these components, materials and other technologies, they may
not utilize our OLED technologies.
There
are numerous potential alternatives to OLEDs, which may limit our ability to
commercialize our OLED technologies and materials.
The flat
panel display market is currently, and will likely continue to be for some time,
dominated by displays based on LCD technology. Numerous companies are making
substantial investments in, and conducting research to improve characteristics
of, LCDs. Plasma and other competing flat panel display technologies have been,
or are being, developed. A similar situation exists in the solid-state lighting
market, which is currently dominated by LED products. Advances in any
of these various technologies may overcome their current limitations and permit
them to become the leading technologies in their field, either of which could
limit the potential market for products utilizing our OLED technologies and
materials. This, in turn, would cause product manufacturers to avoid entering
into commercial relationships with us, or to terminate or not renew their
existing relationships with us.
Other
OLED technologies may be more successful or cost-effective than ours, which may
limit the commercial adoption of our OLED technologies and
materials.
Our
competitors have developed OLED technologies that differ from or compete with
our OLED technologies. In particular, competing fluorescent OLED technology,
which entered the marketplace prior to ours, may become entrenched in the
industry before our OLED technologies have a chance to become widely utilized.
Moreover, our competitors may succeed in developing new OLED technologies that
are more cost-effective or have fewer limitations than our OLED technologies. If
our OLED technologies, and particularly our phosphorescent OLED technology, are
unable to capture a substantial portion of the OLED product market, our business
strategy may fail.
If
we fail to make advances in our OLED research and development activities, we
might not succeed in commercializing our OLED technologies and
materials.
Further
advances in our OLED technologies and materials depend, in part, on the success
of the research and development work we conduct, both alone and with our
research partners. We cannot be certain that this work will yield additional
advances in the research and development of these technologies and
materials.
Our
research and development efforts remain subject to all of the risks associated
with the development of new products based on emerging and innovative
technologies, including, without limitation, unanticipated technical or other
problems and the possible insufficiency of funds for completing development of
these products. Technical problems may result in delays and cause us to incur
additional expenses that would increase our losses. If we cannot complete
research and development of our OLED technologies and materials successfully, or
if we experience delays in completing research and development of our OLED
technologies and materials for use in potential commercial applications,
particularly after incurring significant expenditures, our business may
fail.
The
consumer electronics industry experiences significant downturns from time to
time, any of which may adversely affect the demand for and pricing of our OLED
technologies and materials.
Because
we do not sell any products to consumers, our success depends upon the ability
and continuing willingness of our licensees to manufacture and sell products
utilizing our technologies and materials, and the widespread acceptance of those
products. Any slowdown in the demand for our licensees’ products would adversely
affect our royalty revenues and thus our business. The markets for flat panel
displays and lighting products are highly competitive. Success in the market for
end-user products that may integrate our OLED technologies and materials also
depends on factors beyond the control of our licensees and us, including the
cyclical and seasonal nature of the end-user markets that our licensees serve,
as well as industry and general economic conditions.
The
markets that we hope to penetrate have experienced significant periodic
downturns, often in connection with, or in anticipation of, declines in general
economic conditions. These downturns have been characterized by lower product
demand, production overcapacity and erosion of average selling prices. Our
business strategy is dependent on manufacturers building and selling products
that incorporate our OLED technologies and materials. Industry-wide fluctuations
and downturns in the demand for flat panel displays and solid-state lighting
products could cause significant harm to our business.
The
current U.S. and global economic crisis may have a significant adverse effect on
our business.
With the
recent and significant deterioration of economic conditions in the U.S. and
elsewhere, there has been considerable pressure on consumer demand, and the
resulting impact on consumer spending has had and may continue to have a
material adverse effect on the demand for products that incorporate our OLED
technologies and materials. This decline in demand may have a
significant adverse effect on one or more of our licensees as an enterprise,
which could result in those licensees reducing their efforts to commercialize
these products. Consumer demand and the condition of the flat panel display and
lighting industries may also be impacted by other external factors such as war,
terrorism, geopolitical uncertainties and other business interruptions. The
impact of these external factors is difficult to predict, and one or more of
these factors could adversely impact the demand for our licensees’ products, and
thus our business.
If
we cannot form and maintain lasting business relationships with OLED product
manufacturers, our business strategy will fail.
Our
business strategy ultimately depends upon our development and maintenance of
commercial licensing and material supply relationships with high-volume
manufacturers of OLED products. We have entered into only a limited number of
such relationships. Our other relationships with product manufacturers currently
are limited to technology development and the evaluation of our OLED
technologies and materials for possible use in commercial products. Some or all
of these relationships may not succeed or, even if they are successful, may not
result in the product manufacturers entering into commercial licensing and
material supply relationships with us.
Under our
existing technology development and evaluation agreements, we are working with
manufacturers to incorporate our technologies into their commercial products.
However, these technology development and evaluation
agreements
typically last for limited periods of time, such that our relationships with the
product manufacturers will expire unless they continually are renewed. These
manufacturers may not agree to renew their relationships with us on a continuing
basis. In addition, we regularly continue working with manufacturers evaluating
our OLED technologies and materials after our existing agreements with them have
expired while we are attempting to negotiate contract extensions or new
agreements with them. Should our relationships with the various product
manufacturers not continue or be renewed, or if we are not able to identify
other product manufacturers and enter into contracts with them, our business
would suffer.
Our
ability to enter into additional commercial licensing and material supply
relationships, or to maintain our existing technology development and evaluation
relationships, may require us to make financial or other commitments. We might
not be able, for financial or other reasons, to enter into or continue these
relationships on commercially acceptable terms, or at all. Failure to do so may
cause our business strategy to fail.
Conflicts
may arise with our licensees or joint development partners, resulting in
renegotiation or termination of, or litigation related to, our agreements with
them. This would adversely affect our revenues.
Conflicts
could arise between us and our licensees or joint development partners as to
royalty rates, milestone payments or other commercial terms. Similarly, we may
disagree with our licensees or joint development partners as to which party owns
or has the right to commercialize intellectual property that is developed during
the course of the relationship or as to other non-commercial terms. If such a
conflict were to arise, a licensee or joint development partner might attempt to
compel renegotiation of certain terms of their agreement or terminate their
agreement entirely, and we might lose the royalty revenues and other benefits of
the agreement. Either we or the licensee or joint development partner might
initiate litigation to determine commercial obligations, establish intellectual
property rights or resolve other disputes under the agreement. Such litigation
could be costly to us and require substantial attention of management. If we
were unsuccessful in such litigation, we could lose the commercial benefits of
the agreement, be liable for other financial damages and suffer losses of
intellectual property or other rights that are the subject of dispute. Any of
these adverse outcomes could cause our business strategy to fail.
If
we cannot obtain and maintain appropriate patent and other intellectual property
rights protection for our OLED technologies and materials, our business will
suffer.
The value
of our OLED technologies and materials is dependent on our ability to secure and
maintain appropriate patent and other intellectual property rights protection.
Although we own or license many patents respecting our OLED technologies and
materials that have already been issued, there can be no assurance that
additional patents applied for will be obtained, or that any of these patents,
once issued, will afford commercially significant protection for our OLED
technologies and materials, or will be found valid if challenged. Moreover, we
have not obtained patent protection for some of our OLED technologies and
materials in all foreign countries in which OLED products or materials might be
manufactured or sold. In any event, the patent laws of other countries may
differ from those of the United States as to the patentability of our OLED
technologies and materials and the degree of protection afforded.
The
strength of our current intellectual property position results primarily from
the essential nature of our fundamental patents covering phosphorescent OLED
devices and certain materials utilized in these devices. Our existing
fundamental phosphorescent OLED patents expire in the United States in 2017 and
2019, and in other countries of the world in 2018 and 2020. While we hold a wide
range of additional patents and patent applications whose expiration dates
extend (and in the case of patent applications, will extend) beyond 2020, many
of which are also of key importance in the OLED industry, none are of an equally
essential nature as our fundamental patents, and therefore our competitive
position after 2020 may be less certain.
We may
become engaged in litigation to protect or enforce our patent and other
intellectual property rights, or in International Trade Commission proceedings
to abate the importation of goods that would compete unfairly with those of our
licensees. In addition, we are participating in or have participated in, and
will likely have to participate in the future in, interference or reexamination
proceedings before the U.S. Patent and Trademark Office, and opposition, nullity
or other proceedings before foreign patent offices, with respect to our patents
or patent applications. All of these actions place our patents and other
intellectual property rights at risk and may result in substantial costs to us
as well as a diversion of management attention. Moreover, if successful, these
actions could result in the loss of patent or other intellectual property rights
protection for the key OLED technologies and materials on which our business
depends.
In
addition, we rely in part on unpatented proprietary technologies, and others may
independently develop the same or similar technologies or otherwise obtain
access to our unpatented technologies. To protect our trade secrets, know-how
and other proprietary information, we require employees, consultants, financial
advisors and strategic partners to enter into confidentiality agreements. These
agreements may not ultimately provide meaningful protection for our trade
secrets, know-how or other proprietary information. In particular, we may not be
able to fully or adequately protect our proprietary information as we conduct
discussions with potential strategic partners. If we are unable to protect the
proprietary nature of our technologies, it will harm our business.
We
or our licensees may incur substantial costs or lose important rights as a
result of litigation or other proceedings relating to our patent and other
intellectual property rights.
There are
a number of other companies and organizations that have been issued patents and
are filing patent applications relating to OLED technologies and materials,
including, without limitation, Eastman Kodak Company, Cambridge Display
Technology (acquired by Sumitomo Chemical Company in 2007), Fuji Film Co., Ltd.,
Canon, Inc., Semiconductor Energy Laboratories Co., Idemitsu Kosan Co., Ltd. and
Mitsubishi Chemical Corporation. As a result, there may be issued patents or
pending patent applications of third parties that would be infringed by the use
of our OLED technologies or materials, thus subjecting our licensees to possible
suits for patent infringement in the future. Such lawsuits could result in our
licensees being liable for damages or require our licensees to obtain additional
licenses that could increase the cost of their
products, which might have an adverse affect on their sales and thus our
royalties or cause them to seek to renegotiate our royalty
rates.
In
addition, we may be required from time-to-time to assert our intellectual
property rights by instituting legal proceedings against others. We cannot
assure you that we will be successful in enforcing our patents in any lawsuits
we may commence. Defendants in any litigation we may commence to enforce our
patents may attempt to establish that our patents are invalid or are
unenforceable. Thus, any patent litigation we commence could lead to a
determination that one or more of our patents are invalid or unenforceable. If a
third party succeeds in invalidating one or more of our patents, that party and
others could compete more effectively against us. Our ability to derive
licensing revenues from products or technologies covered by these patents would
also be adversely affected.
Whether
our licensees are defending the assertion of third-party intellectual property
rights against their businesses arising as a result of the use of our
technology, or we are asserting our own intellectual property rights against
others, such litigation can be complex, costly, protracted and highly disruptive
to our or our licensees’ business operations by diverting the attention and
energies of management and key technical personnel. As a result, the pendency or
adverse outcome of any intellectual property litigation to which we or our
licensees are subject could disrupt business operations, require the incurrence
of substantial costs and subject us or our licensees to significant liabilities,
each of which could severely harm our business. Costs associated with these
actions are likely to increase as active matrix OLED products using our PHOLED
and other OLED technologies and materials enter the consumer
marketplace.
Plaintiffs
in intellectual property cases often seek injunctive relief in addition to money
damages. Any intellectual property litigation commenced against our licensees
could force them to take actions that could be harmful to their business and
thus to our royalties, including the following:
·
|
stop
selling their products that incorporate or otherwise use technology that
contains our allegedly infringing intellectual
property;
|
·
|
attempt
to obtain a license to the relevant third-party intellectual property,
which may not be available on reasonable terms or at all;
or
|
·
|
attempt
to redesign their products to remove our allegedly infringing intellectual
property to avoid infringement of the third-party intellectual
property.
|
If our
licensees are forced to take any of the foregoing actions, they may be unable to
manufacture and sell their products that incorporate our technology at a profit
or at all. Furthermore, the measure of damages in intellectual property
litigation can be complex, and is often subjective or uncertain. If our
licensees were to be found liable for infringement of proprietary rights of a
third party, the amount of damages they might have to pay could be substantial
and is difficult to predict. Decreased sales of our licensees’ products
incorporating our technology would have an adverse effect on our royalty
revenues under existing licenses. Any necessity to procure rights to the
third-party technology might cause our existing
licensees
to renegotiate the royalty terms of their license with us to compensate for this
increase in their cost of production or, in certain cases, to terminate their
license with us entirely. Were this renegotiation to occur, it would likely harm
our ability to compete for new licensees and have an adverse effect on the terms
of the royalty arrangements we could enter into with any new
licensees.
As is
commonplace in technology companies, we employ individuals who were previously
employed at other technology companies. To the extent our employees are involved
in research areas that are similar to those areas in which they were involved at
their former employers, we may be subject to claims that such employees or we
have, inadvertently or otherwise, used or disclosed the alleged trade secrets or
other proprietary information of the former employers. Litigation may be
necessary to defend against such claims. The costs associated with these actions
or the loss of rights critical to our or our licensees’ business could
negatively impact our revenues or cause our business to fail.
A
2007 U.S. Supreme Court decision may raise the standards for all patent
applicants and holders for patentability.
On
April 30, 2007, the U.S. Supreme Court, in KSR International Co. vs. Teleflex,
Inc., mandated a more expansive and flexible approach towards a
determination as to whether a patent is obvious and invalid. This ruling may
make it more difficult for patent holders to secure or maintain existing
patents. At the present time, we are unable to predict the impact, if any, that
this recent ruling will have on our currently issued or future patents. As a
result of the Supreme Court ruling, however, it may be more difficult for us to
defend our currently issued patents or to obtain additional patents in the
future. If we are unable to defend our currently issued patents, or to obtain
new patents for any reason, our business would suffer.
We
have a history of losses and may never be profitable.
Since
inception, we have incurred significant losses and we expect to incur losses
until such time, if ever, as we are able to achieve sufficient levels of revenue
from the commercial exploitation of our OLED technologies and materials to
support our operations. This may never occur because:
·
|
OLED
technologies might not be adopted for broad commercial
usage;
|
·
|
markets
for flat panel displays and solid-state lighting products utilizing OLED
technologies may be limited; and
|
·
|
amounts
we can charge for access to our OLED technologies and materials may not be
sufficient for us to make a profit.
|
We
may require additional funding in the future in order to continue our
business.
Our
capital requirements have been and will continue to be significant. We may
require additional funding in the future for the research, development and
commercialization of our OLED technologies and materials, to obtain and maintain
patents and other intellectual property rights in these technologies and
materials, and for working capital and other purposes, the timing and amount of
which are difficult to ascertain. Our cash on hand may not be sufficient to meet
all of our future needs. When we need additional funds, such funds may not be
available on commercially reasonable terms or at all. If we cannot obtain more
money when needed, our business might fail. Additionally, if we attempt to raise
money in an offering of shares of our common stock, preferred stock, warrants or
depositary shares, or if we engage in acquisitions involving the issuance of
such securities, the issuance of these shares will dilute our then-existing
shareholders.
Many
of our competitors have greater resources, which may make it difficult for us to
compete successfully against them.
The flat
panel display and solid-state lighting industries are characterized by intense
competition. Many of our competitors have better name recognition and greater
financial, technical, marketing, personnel and research capabilities than us.
Because of these differences, we may never be able to compete successfully in
these markets.
We
rely solely on PPG Industries to manufacture the OLED materials we use and sell
to product manufacturers.
Our
business prospects depend significantly on our ability to obtain proprietary
OLED materials for our own use and for sale to product manufacturers. Our
agreement with PPG Industries provides us with a source for these materials for
development
and evaluation purposes, as well as for commercial purposes. This agreement,
however, is scheduled to expire on December 31, 2011. Our inability to
continue obtaining these OLED materials from PPG Industries or another source
would have a material adverse effect on our revenues from sales of these
materials, as well as on our ability to perform development work and to support
those product manufacturers currently evaluating our OLED technologies and
materials for possible commercial use.
Because
the vast majority of OLED product manufacturers are located in the Asia-Pacific
region, we are subject to international operational, financial, legal and
political risks which may negatively impact our operations.
Many of
our licensees and prospective licensees have a majority of their operations in
countries other than the United States, particularly in the Asia-Pacific region.
Risks associated with our doing business outside of the United States include,
without limitation:
·
|
compliance
with a wide variety of foreign laws and
regulations;
|
·
|
legal
uncertainties regarding taxes, tariffs, quotas, export controls, export
licenses and other trade barriers;
|
·
|
economic
instability in the countries of our licensees, causing delays or
reductions in orders for their products and therefore our
royalties;
|
·
|
political
instability in the countries in which our licensees operate, particularly
in South Korea relating to its disputes with North Korea and in Taiwan
relating to its disputes with
China;
|
·
|
difficulties
in collecting accounts receivable and longer accounts receivable payment
cycles; and
|
·
|
potentially
adverse tax consequences.
|
Any of
these factors could impair our ability to license our OLED technologies and sell
our OLED materials, thereby harming our business.
The
U.S. government has rights to our OLED technologies that might prevent us from
realizing the benefits of these technologies.
The U.S.
government, through various government agencies, has provided and continues to
provide funding to us, Princeton University, the University of Southern
California and the University of Michigan for research activities related to
certain aspects of our OLED technologies. Because we have been provided with
this funding, the government has rights to these OLED technologies that could
restrict our ability to market them to the government for military and other
applications, or to third parties for commercial applications. Moreover, if the
government determines that we have not taken effective steps to achieve
practical application of these OLED technologies in any field of use in a
reasonable time, the government could require us to grant licenses to other
parties in that field of use. Any of these occurrences would limit our ability
to obtain the full benefits of our OLED technologies.
If
we cannot keep our key employees or hire other talented persons as we grow, our
business might not succeed.
Our
performance is substantially dependent on the continued services of senior
management and other key personnel, and on our ability to offer competitive
salaries and benefits to our employees. We do not have employment agreements
with any of our management or other key personnel. Additionally, competition for
highly skilled technical, managerial and other personnel is intense. We might
not be able to attract, hire, train, retain and motivate the highly skilled
managers and employees we need to be successful. If we fail to attract and
retain the necessary technical and managerial personnel, our business will
suffer and might fail.
We
can issue shares of preferred stock that may adversely affect the rights of
shareholders of our common stock.
Our
Articles of Incorporation authorize us to issue up to 5,000,000 shares of
preferred stock with designations, rights and preferences determined from
time-to-time by our Board of Directors. Accordingly, our Board of Directors is
empowered, without shareholder approval, to issue preferred stock with dividend,
liquidation, conversion, voting or other rights superior to those of
shareholders of our common stock. For example, an issuance of shares of
preferred stock could:
·
|
adversely
affect the voting power of the shareholders of our common
stock;
|
·
|
make
it more difficult for a third party to gain control of
us;
|
·
|
discourage
bids for our common stock at a premium;
or
|
·
|
otherwise
adversely affect the market price of our common
stock.
|
As of
March 9, 2009, we have issued and outstanding 200,000 shares of Series A
Nonconvertible Preferred Stock, all of which are held by an entity controlled by
members of the family of Sherwin I. Seligsohn, our Founder and Chairman of the
Board of Directors. Our Board of Directors has authorized and issued other
shares of preferred stock in the past, none of which are currently outstanding,
and may do so again at any time in the future.
If
the price of our common stock goes down, we may have to issue more shares than
are presently anticipated to be issued under our agreement with PPG
Industries.
Under our
agreement with PPG Industries, we are required to issue to PPG Industries shares
of our common stock as partial payment for services rendered by it, though under
limited circumstances we are required to compensate PPG Industries fully in cash
in lieu of common stock. The number of shares of common stock that we are
required to deliver to PPG Industries is based on a specified
formula. Under this formula, the lower the price of our common stock
at and around the time of issuance, the greater the number of shares that we are
required to issue to PPG Industries. Lower than anticipated market prices for
our common stock, and correspondingly greater numbers of shares issuable to PPG
Industries, with a resulting increase in the number of shares available for
public sale, could cause people to sell our common stock, including in short
sales, which could drive down the price of our common stock, thus reducing its
value and perhaps hindering our ability to raise additional funds in the future.
In addition, such an increase in the number of outstanding shares of our common
stock would further dilute existing holders of this stock.
Our
executive officers and directors own a large percentage of our common stock and
could exert significant influence over matters requiring shareholder approval,
including takeover attempts.
Our
executive officers and directors, their respective affiliates and the adult
children of Sherwin Seligsohn, our Founder and Chairman of the Board of
Directors, beneficially own, as of March 9, 2009, approximately 15% of the
outstanding shares of our common stock. Accordingly, these individuals may, as a
practical matter, be able to exert significant influence over matters requiring
approval by our shareholders, including the election of directors and the
approval of mergers or other business combinations. This concentration also
could have the effect of delaying or preventing a change in control of
us.
The
market price of our common stock might be highly volatile.
The
market price of our common stock might be highly volatile, as has been the case
with our common stock in the past as well as the securities of many companies,
particularly other small and emerging-growth companies. We have included in the
section of this report entitled “Market for Registrant’s Common Equity, Related
Stockholder Matters and Issuer Purchases of Equity Securities,” a table
indicating the high and low closing prices of our common stock as reported on
the NASDAQ Global Market for the past two years. Factors such as the following
may have a significant impact on the market price of our common stock in the
future:
·
|
our
expenses and operating results;
|
·
|
announcements
by us or our competitors of technological developments, new product
applications or license arrangements;
and
|
·
|
other
factors affecting the flat panel display and solid-state lighting
industries in general.
|
Our
operating results may have significant period-to-period fluctuations, which
would make it difficult to predict our future performance.
Due to
the current stage of commercialization of our OLED technologies and the
significant development and manufacturing objectives that we and our licensees
must achieve to be successful, our quarterly operating results will be difficult
to predict and may vary significantly from quarter to quarter.
We
believe that period-to-period comparisons of our operating results are not a
reliable indicator of our future performance at this time. Among other factors
affecting our period-to-period results, our license and technology development
fees often consist of large one-time or annual payments, resulting in
significant fluctuations in our revenues. If, in some future period, our
operating results or business outlook fall below the expectations of securities
analysts or investors, our stock price would be likely to decline and investors
in our common stock may not be able to resell their shares at or above their
purchase price. Broad market, industry and global economic factors may also
materially reduce the market price of our common stock, regardless of our
operating performance.
The
issuance of additional shares of our common stock could drive down the price of
our stock.
The price
of our common stock might decrease if:
·
|
other
shares of our common stock that are currently subject to restriction on
sale become freely salable, whether through an effective registration
statement or based on Rule 144 under the Securities Act of 1933, as
amended; or
|
·
|
we
issue additional shares of our common stock that might be or become freely
salable, including shares that would be issued upon conversion of our
preferred stock or the exercise of outstanding warrants and
options.
|
Because
we do not intend to pay dividends, shareholders will benefit from an investment
in our common stock only if it appreciates in value.
We have
never declared or paid any cash dividends on our common stock. We currently
intend to retain our future earnings, if any, to finance further research and
development and do not expect to pay any cash dividends in the foreseeable
future. As a result, the success of an investment in our common stock will
depend upon any future appreciation in its value. There is no guarantee that our
common stock will appreciate in value or even maintain the price at which
shareholders have purchased their shares.
|
UNRESOLVED
STAFF COMMENTS
|
None.
Our
corporate offices and research and development laboratories are located at 375
Phillips Boulevard in Ewing, New Jersey. On December 1, 2004, we acquired
the building and property at which this facility is located. During 2005, we
conducted a two-stage expansion of our laboratory and office space in the
building. We currently occupy the entire 40,200 square feet facility. Through
February 2008, we leased a small portion of this office space to Global Photonic
Energy Corporation (GPEC).
ITEM
3.
|
LEGAL
PROCEEDINGS
|
Notice
of Opposition to European Patent No. 0946958
On
December 8, 2006, Cambridge Display Technology, Ltd. (“CDT”), which was acquired
in 2007 by Sumitomo Chemical Company (“Sumitomo”), filed a Notice of Opposition
to European Patent No. 0946958 (the “EP ‘958 patent”). The EP ‘958
patent, which was issued on March 8, 2006, is a European counterpart patent to
U.S. patents 5,844,363, 6,602,540, 6,888,306 and 7,247,073. These
patents relate to our FOLED technology. They are exclusively licensed
to us by Princeton, and under the license agreement we are required to pay all
legal costs and fees associated with this proceeding.
The
European Patent Office (the “EPO”) set a date of May 12, 2007 for us to file a
response to the facts and arguments presented by CDT in its Notice of
Opposition. The response was timely filed. The opponents
then filed their reply to our response on December 7, 2007. We have
decided that there is no need to file another response before the oral hearing
date is set. We are currently waiting for the EPO to notify us of the
date of the oral hearing.
At this
stage of the proceeding, we cannot make any prediction as to the probable
outcome of this opposition. However, based on an analysis of the
evidence presented to date, we continue to believe there is a substantial
likelihood that the patent being challenged will be declared valid, and that all
or a significant portion of its claims will be upheld.
Notices
of Opposition to European Patent No. 1449238
On March
8, 2007, Sumation Company Limited (“Sumation”), a joint venture between Sumitomo
and CDT, filed a first Notice of Opposition to European Patent No. 1449238 (the
“EP ‘238 patent”). The EP ‘238 patent, which was issued on November
2, 2006, is a European counterpart patent, in part, to U.S. patents 6,830,828,
6,902,830, 7,001,536 and 7,291,406, and to pending U.S. patent application
11/879,379, filed on July 16, 2007. These patents and this patent
application relate to our PHOLED technology. They are exclusively
licensed to us by Princeton, and under the license agreement we are required to
pay all legal costs and fees associated with this proceeding.
Two other
parties filed additional oppositions to the EP ‘238 patent just prior to the
August 2, 2007 expiration date for such filings. On July 24, 2007,
Merck Patent GmbH, of Darmstadt, Germany, filed a second Notice of Opposition to
the EP ‘238 patent, and on July 27, 2007, BASF Aktiengesellschaft, of Mannheim,
Germany, filed a third Notice of Opposition to the EP ‘238
patent. The EPO combined all three oppositions into a single
opposition proceeding.
The EPO
set a January 6, 2008 due date for us to file our response to the
opposition. We requested a two-month extension to file this response,
and we subsequently filed our response in a timely manner. We are
currently waiting for the EPO to notify us of the date of the oral
hearing. We are also waiting to see whether the other parties in the
opposition file any additional documents, to which we may respond.
At this
stage of the proceeding, we cannot make any prediction as to the probable
outcome of the opposition. However, based on an analysis of the
evidence presented to date, we continue to believe there is a substantial
likelihood that the patent being challenged will be declared valid, and that all
or a significant portion of its claims will be upheld.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY
HOLDERS
|
The
following table sets forth certain information with respect to our executive
officers as of March 9, 2009:
Name
|
Age
|
Position
|
Sherwin
I. Seligsohn
|
73
|
Founder
and Chairman of the Board of Directors
|
Steven
V. Abramson
|
57
|
President,
Chief Executive Officer and Director
|
Sidney
D. Rosenblatt
|
61
|
Executive
Vice President, Chief Financial Officer, Treasurer, Secretary and
Director
|
Julia
J. Brown
|
48
|
Vice
President and Chief Technical Officer
|
Janice
K. Mahon
|
51
|
Vice
President of Technology Commercialization and General Manager of Material
Supply Business
|
Our Board
of Directors has appointed these executive officers to hold office until their
successors are duly appointed.
Sherwin I.
Seligsohn is our Founder and has been the Chairman of our Board of
Directors since June 1995. He also served as our Chief Executive
Officer from June 1995 through December 2007, and as our President from June
1995 through May 1996. Mr. Seligsohn serves as the sole Director,
President and Secretary of American Biomimetics Corporation, International
Multi-Media Corporation, and Wireless Unified Network Systems
Corporation. He is also Chairman of the Board of Directors, President
and Chief Executive Officer of Global Photonic Energy
Corporation. From June 1990 to October 1991, Mr. Seligsohn was
Chairman Emeritus of InterDigital Communications, Inc. (InterDigital), formerly
International Mobile Machines Corporation. He founded InterDigital
and from August 1972 to June 1990 served as its Chairman of the Board of
Directors. Mr. Seligsohn is a member of the Industrial Advisory Board
of the Princeton Institute for the Science and Technology of Materials (PRISM)
at Princeton University.
Steven V.
Abramson is our President and Chief Executive Officer, and has been a
member of our Board of Directors since May 1996. Mr. Abramson served
as our President and Chief Operating Officer from May 1996 through December
2007. From March 1992 to May 1996, Mr. Abramson was Vice President,
General Counsel, Secretary and Treasurer of Roy F. Weston, Inc., a worldwide
environmental consulting and engineering firm. From December 1982 to
December 1991, Mr. Abramson held various positions at InterDigital, including
General Counsel, Executive Vice President and General Manager of the Technology
Licensing Division.
Sidney D.
Rosenblatt is an Executive Vice President and has been our Chief
Financial Officer, Treasurer and Secretary since June 1995. He also
has been a member of our Board of Directors since May 1996. Mr.
Rosenblatt is the owner of and served as the President of S. Zitner Company from
August 1990 through December 1998. From May 1982 to August 1990, Mr.
Rosenblatt served as the Senior Vice President, Chief Financial Officer and
Treasurer of InterDigital.
Julia J. Brown,
Ph.D. is a Senior Vice President and has been our Chief Technical Officer
since June 2002. She joined us in June 1998 as our Vice President of Technology
Development. From November 1991 to June 1998, Dr. Brown was a Research
Department Manager at Hughes Research Laboratories where she directed the pilot
line production of high-speed Indium Phosphide-based integrated circuits for
insertion into advanced airborne radar and satellite communication systems. Dr.
Brown received an M.S. and Ph.D. in Electrical Engineering/Electrophysics at the
University of Southern California under the advisement of Professor Stephen R.
Forrest. Dr. Brown has served as an Associate Editor of the Journal of
Electronic Materials and as an elected member of the Electron Device Society
Technical Board. She co-founded an international engineering mentoring program
sponsored by the Institute of Electrical and Electronics Engineers (“IEEE”) and
is a Fellow of the IEEE. Dr. Brown has served on numerous technical
conference committees and is presently a member of the Society of Information
Display.
Janice K.
Mahon has been our Vice President of Technology Commercialization since
January 1997, and became the General Manager of our Materials Supply Business in
January 2007. From 1992 to 1996, Ms. Mahon was Vice President of SAGE
Electrochromics, Inc., a thin-film electrochromic technology company, where she
oversaw a variety of business development, marketing and finance and
administrative activities. From 1984 to 1989, Ms. Mahon was a Vice President and
General Manager for Chronar Corporation, a leading developer and manufacturer of
amorphous silicon photovoltaic (PV) panels. Prior to that, Ms. Mahon worked as
Senior Engineer for the Industrial Chemicals Division of FMC Corporation. Ms.
Mahon received her B. S. in Chemical Engineering from Rensselaer Polytechnic
Institute in 1979, and an M. B. A. from Harvard University in 1984. Ms. Mahon
has been a member of the USDC Technical Council since 1997, and a member of its
Governing Board since January 2008.
ITEM
5.
|
MARKET
FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
PURCHASES OF EQUITY SECURITIES
|
Our
Common Stock
Our
common stock is quoted on the NASDAQ Global Market under the symbol “PANL.” The
following table sets forth, for the periods indicated, the high and low closing
prices of our common stock as reported on the NASDAQ Global Market.
|
High
Close
|
Low
Close
|
2008
|
|
|
Fourth
Quarter…………………………………….
|
$11.75
|
$5.51
|
Third
Quarter……………………………………….
|
16.08
|
10.96
|
Second
Quarter……………………………………..
|
15.95
|
12.32
|
First
Quarter………………………………………..
|
20.78
|
13.43
|
2007
|
|
|
Fourth
Quarter…………………………………….
|
$21.88
|
$15.67
|
Third
Quarter……………………………………….
|
18.44
|
13.80
|
Second
Quarter……………………………………..
|
17.70
|
14.59
|
First
Quarter………………………………………..
|
15.80
|
12.03
|
As of
March 9, 2009, there were approximately 17,500 holders of record of our common
stock.
We have
never declared or paid cash dividends on our common stock. We currently intend
to retain any future earnings for the operation and expansion of our business.
We do not anticipate declaring or paying cash dividends on our common stock in
the foreseeable future. Any future payment of cash dividends on our common stock
will be at the discretion of our Board of Directors and will depend upon our
results of operations, earnings, capital requirements, contractual restrictions
and other factors deemed relevant by our Board of Directors.
Issuance
of Securities to PPG Industries
Under our
OLED Materials Supply and Service Agreement, we have the option to issue shares
of our common stock to PPG Industries on a periodic basis as payment for up to
50% of the amounts due for certain services performed for us by PPG Industries.
During the quarter ended December 31, 2008, we issued an aggregate of 48,142
shares of our common stock to PPG Industries as partial payment for these
services. The shares were issued in reliance on the exemption from
registration contained in Section 4(2) of the Securities Act of 1933, as
amended.
Receipt
of Shares Upon the Exercise of Outstanding Stock Options
As
illustrated in the following table, on December 8, 2008, certain of our
executive officers and a former executive officer tendered to us a total of
46,286 shares of our common stock as payment of the exercise price for stock
options that had previously been granted to these individuals under our Equity
Compensation Plan. These stock options had an exercise price of $4.50
per share, and an expiration date of December 18, 2008. The shares we received
were valued at $8.75 per share, which was the closing price of our common stock
on the NASDAQ Global Market on December 8, 2008. The total value of
the shares we received was $405,003.
The
following table provides information relating to the shares we received during
the fourth quarter of 2008.
Period
|
|
Total
Number of Shares Purchased
|
|
Average
Price Paid per Share
|
|
Total
Number of Shares Purchased as Part of Publicly Announced
Program
|
|
Approximate
Dollar Value of Shares that May Yet Be Purchased Under the
Program
|
|
|
|
|
|
|
|
|
|
October
1 – October 31
|
|
--
|
|
--
|
|
--
|
|
--
|
November
1 – November 30
|
|
--
|
|
--
|
|
--
|
|
--
|
December
1 – December 31
|
|
46,286
|
|
$8.75
|
|
46,286
|
|
--
|
Total
|
|
46,286
|
|
$8.75
|
|
46,286
|
|
--
|
The
performance graph below compares the change in the cumulative shareholder return
of our common stock from December 31, 2003 to December 31, 2008, with the
percentage change in the cumulative total return over the same period on (i) the
Russell 2000 Index, and (ii) the Nasdaq Electronics Components
Index. This performance graph assumes an initial investment of $100
on December 31, 2002 in each of our common stock, the Russell 2000 Index and the
Nasdaq Electronics Components Index.
|
Cumulative
Total Return
|
|
12/03
|
12/04
|
12/05
|
12/06
|
12/07
|
12/08
|
Universal
Display Corp.
|
100.00
|
65.60
|
76.60
|
109.40
|
150.66
|
68.88
|
Russell
2000
|
100.00
|
118.33
|
123.72
|
146.44
|
144.15
|
95.44
|
NASDAQ
Electronic Components
|
100.00
|
78.30
|
84.93
|
79.38
|
92.16
|
47.68
|
The
following selected condensed consolidated financial data has been derived from,
and should be read in conjunction with, our Consolidated Financial Statements
and the notes thereto, and with “Management’s Discussion and Analysis of
Financial Condition and Results of Operations,” included elsewhere in this
report.
|
|
Year
Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
Operating
Results:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
revenue
|
|
$ |
11,075,224 |
|
|
$ |
11,305,907 |
|
|
$ |
11,921,292 |
|
|
$ |
10,147,995 |
|
|
$ |
7,006,913 |
|
Research
and development expense
|
|
|
22,257,634 |
|
|
|
20,909,262 |
|
|
|
19,562,004 |
|
|
|
18,798,024 |
|
|
|
16,226,517 |
|
General
and administrative expense
|
|
|
10,170,593 |
|
|
|
9,569,381 |
|
|
|
8,902,462 |
|
|
|
7,704,931 |
|
|
|
7,052,047 |
|
Interest
income
|
|
|
2,607,897 |
|
|
|
3,599,229 |
|
|
|
2,168,933 |
|
|
|
1,419,858 |
|
|
|
795,620 |
|
Income
tax benefit
|
|
|
962,478 |
|
|
|
804,980 |
|
|
|
544,567 |
|
|
|
424,207 |
|
|
|
612,966 |
|
Net
loss
|
|
|
(19,139,736 |
) |
|
|
(15,975,841 |
) |
|
|
(15,186,804 |
) |
|
|
(15,801,612 |
) |
|
|
(15,776,574 |
) |
Net
loss attributable to common shareholders
|
|
|
(19,139,736 |
) |
|
|
(15,975,841 |
) |
|
|
(15,186,804 |
) |
|
|
(15,801,612 |
) |
|
|
(15,906,198 |
) |
Net
loss per share, basic and diluted
|
|
|
(0.53 |
) |
|
|
(0.47 |
) |
|
|
(0.49 |
) |
|
|
(0.56 |
) |
|
|
(0.59 |
) |
Balance
Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
assets
|
|
$ |
96,228,505 |
|
|
$ |
105,000,071 |
|
|
$ |
72,331,536 |
|
|
$ |
73,819,417 |
|
|
$ |
73,892,163 |
|
Current
liabilities
|
|
|
15,769,505 |
|
|
|
12,790,531 |
|
|
|
14,382,673 |
|
|
|
11,974,854 |
|
|
|
7,404,278 |
|
Long-tem
debt
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
4,200,000 |
|
Shareholders’
equity
|
|
|
76,714,463 |
|
|
|
89,215,957 |
|
|
|
54,382,363 |
|
|
|
57,616,463 |
|
|
|
59,187,885 |
|
Other
Financial Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Working
capital
|
|
$ |
64,600,256 |
|
|
$ |
73,979,638 |
|
|
$ |
37,422,740 |
|
|
$ |
38,347,913 |
|
|
$ |
40,630,913 |
|
Capital
expenditures
|
|
|
1,277,098 |
|
|
|
1,225,857 |
|
|
|
2,349,033 |
|
|
|
5,656,905 |
|
|
|
7,418,053 |
|
Weighted
average shares used in computing basic and diluted net loss per common
share
|
|
|
35,932,372 |
|
|
|
33,759,581 |
|
|
|
30,855,297 |
|
|
|
28,462,925 |
|
|
|
26,791,158 |
|
Shares
of common stock outstanding, end of period
|
|
|
36,131,981 |
|
|
|
35,563,201 |
|
|
|
31,385,408 |
|
|
|
29,545,471 |
|
|
|
27,903,385 |
|
ITEM
7.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
The
following discussion and analysis of our financial condition and results of
operations should be read in conjunction with the section entitled “Selected
Financial Data” in this report and our Consolidated Financial Statements and
related notes to this report. This discussion and analysis contains
forward-looking statements based on our current expectations, assumptions,
estimates and projections. These forward-looking statements involve risks and
uncertainties. Our actual results could differ materially from those indicated
in these forward-looking statements as a result of certain factors, as more
fully discussed in Section 1A of this report, entitled “Risk
Factors.”
Overview
We are a
leader in the research, development and commercialization of organic light
emitting diode, or OLED, technologies for use in flat panel display, solid-state
lighting and other applications. Since 1994, we have been exclusively engaged,
and expect to continue to be exclusively engaged, in funding and performing
research and development activities relating to OLED technologies and materials,
and in attempting to commercialize these technologies and materials. Our
revenues are generated through contract research, sales of development and
commercial chemicals, license fees and royalties, technology development and
evaluation agreements, and commercialization assistance agreements. In the
future, we anticipate that the revenues from licensing our intellectual property
will become a more significant part of our revenue stream.
While we
have made significant progress over the past few years developing and
commercializing our family of OLED technologies (PHOLED, TOLED, FOLED, etc.) and
materials, we have incurred significant losses and will likely continue to do so
until our OLED technologies and materials become more widely adopted by product
manufacturers. We
have
incurred significant losses since our inception, resulting in an accumulated
deficit of $180,470,203 as of December 31, 2008.
We
anticipate fluctuations in our annual and quarterly results of operations due to
uncertainty regarding:
·
|
the
timing of our receipt of license fees and royalties, as well as fees for
future technology development and
evaluation;
|
·
|
the
timing and volume of sales of our OLED materials for both commercial usage
and evaluation purposes;
|
·
|
the
timing and magnitude of expenditures we may incur in connection with our
ongoing research and development activities;
and
|
·
|
the
timing and financial consequences of our formation of new business
relationships and alliances.
|
Critical
Accounting Policies and Estimates
The
discussion and analysis of our financial condition and results of operations is
based on our consolidated financial statements, which have been prepared in
accordance with U.S. generally accepted accounting principles. The preparation
of these financial statements requires us to make estimates and judgments that
affect our reported assets and liabilities, revenues and expenses, and other
financial information. Actual results may differ significantly from our
estimates under other assumptions and conditions.
We
believe that our accounting policies related to revenue recognition and deferred
license fees, valuation of acquired technology and stock-based compensation, as
described below, are our “critical accounting policies” as contemplated by the
SEC. These policies, which have been reviewed with our Audit Committee, are
discussed in greater detail below.
Revenue
Recognition and Deferred License Fees
Contract
research revenue represents reimbursements by the U.S. government for all or a
portion of the research and development expenses we incur related to our
government contracts. Revenue is recognized proportionally as research and
development expenses are incurred or as defined milestones are achieved. In
order to ascertain the revenue associated with these contracts for a period, we
estimate the proportion of related research and development expenses incurred
and whether defined milestones have been achieved. Different estimates would
result in different revenues for the period.
We
receive non-refundable cash payments under certain development and technology
evaluation agreements with our customers. These payments are generally
recognized as revenue over the term of the agreement. On occasion,
however, these payments are creditable against license fees and/or royalties
payable by the customer if a license agreement is subsequently executed with the
customer. These payments are classified as deferred license fees or
deferred revenues, and are recorded as liabilities in the consolidated balance
sheet until such time as revenue can be recognized. Revenue is
deferred until a license agreement is executed or negotiations have ceased and
there is no appreciable likelihood of executing a license agreement with the
customer. If a license agreement is executed, these payments are recorded as
revenue over the estimated useful life of the licensed technology and the
revenue is classified based on the terms of the license. Otherwise,
these payments are recorded as revenue at the time negotiations with the
customer show that there is no appreciable likelihood of executing a license
agreement. If we used different estimates for the useful life of the
licensed technology, reported revenue during the relevant period would differ.
As of December 31, 2008, $12,632,594 was recorded as deferred license fees and
deferred revenue, of which $6,966,667 may be recognized under license agreements
that have not yet been executed or deemed effective.
Valuation
of Acquired Technology
We
regularly review our acquired OLED technologies for events or changes in
circumstances that might indicate the value of these technologies may have been
impaired. Factors considered important that could cause impairment include,
among others, significant changes in our anticipated future use of these
technologies and our overall business strategy as it pertains to these
technologies, particularly in light of patents owned by others in the same field
of use. When factors indicate that long-lived assets should be evaluated for
possible impairment, the Company uses an estimate of the related
undiscounted
cash
flows in measuring whether the long-lived asset should be written down to fair
value. Measurement of the amount of impairment would be based on generally
accepted valuation methodologies, as deemed appropriate. As of December 31,
2008, we believe that no revision of the remaining useful lives or write-down of
our acquired technology was required for 2008, nor was such a revision needed in
2007 or 2006. The net book value of our acquired technology was $2,929,344 as of
December 31, 2008.
Valuation
of Stock-Based Compensation
We
account for our stock-based compensation (see Notes 2 and 10 of the Notes to
Consolidated Financial Statements) under Statement of Financial Accounting
Standards (SFAS) No. 123(R), Share-Based Payment. We
recognize in the statement of operations the grant-date fair value of stock
options and other equity-based compensation issued to employees and directors.
We account for our stock option and warrant grants to non-employees in exchange
for goods or services in accordance with SFAS No. 123(R) and Emerging Issues
Task Force 96-18 (EITF 96-18). SFAS No. 123(R) and EITF 96-18 require that we
record an expense for our option and warrant grants to non-employees based on
the fair value of the options and warrants, which is remeasured over the vesting
period of such awards.
We use
the Black-Scholes option-pricing model to estimate the fair value of options we
have granted for purposes of recording charges to the statement of operations.
In order to calculate the fair value of the options, assumptions are made for
certain components of the model, including expected volatility, expected
dividend yield rate and expected option life. Although we use available
resources and information when setting these assumptions, changes to the
assumptions could cause significant adjustments to the valuation of future
grants or the remeasurement of non-employee awards.
Results
of Operations
Year
Ended December 31, 2008 Compared to Year Ended December 31, 2007
We had a
net loss of $19,139,736 (or $0.53 per diluted share) for the year ended
December 31, 2008, compared to a net loss of $15,975,841 (or $0.47 per
diluted share) for the year ended December 31, 2007. The increase in net loss
was primarily due to:
·
|
an
increase in operating expenses of $2,060,373;
and
|
·
|
a
decrease in interest income of
$991,332.
|
Our
revenues were $11,075,224 for the year ended December 31, 2008, compared to
$11,305,907 for the same period in 2007. Commercial revenue increased to
$5,630,758 for 2008 from $4,428,048 for 2007. Commercial revenue
relates to the incorporation our OLED technologies and materials into our
customers’ commercial products, and includes commercial chemical revenue,
royalty and license revenues, and commercialization assistance
revenue. Developmental revenue decreased to $5,444,466 for 2008 from
$6,877,859 for 2007. Developmental revenue relates to OLED technology
and material development activities for which we are paid, and includes contract
research revenue, development chemical revenue and technology development
revenue. We believe these revenue categories, which now combine accounts
previously reported separately, better reflect our business strategies and core
business efforts.
Our
commercial chemical revenue and our royalty and license revenues for the year
ended December 31, 2008 were $3,751,890 and $1,711,970, respectively, compared
to $3,599,677 and $828,371, respectively, for the same period in
2007. For the year ended December 31, 2008, the majority of our
commercial chemical revenue and our royalty and license revenues were from
Samsung SDI Co., Ltd., whose OLED business was transferred to Samsung Mobile
Display Co., Ltd. (Samsung SMD) in September 2008. Samsung SMD
represented approximately 68% of our commercial revenue and approximately 42% of
our total revenue in 2008. We also recorded commercial chemical revenue and
license revenue from sales of small quantities of our proprietary OLED materials
to two other commercial chemical customers during the year. For the year ended
December 31, 2007, the majority of our commercial chemical revenue and our
royalty and license revenues were also from Samsung SMD. For 2007, we
also recorded commercial chemical revenue and license revenue from sales of
small quantities of our proprietary OLED materials to three other commercial
chemical customers. We cannot accurately predict how long our material sales to
Samsung SMD or other customers will continue, as they frequently update and
alter their product offerings. Continued sales of our OLED materials to these
customers will depend on several factors, including, pricing, availability,
continued technical improvement and competitive product offerings.
We
recorded royalty revenue of $796,838 for the year ended December 31, 2008,
compared to $61,317 for the same period in 2007. The increase in
royalty revenue was due mainly to increased sales of licensed products by
Samsung SMD. For both 2008 and 2007, we received royalty revenue from Samsung
SMD under a patent license agreement entered into in April 2005. Under this
agreement, we receive royalty reports at a specified period of time after the
end of the quarter during which royalty-bearing products are sold by Samsung
SMD. Consequently, our royalty revenues from Samsung SMD for the years ended
December 31, 2008 and 2007 represent royalties for licensed products sold
by Samsung SMD during the 12-month periods ended September 30, 2008 and 2007,
respectively. In addition, we recorded a small amount of royalty
revenue from two other customers in 2008.
License
revenue for the years ended December 31, 2008 and 2007 included license fees of
$915,132 and $767,054, respectively. For both years, we received license revenue
under our patent license agreement with Samsung SMD and under a cross-license
agreement we executed with DuPont Displays, Inc. (DuPont) in
December 2002. License revenue for the year ended December 31,
2008 also included amounts received under a patent license agreement we entered
into with Konica Minolta Holdings, Inc. (Konica Minolta) in August 2008, a joint
development agreement we previously entered into with a subsidiary of Konica
Minolta, and two other agreements we entered into during the fourth quarter of
2008. Under our agreements with Samsung SMD, DuPont and Konica
Minolta, we received upfront payments that have been classified as deferred
license fees and deferred revenue. The deferred license fees are being
recognized as license revenue over the term of the agreement with Samsung SMD
and, based on current assumptions, over 10 years with DuPont and Konica
Minolta.
Commercial
revenue for the year ended December 31, 2008 also included $166,898 in
commercialization assistance revenue that we received under a business support
agreement executed during the fourth quarter of 2008. We received no such
revenue for the year ended December 31, 2007.
We earned
$2,815,062 in contract research revenue from agencies of the U.S. Government for
the year ended December 31, 2008, compared to $4,600,693 in corresponding
revenue for the same period in 2007. The decrease was due principally
to the timing of work performed and costs incurred in connection with several
new and completed government programs during 2008. However, the
overall value of our government contracts remained relatively constant during
both years.
We earned
$2,047,823 in development chemical revenue for the year ended December 31, 2008,
compared to $1,049,854 in corresponding revenue for the year ended December 31,
2007. Our development chemical customer base increased significantly during
2008, as did the average dollar value of development chemical sales per
customer. We cannot accurately predict the timing and frequency of
development chemical purchases by our customers due to participants in the OLED
industry having differing OLED technology development and product launch
strategies, which are subject to change at any time.
We
recognized $581,581 in technology development revenue for the year ended
December 31, 2008, compared to $1,227,312 in corresponding revenue for the same
period in 2007. Technology development revenue for 2008 included
amounts received under a new joint development agreement we entered into in
August 2008. Payments received under this new agreement are
classified as deferred revenue and are being recognized as technology
development revenue over a period of three years. During 2007, we
completed work on a major joint development program with another
customer. Payments received under this agreement accounted for all of
our technology development revenue for 2007. In 2008, we began work
on two new joint development programs with this customer, but neither of these
programs is as large as the program completed in 2007. Technology
development revenue for 2008 also included amounts received for a technical
assistance program that began in November 2008. The amount and timing
of our receipt of fees for technology development and similar services is
difficult to predict due to participants in the OLED industry having different
technology development strategies, which are subject to change at any
time.
We
received $3,715,580 and $1,150,000 in cash payments during 2008 and 2007,
respectively, from various customers for license rights granted to these
customers, and/or for joint development work performed or technical assistance
provided at the request of these customers. These payments were
recorded as deferred revenue and deferred license fees and we are recognizing
these over the life of the agreements to which they relate.
We
incurred research and development expenses of $22,257,634 for the year ended
December 31, 2008, compared to $20,909,262 for the year ended
December 31, 2007. The increase was mainly due to:
·
|
an
increase in patent costs of
$800,099;
|
·
|
an
increase of $396,885 attributable to higher operating costs associated
with our Ewing facility; and
|
·
|
an
increase of $344,087 in personnel costs due mainly to increased personnel
during 2008.
|
General
and administrative expenses were $10,170,593 for the year ended December 31,
2008, compared to $9,569,381 for the same period in 2007. The increase was
mainly due to an increase of $593,032 in personnel costs.
Interest
income decreased to $2,607,897 for the year ended December 31, 2008, compared to
$3,599,229 for the same period in 2007. The decrease was mainly
attributable to decreased rates of return on investments during 2008, compared
to rates of return during 2007. Due to current market conditions, we
anticipate that these lower rates of return will continue for the foreseeable
future.
During
2008, we sold approximately $12.5 million of our state-related income tax net
operating losses (NOLs) under the New Jersey Technology Tax Certificate Transfer
Program. In 2008, we received proceeds of $962,478 from our sale of these NOLs
and research and development tax credits, and we recorded these proceeds as an
income tax benefit. In 2007, we received proceeds of $804,980 from
corresponding sales of approximately $7.8 million in NOLs and research and
development tax credits. We expect to sell a similar quantity of NOLs
and tax credits to New Jersey under the program in 2009, if
approved.
Year
Ended December 31, 2007 Compared to Year Ended December 31,
2006
We had a
net loss of $15,975,841 (or $0.47 per diluted share) for the year ended
December 31, 2007, compared to a net loss of $15,186,804 (or $0.49 per
diluted share) for the year ended December 31, 2006. The increase in net
loss was primarily due to:
·
|
a
decrease in revenues of $615,385;
and
|
·
|
an
increase in operating expenses of
$1,866,356.
|
The
increase in operating loss was offset to some extent by an increase of
$1,430,296 in interest income. The decrease in net loss per diluted share,
despite the increase in total net loss, resulted from an increase in the
weighted average number of shares of our common stock outstanding in 2007, as
compared to 2006.
Our
revenues were $11,305,907 for the year ended December 31, 2007, compared to
$11,921,292 for the year ended December 31, 2006. Commercial revenue
increased to $4,428,048 for 2007 from $4,276,250 for
2006. Developmental revenue decreased to $6,877,859 in 2007 from
$7,645,042 for 2006.
Our
commercial chemical revenue and our royalty and license revenues for the year
ended December 31, 2007 were $3,599,677 and $828,371, respectively, compared to
$1,876,071 and $2,400,179, respectively, for the same period in 2006. The
increase in commercial chemical revenue was due to increased purchases of our
proprietary OLED materials for use in commercial OLED products. In the fourth
quarter of 2006, we began supplying our proprietary OLED materials to Samsung
SMD for use in a commercial active-matrix OLED display product. This activity
continued in 2007, with Samsung SMD being responsible for the vast majority of
our commercial chemical revenue for the year. As discussed further below, we
also began recognizing royalty revenue from Samsung SMD in 2007.
In 2007,
we began supplying our proprietary OLED materials to Chi Mei EL Corporation and
LG Display Co., Ltd. (formerly LG.Philips Co., Ltd.), with whom we signed
commercial supply agreements during the year. These agreements are similar to
the agreement we had entered into with AU Optronics Corporation, in that we
record both commercial chemical revenue and license revenue from our sales of
OLED materials under these agreements. A small portion of our commercial
chemical revenue and our license revenue for 2007 were from sales of our
proprietary OLED materials to Chi Mei EL and LG Display.
For the
first seven months of 2006, we supplied one of our proprietary OLED materials to
AU Optronics for use in a commercial OLED display product. For 2006,
we recognized commercial chemical revenue of $886,676 and license revenue of
$1,773,324 on account of our sales of this material to AU
Optronics. However, those sales ended when AU Optronics discontinued
manufacturing its commercial OLED display product during the third quarter of
2006. Commercial chemical revenue and license revenue from sales of
our proprietary OLED material to AU Optronics represented a substantial
component of our revenues for 2006.
Our
royalty and license revenues for 2007 decreased substantially from 2006 due in
large part to the difference in our business agreements with Samsung SMD and AU
Optronics. As previously indicated, under the terms of our agreement with AU
Optronics we recognized license revenue at the time we sold our proprietary OLED
material to AU Optronics. In contrast, under the terms of our agreement with
Samsung SMD, we recognize royalty revenue when Samsung SMD reports to us the
sale of licensed products that use our proprietary OLED materials or
technologies. This can occur up to six months or more after the date on which we
sell our OLED materials to Samsung SMD. For 2007, we recognized $61,317 in
royalty revenue on account of sales of these licensed products reported to us by
Samsung SMD for the first three quarters of the year. There was no
corresponding royalty revenue reported to us by Samsung SMD for
2006.
Our
royalty and license revenues for 2006 did, however, include license fees and
upfront royalty payments received under our patent license agreement with
Samsung SMD, as well as license fees received under our cross-license agreement
executed with DuPont. All of these payments have been classified as deferred
revenue. The deferred license fees are being recognized as license revenue over
the life of our agreement with Samsung SMD, and over 10 years for our
agreement with DuPont. The deferred royalties are being recognized as royalty
revenue when sales of licensed products are reported to us by Samsung
SMD.
We earned
$4,600,693 in contract research revenue from agencies of the U.S. Government for
the year ended December 31, 2007, compared to $3,821,903 in corresponding
revenue for the same period in 2006. The increase was mainly attributable to
increased work performed under our government contracts and the achievement of
milestones as specified within certain of those contracts. We commenced work on
10 new government contracts during 2007 and completed work on eight government
programs during the year.
We earned
$1,049,854 in development chemical revenue for the year ended December 31, 2007,
compared to $1,656,851 in corresponding revenue for the year ended December 31,
2006. The decrease was mainly due to a decreased volume of development chemical
purchases as a result of Samsung SMD transitioning from exclusively development
chemical purchases in 2006 to primarily commercial chemical purchases in
2007.
We
recognized $1,227,312 in technology development revenue for the year ended
December 31, 2007, compared to $2,166,288 in corresponding revenue for the same
period in 2006. Technology development revenue for 2007 was derived from one
technology development contract that we renewed and continued working under for
the entire year. For 2006, we derived technology development revenue from this
and three other contracts for technology development and similar services.
Although in 2007 we continued working with all of the companies from which we
derived technology development revenue for 2006, our business arrangements with
these companies changed as the OLED industry evolved and our customers refined
their technology development strategies. For example, we received a
non-refundable payment for the continuation of one of these technology
development agreements in the third quarter of 2006, which payment is creditable
against future amounts payable under a commercial license agreement with the
customer, if one is executed by a specified date. Due to this business
arrangement, the payment has been recorded as deferred license fees rather than
technology development revenue. The amount and timing of our receipt of fees for
technology development and similar services is difficult to predict due to
business changes such as this one, and participants in the OLED industry having
different technology development strategies, which are subject to change at any
time.
We
incurred research and development expenses of $20,909,262 for the year ended
December 31, 2007, compared to $19,562,004 for the year ended
December 31, 2006. The increase was mainly due to:
·
|
an
increase of $1,916,862 attributable to higher operating costs associated
with our Ewing facility;
|
·
|
a
refund received from Princeton University in 2006 for unspent research and
development funds of $1,011,358;
and
|
·
|
an
increase of $724,254 in personnel costs due mainly to increased salaries
during 2007; and
|
·
|
an
increase of $242,281 relating to the recognition of expenses for stock
issuances to non-employee members of our Scientific Advisory Board, and
for the vesting of shares of restricted stock previously issued to these
individuals.
|
The
increase was offset to some extent by a decrease of $1,673,560 in amounts paid
to PPG Industries under our OLED Materials Supply and Service Agreement, as we
started performing at our Ewing facility certain the work previously performed
for us by PPG Industries.
General
and administrative expenses were $9,569,381 for the year ended December 31,
2007, compared to $8,902,462 for the same period in 2006. The increase was
mainly due to:
·
|
an
increase of $465,243 in personnel costs due mainly to increased salaries
during 2007; and
|
·
|
an
increase of $153,493 attributable to higher operating costs associated
with our Ewing facility.
|
Royalty
and license expenses were $305,846 for the year ended December 31, 2007,
compared to $687,436 for the same period in 2006. The decrease was due to a
reduction of $370,998 in royalties owed to Motorola. For 2006, we had a minimum
royalty obligation to Motorola of $500,000. Beginning with 2007,
however, we were no longer required to make minimum royalty payments to
Motorola.
Interest
income increased to $3,599,229 for the year ended December 31, 2007,
compared to $2,168,933 for the same period in 2006. The increase was mainly
attributable to increased cash for investment due to funds received from a
common stock offering that we completed in May 2007, as well as higher rates of
return on investments during 2007.
During
2007, we sold approximately $7.5 million of our state-related income tax
NOLs and approximately $263,000 of our research and development tax credits
under the New Jersey Technology Tax Certificate Transfer Program. In 2007, we
received proceeds of $804,980 from our sale of these NOLs and research and
development tax credits, and we recorded these proceeds as an income tax
benefit. In 2006, we received proceeds of $544,567 from corresponding sales of
approximately $7 million in NOLs and research and development tax
credits.
Liquidity
and Capital Resources
As of
December 31, 2008, we had cash and cash equivalents of $28,321,581 and
short-term investments of $49,132,619, for a total of
$77,454,200. This compares to cash and cash equivalents of
$33,870,696 and short-term investments of $49,788,961, for a total of
$83,659,657, as of December 31, 2007. The decrease in cash and cash
equivalents of $5,549,115 was primarily due to the usage of cash in operating
activities.
Cash used
in operating activities was $7,785,164 for 2008, compared to $10,439,279 for
2007. The decreased usage of cash in operating activities was mainly due to a
net increase in deferred license fees and deferred revenue of $2,838,284 related
to cash payments from various customers for license rights granted to these
customers, and/or joint development work performed or technical assistance
provided at the request of these customers.
Cash
provided by investing activities was $600,444 for 2008, compared to $32,670,039
of cash used in investing activities for 2007. In 2007 we increased our net
investments by $31,444,182 primarily from the investment of the proceeds from
the sale of common stock. There were no stock sales in
2008.
Cash
provided by financing activities was $1,635,605 for 2008, as compared to
$45,882,481 for 2007. In May 2007 the Company completed a public
offering of 2,800,000 shares of our common stock at a price of $14.50 per share.
The offering resulted in proceeds to us of $38,000,023, net of $2,599,977 in
underwriting discounts and commissions and other costs associated with
completion of the offering.
Working
capital decreased to $64,600,256 as of December 31, 2008, from $73,979,638 as of
December 31, 2007. The decrease was mainly due to the use of cash and cash
equivalents of $5,549,115, an increase in accounts payable of $723,587, an
increase in accrued expenses of $718,286, and a net increase in deferred license
fees and deferred revenue of $1,537,101. We anticipate, based on our
internal forecasts and assumptions relating to our operations (including, among
others, assumptions regarding our working capital requirements, the progress of
our research and development efforts, the
availability
of sources of funding for our research and development work, and the timing and
costs associated with the preparation, filing, prosecution, maintenance and
defense of our patents and patent applications), that we have sufficient cash,
cash equivalents and short-term investments to meet our obligations through at
least 2009.
We
believe that potential additional financing sources for us include long-term and
short-term borrowings, public and private sales of our equity and debt
securities and the receipt of cash upon the exercise of warrants and options. It
should be noted, however, that additional funding may be required in the future
for research, development and commercialization of our OLED technologies and
materials, to obtain, maintain and enforce patents respecting these technologies
and materials, and for working capital and other purposes, the timing and amount
of which are difficult to ascertain. There can be no assurance that additional
funds will be available to us when needed, on commercially reasonable terms or
at all, particularly in the
current economic environment.
Contractual
Obligations
As of
December 31, 2008, we had the following contractual commitments:
|
|
Payments
due by period
|
|
Contractual
Obligations
|
|
Total
|
|
|
Less
than 1 year
|
|
|
1-3
years
|
|
|
3-5
years
|
|
|
More
than 5 years
|
|
Sponsored
research obligation
|
|
$ |
1,064,691 |
|
|
$ |
1,064,691 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Minimum
royalty obligation (1)
|
|
|
500,000 |
|
|
|
100,000 |
|
|
|
200,000 |
|
|
|
200,000 |
|
|
100,000/year(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
(2)
|
|
$ |
1,564,691 |
|
|
$ |
1,164,691 |
|
|
$ |
200,000 |
|
|
$ |
200,000 |
|
|
$100,000/year(1)
|
|
-------------------
(1)
|
Under
our Amended License Agreement with Princeton University, the University of
Southern California and the University of Michigan, we are obligated to
pay minimum royalties of $100,000 per year until such time as the
agreement is no longer in effect. The agreement has no scheduled
expiration date.
|
(2)
|
See
Note 11 to the Consolidated Financial Statements for discussion of
obligations upon termination of employment of executive officers as a
result of a change in control of the
Company.
|
Off-Balance
Sheet Arrangements
As of
December 31, 2008, we had no off-balance sheet arrangements in the nature of
guarantee contracts, retained or contingent interests in assets transferred to
unconsolidated entities (or similar arrangements serving as credit, liquidity or
market risk support to unconsolidated entities for any such assets), or
obligations (including contingent obligations) arising out of variable interests
in unconsolidated entities providing financing, liquidity, market risk or credit
risk support to us, or that engage in leasing, hedging or research and
development services with us.
Recently
Issued Accounting Pronouncements
Recently
issued accounting pronouncements are addressed in Note 2 in the Notes to
Consolidated Financial Statements.
ITEM
7A.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
|
We do not
utilize financial instruments for trading purposes and hold no derivative
financial instruments, other financial instruments or derivative commodity
instruments that could expose us to significant market risk. As such, a change
in interest rates of 1 percentage point would not have a material impact on our
operating results and cash flows. Our primary market risk exposure with regard
to financial instruments is to changes in interest rates, which would impact
interest income earned on investments.
ITEM
8.
|
FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA
|
Our
Consolidated Financial Statements and the relevant notes to those statements are
attached to this report beginning on page F-1.
ITEM
9.
|
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
|
None.
Evaluation
of Disclosure Controls and Procedures
Our management, with the participation of our
Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures as of December 31, 2008. Based on that
evaluation, the Chief Executive Officer and Chief Financial Officer concluded
that our disclosure controls and procedures, as of the end of the period covered
by this report, are functioning effectively to provide reasonable assurance that
the information required to be disclosed by us in reports filed or submitted
under the Securities Exchange Act of 1934, as amended, is (i) recorded,
processed, summarized and reported within the time periods specified in the
SEC’s rules and forms, and (ii) accumulated and communicated to our management,
including the Chief Executive Officer and Chief Financial Officer, as
appropriate to allow timely decisions regarding disclosure. However, a controls
system, no matter how well designed and operated, cannot provide absolute
assurance that the objectives of the controls system are met, and no evaluation
of controls can provide absolute assurance that all control issues and instances
of fraud, if any, within a company have been detected.
Management’s
Report on Internal Control over Financial Reporting and Report of Independent
Registered Public Accounting Firm on Internal Control over Financial
Reporting
The
report of management on our internal control over financial reporting and the
associated attestation report of our independent registered public accounting
firm are set forth in Item 8 of this report.
Changes
in Internal Control over Financial Reporting
There
were no changes in our internal control over financial reporting during the
quarter ended December 31, 2008 that have materially affected, or are reasonably
likely to materially affect, our internal control over financial
reporting.
None.
PART
III
|
DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE
|
Information
with respect to this item is set forth in our definitive Proxy Statement for the
2009 Annual Meeting of Shareholders, which is to be filed with the Securities
and Exchange Commission no later than April 30, 2009, (our “Proxy
Statement”), and which is incorporated herein by reference. Information
regarding our executive officers is included at the end of Part I of this
report.
Information
with respect to this item is set forth in our Proxy Statement, and is
incorporated herein by reference.
ITEM
12.
|
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
|
Information
with respect to this item is set forth in our Proxy Statement, and is
incorporated herein by reference.
ITEM
13.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
|
Information
with respect to this item is set forth in our Proxy Statement, and is
incorporated herein by reference.
ITEM
14.
|
PRINCIPAL
ACCOUNTING FEES AND SERVICES
|
Information
with respect to this item is set forth in our Proxy Statement, and is
incorporated herein by reference.
PART
IV
|
EXHIBITS,
FINANCIAL STATEMENT SCHEDULES
|
(a) The
following documents are filed as part of this report:
(1) Financial
Statements:
Management’s
Report on Internal Control Over Financial
Reporting………………...………………...………………...………………...........
|
F-2
|
Reports
of Independent Registered Public Accounting
Firm…………………………...………………...………………...………………...…..
|
F-3
|
Consolidated
Balance
Sheets…………………………………..………………...………………...………………...………………...…………......
|
F-5
|
Consolidated
Statements of
Operations…………………………………..………………...………………...………………...……………….......
|
F-6
|
Consolidated
Statements of Shareholders’ Equity and Comprehensive
Loss………………...………………...………………...………….....
|
F-7
|
Consolidated
Statements of Cash
Flows………………...………………...………………...………………...………………...……………….....
|
F-9
|
Notes
to Consolidated Financial
Statements………………………………………………...………………...………………...………………....
|
F-10
|
(2) Financial
Statement Schedules:
None.
(3) Exhibits:
The
following is a list of the exhibits filed as part of this report. Where so
indicated by footnote, exhibits that were previously filed are incorporated by
reference. For exhibits incorporated by reference, the location of the exhibit
in the previous filing is indicated parenthetically, together with a reference
to the filing indicated by footnote.
Exhibit
Number
Description
3.1
|
Amended
and Restated Articles of Incorporation of the registrant (1)
|
3.2
|
Amendment
to Amended and Restated Articles of Incorporation of the registrant (2)
|
3.3
|
Bylaws
of the registrant (1)
|
10.1#
|
Warrant
Agreement between the registrant and Julia J. Brown, dated as of
April 18, 2000 (3)
|
10.2#
|
Amendment
No. 1 to Warrant Agreement between the registrant and Julia J. Brown,
dated as of April 18, 2000 (1)
|
10.3
#*
|
Amended
and Restated Change in Control Agreement between the registrant and
Sherwin I. Seligsohn, dated as of November 4,
2008
|
10.4
#*
|
Amended
and Restated Change in Control Agreement between the registrant and Steven
V. Abramson, dated as of November 4,
2008
|
10.5
#*
|
Amended
and Restated Change in Control Agreement between the registrant and Sidney
D. Rosenblatt, dated as of November 4,
2008
|
10.6
#*
|
Amended
and Restated Change in Control Agreement between the registrant and Julia
J. Brown, dated as of November 4,
2008
|
10.7
#*
|
Amended
and Restated Change in Control Agreement between the registrant and Janice
K. Mahon, dated as of November 4,
2008
|
10.8
#
|
Non-Competition
and Non-Solicitation Agreement between the registrant and Sherwin I.
Seligsohn, dated as of February 23, 2007 (4)
|
10.9
#
|
Non-Competition
and Non-Solicitation Agreement between the registrant and Steven V.
Abramson, dated as of January 26, 2007 (4)
|
10.10
#
|
Non-Competition
and Non-Solicitation Agreement between the registrant and Sidney D.
Rosenblatt, dated as of February 7, 2007 (4)
|
10.11
#
|
Non-Competition
and Non-Solicitation Agreement between the registrant and Julia J. Brown,
dated as of February 5, 2007 (4)
|
10.12
#*
|
Non-Competition
and Non-Solicitation Agreement between the registrant and Janice K. Mahon,
dated as of February 23, 2007
|
10.13
|
Equity
Compensation Plan, dated as of June 29, 2006 (5)
|
10.14
|
Sponsored
Research Agreement between the registrant and the University of Southern
California, dated as of May 1, 2006 (6)
|
10.15
*
|
Amendment
No. 1 to the Sponsored Research Agreement between the registrant and the
University of Southern California, dated as of May 1,
2006
|
10.16
|
1997
Amended License Agreement among the registrant, The Trustees of Princeton
University and the University of Southern California, dated as of
October 9, 1997 (7)
|
10.17
|
Amendment
#1 to the Amended License Agreement among the registrant, the Trustees of
Princeton University and the University of Southern California, dated as
of August 7, 2003 (8)
|
10.18
|
Amendment
#2 to the Amended License Agreement among the registrant, the Trustees of
Princeton University, the University of Southern California and the
Regents of the University of Michigan, dated as of January 1, 2006
(8)
|
10.19
|
Termination,
Amendment and License Agreement by and among the registrant, PD-LD, Inc.,
Dr. Vladimir S. Ban, and The Trustees of Princeton University, dated as of
July 19, 2000 (9)
|
10.20
|
Letter
of Clarification of UDC/GPEC Research and License Arrangements between the
registrant and Global Photonic Energy Corporation, dated as of
June 4, 2004 (4)
|
10.21
+
|
License
Agreement between the registrant and Motorola, Inc., dated as of
September 29, 2000 (9)
|
10.22
+
|
OLED
Materials Supply and Service Agreement between the registrant and PPG
Industries, Inc., dated as of July 29, 2005 (10)
|
10.23
|
Amendment
No. 1 to the OLED Materials Supply and Service Agreement between the
registrant and PPG Industries, Inc., dated as of January 4, 2008 (11)
|
10.24
+
|
OLED
Patent License Agreement between the registrant and Samsung SDI Co., Ltd.,
dated as of April 19, 2005 (12)
|
10.25
+
|
OLED
Supplemental License Agreement between the registrant and Samsung SMD Co.,
Ltd., dated as of April 19, 2005 (12)
|
10.26
+
|
Amendment
No. 1 to the OLED Patent License Agreement between the registrant and
Samsung SDI Co., Ltd., dated as of July 30, 2008 (13)
|
10.27
+
|
Settlement
and License Agreement between the registrant and Seiko Epson Corporation,
dated as of July 31, 2006 (14)
|
10.28
+
|
Commercial
Supply Agreement between the registrant and Chi Mei EL Corporation, dated
as of April 5, 2007 (15)
|
10.29
+
|
Commercial
Supply Agreement between the registrant and LG.Philips LCD Co., Ltd. (now
known as LG Display), dated as of May 23, 2007 (15)
|
10.30
*
|
Amendment
No. 1 to the Commercial Supply Agreement between the registrant and
LG.Philips LCD Co., Ltd. (now known as LG Display), dated as of November
21, 2008
|
10.31
+
|
OLED
Technology License and Technical Assistance Agreement between the
registrant and Kyocera Corporation, dated as of July 28, 2008(13)
|
10.32
+
|
Commercial
OLED Material Supply Agreement between the registrant and Kyocera
Corporation, dated as of July 28, 2008(13)
|
10.33
+
|
OLED
Technology License Agreement between the registrant and Konica Minolta
Holdings, Inc., dated as of August 11, 2008(13)
|
21
*
|
Subsidiaries
of the registrant
|
23.1
*
|
Consent
of KPMG LLP
|
31.1
*
|
Certifications
of Steven V. Abramson, Chief Executive Officer, as required by Rule
13a-14(a) or Rule 15d-14(a)
|
31.2
*
|
Certifications
of Sidney D. Rosenblatt, Chief Financial Officer, as required by Rule
13a-14(a) or Rule 15d-14(a)
|
32.1
**
|
Certifications
of Steven V. Abramson, Chief Executive Officer, as required by Rule
13a-14(b) or Rule 15d-14(b), and by 18 U.S.C. Section
1350. (This exhibit shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liability of that section. Further,
this exhibit shall not be deemed to be incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, as amended.)
|
32.2
**
|
Certifications
of Sidney D. Rosenblatt, Chief Financial Officer, as required by Rule
13a-14(b) or Rule 15d-14(b), and by 18 U.S.C. Section
1350. (This exhibit shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liability of that section. Further,
this exhibit shall not be deemed to be incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, as amended.)
|
Explanation
of footnotes to listing of exhibits:
* Filed
herewith.
** Furnished
herewith.
# Management
contract or compensatory plan or arrangement.
|
+
|
Confidential
treatment has been accorded to certain portions of this exhibit pursuant
to Rule 406 under the Securities Act of 1933, as amended, or Rule 24b-2
under the Securities Exchange Act of 1934, as
amended.
|
(1)
|
Filed
as an Exhibit to the Annual Report on Form 10-K for the year ended
December 31, 2003, filed with the SEC on March 1,
2004.
|
(2)
|
Filed
as an Exhibit to a Current Report on Form 8-K, filed with the SEC on
December 21, 2007.
|
(3)
|
Filed
as an Exhibit to the Annual Report on Form 10-K for the year ended
December 31, 2000, filed with the SEC on March 29,
2001.
|
(4)
|
Filed
as an Exhibit to the Annual Report on Form 10-K for the year ended
December 31, 2006, filed with the SEC on March 15,
2007.
|
(5)
|
Filed
as an Exhibit to the Definitive Proxy Statement for the 2006 Annual
Meeting of Shareholders, filed with the SEC on April 27,
2006.
|
(6)
|
Filed
as an Exhibit to the Quarterly Report on Form 10-Q for the quarter ended
June 30, 2006, filed with the SEC on August 9,
2006.
|
(7)
|
Filed
as an Exhibit to the Annual Report on Form 10K-SB for the year ended
December 31, 1997, filed with the SEC on March 31,
1998.
|
(8)
|
Filed
as an Exhibit to the Quarterly Report on Form 10-Q for the quarter ended
September 30, 2003, filed with the SEC on November 10,
2003.
|
(9)
|
Filed
as an Exhibit to the amended Quarterly Report on Form 10-Q for the quarter
ended September 30, 2000, filed with the SEC on November 20,
2001.
|
(10)
|
Filed
as an Exhibit to the Quarterly Report on Form 10-Q for the quarter ended
September 30, 2005, filed with the SEC on November 7,
2005.
|
(11)
|
Filed
as an Exhibit to the Quarterly Report on Form 10-Q for the quarter ended
March 30, 2008, filed with the SEC on May 8,
2008.
|
(12)
|
Filed
as an Exhibit to the Quarterly Report on Form 10-Q for the quarter ended
June 30, 2005, filed with the SEC on August 9,
2005.
|
(13)
|
Filed
as an Exhibit to the Quarterly Report on Form 10-Q for the quarter ended
September 30, 2008, filed with the SEC on November 6,
2008.
|
(14)
|
Filed
as an Exhibit to the Quarterly Report on Form 10-Q for the quarter ended
September 30, 2006, filed with the SEC on November 6,
2006.
|
|
Filed
as an Exhibit to the Quarterly Report on Form 10-Q for the quarter ended
June 30, 2007, filed with the SEC on August 9,
2007.
|
Note: Any
of the exhibits listed in the foregoing index not included with this report may
be obtained, without charge, by writing to Mr. Sidney D. Rosenblatt, Corporate
Secretary, Universal Display Corporation, 375 Phillips Boulevard, Ewing, New
Jersey 08618.
(b) The
exhibits required to be filed by us with this report are listed
above.
(c) The
consolidated financial statement schedules required to be filed by us with this
report are listed above.
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized:
UNIVERSAL
DISPLAY CORPORATION
|
By:/s/ Sidney D. Rosenblatt
|
|
Sidney
D. Rosenblatt
|
|
Executive
Vice President, Chief Financial Officer,
|
|
Treasurer
and Secretary
|
|
|
|
Date: March
12, 2009
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the registrant and in the
capacities and on the dates indicated.
Name
|
Title
|
Date
|
/s/
Sherwin I. Seligsohn
Sherwin I.
Seligsohn
|
Founder
and Chairman of the Board of Directors
|
March
12, 2009
|
/s/ Steven V. Abramson
Steven
V. Abramson
|
President,
Chief Executive Officer and Director
|
March
12, 2009
|
/s/ Sidney D. Rosenblatt
Sidney
D. Rosenblatt
|
Executive
Vice President, Chief Financial Officer, Treasurer, Secretary and
Director
|
March
12, 2009
|
/s/ Leonard Becker
Leonard
Becker
|
Director
|
March
12, 2009
|
/s/ Elizabeth H. Gemmill
Elizabeth
H. Gemmill
|
Director
|
March
12, 2009
|
/s/ C. Keith Hartley
C.
Keith Hartley
|
Director
|
March
12, 2009
|
/s/ Lawrence Lacerte
Lawrence
Lacerte
|
Director
|
March
12, 2009
|
UNIVERSAL
DISPLAY CORPORATION AND SUBSIDIARIES
INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS
|
|
Consolidated
Financial Statements:
|
|
Management’s
Report on Internal Control Over Financial Reporting
|
F-2
|
Reports
of Independent Registered Public Accounting Firm
|
F-3
|
Consolidated
Balance Sheets
|
F-5
|
Consolidated
Statements of Operations
|
F-6
|
Consolidated
Statements of Shareholders’ Equity and Comprehensive Loss
|
F-7
|
Consolidated
Statements of Cash Flows
|
F-9
|
Notes
to Consolidated Financial Statements
|
F-10
|
MANAGEMENT’S
REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
Our
management is responsible for establishing and maintaining adequate internal
control over financial reporting for the Company. Internal control over
financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of
consolidated financial statements for external purposes in accordance with
generally accepted accounting principles. Our system of internal control over
financial reporting includes those policies and procedures that (i) pertain
to the maintenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the Company;
(ii) provide reasonable assurance that transactions are recorded as
necessary to permit preparation of financial statements in accordance with
generally accepted accounting principles, and that receipts and expenditures of
the Company are being made only in accordance with authorizations of management
and directors of the Company; and (iii) provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use or
disposition of the Company’s assets that could have a material effect on the
financial statements.
Because
of its inherent limitations, internal control over financial reporting may not
prevent or detect misstatements. Also, projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may
become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.
Management
performed an assessment of the effectiveness of our internal control over
financial reporting as of December 31, 2008 based upon criteria in Internal Control — Integrated
Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission (“COSO”). Based on this assessment, management determined
that the Company’s internal control over financial reporting was effective as of
December 31, 2008, based on the criteria in Internal Control-Integrated
Framework issued by COSO.
The
effectiveness of our internal control over financial reporting as of December
31, 2008, has been attested to by KPMG LLP, an independent registered public
accounting firm, as stated in its report which appears on the following
page.
Steven
V. Abramson
President
and Chief Executive Officer
|
|
Sidney
D. Rosenblatt
Executive
Vice President and Chief Financial
Officer
|
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board
of Directors and Shareholders
Universal
Display Corporation:
We have
audited Universal Display Corporation’s internal control over financial
reporting as of December 31, 2008, based on criteria established in Internal Control - Integrated
Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO). Universal Display
Corporation's management is responsible for maintaining effective internal
control over financial reporting and for its assessment of the effectiveness of
internal control over financial reporting, included in the accompanying
Management’s Report on Internal Control Over Financial Reporting. Our
responsibility is to express an opinion on the Company’s internal control over
financial reporting based on our audit.
We
conducted our audit in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether effective
internal control over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of internal control over
financial reporting, assessing the risk that a material weakness exists, and
testing and evaluating the design and operating effectiveness of internal
control based on the assessed risk. Our audit also included performing such
other procedures as we considered necessary in the circumstances. We believe
that our audit provides a reasonable basis for our opinion.
A
company's internal control over financial reporting is a process designed to
provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles. A company's internal
control over financial reporting includes those policies and procedures that (1)
pertain to the maintenance of records that, in reasonable detail, accurately and
fairly reflect the transactions and dispositions of the assets of the company;
(2) provide reasonable assurance that transactions are recorded as necessary to
permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the company are
being made only in accordance with authorizations of management and directors of
the company; and (3) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of the company’s
assets that could have a material effect on the financial
statements.
Because
of its inherent limitations, internal control over financial reporting may not
prevent or detect misstatements. Also, projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may
become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.
In our
opinion, Universal Display Corporation maintained, in all material respects,
effective internal control over financial reporting as of December 31, 2008,
based on criteria established in Internal Control - Integrated
Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission.
We also
have audited, in accordance with the standards of the Public Company Accounting
Oversight Board (United States), the consolidated balance sheets of Universal
Display Corporation and subsidiaries as of December 31, 2008 and 2007, and the
related consolidated statements of operations, shareholders’ equity and
comprehensive loss and cash flows for each of the years in the three-year period
ended December 31, 2008, and our report dated March 12, 2009 expressed an
unqualified opinion on those consolidated financial statements .
/s/ KPMG
LLP
Philadelphia,
Pennsylvania
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board
of Directors and Shareholders
Universal
Display Corporation:
We have
audited the accompanying consolidated balance sheets of Universal Display
Corporation and subsidiaries as of December 31, 2008 and 2007, and
the related consolidated statements of operations, shareholders’ equity and
comprehensive loss and cash flows for each of the years in the three-year period
ended December 31, 2008. These consolidated financial statements are the
responsibility of the Company’s management. Our responsibility is to express an
opinion on these consolidated financial statements based on our
audits.
We
conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our
opinion, the consolidated financial statements referred to above present fairly,
in all material respects, the financial position of Universal Display
Corporation and subsidiaries as of December 31, 2008 and 2007, and the results
of their operations and their cash flows for each of the years in the three-year
period ended December 31, 2008, in conformity with U.S. generally accepted
accounting principles.
We also
have audited, in accordance with the standards of the Public Company Accounting
Oversight Board (United States), Universal Display Corporation’s internal
control over financial reporting as of December 31, 2008, based on criteria
established in Internal
Control — Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO), and our report dated
March 12, 2009 expressed an unqualified opinion on the effectiveness of the
Company’s internal control over financial reporting.
/s/
KPMG LLP
Philadelphia,
Pennsylvania
UNIVERSAL
DISPLAY CORPORATION AND SUBSIDIARIES
CONSOLIDATED
BALANCE SHEETS
|
|
December
31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
|
|
ASSETS
|
|
CURRENT
ASSETS:
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$ |
28,321,581 |
|
|
$ |
33,870,696 |
|
Short-term
investments
|
|
|
49,132,619 |
|
|
|
49,788,961 |
|
Accounts
receivable
|
|
|
2,450,444 |
|
|
|
2,395,416 |
|
Inventory
|
|
|
2,209 |
|
|
|
41,165 |
|
Other
current assets
|
|
|
462,908 |
|
|
|
673,931 |
|
|
|
|
|
|
|
|
|
|
Total
current assets
|
|
|
80,369,761 |
|
|
|
86,770,169 |
|
PROPERTY
AND EQUIPMENT, net
|
|
|
12,859,628 |
|
|
|
13,525,714 |
|
ACQUIRED
TECHNOLOGY, net
|
|
|
2,929,344 |
|
|
|
4,624,416 |
|
OTHER
ASSETS
|
|
|
69,772 |
|
|
|
79,772 |
|
|
|
|
|
|
|
|
|
|
TOTAL
ASSETS
|
|
$ |
96,228,505 |
|
|
$ |
105,000,071 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND SHAREHOLDERS’ EQUITY
|
|
CURRENT
LIABILITIES:
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$ |
1,585,015 |
|
|
$ |
861,428 |
|
Accrued
expenses
|
|
|
5,296,433 |
|
|
|
4,578,147 |
|
Deferred
license fees
|
|
|
6,148,267 |
|
|
|
7,178,268 |
|
Deferred
revenue
|
|
|
2,739,790 |
|
|
|
172,688 |
|
|
|
|
|
|
|
|
|
|
Total
current liabilities
|
|
|
15,769,505 |
|
|
|
12,790,531 |
|
DEFERRED
LICENSE FEES
|
|
|
3,407,037 |
|
|
|
2,454,900 |
|
DEFERRED
REVENUE
|
|
|
337,500 |
|
|
|
538,683 |
|
|
|
|
|
|
|
|
|
|
Total
liabilities
|
|
|
19,514,042 |
|
|
|
15,784,114 |
|
|
|
|
|
|
|
|
|
|
COMMITMENTS
AND CONTINGENCIES (Note 11)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHAREHOLDERS’
EQUITY:
|
|
|
|
|
|
|
|
|
Preferred
Stock, par value $0.01 per share, 5,000,000 shares authorized, 200,000
shares of Series A Nonconvertible Preferred Stock issued and outstanding
(liquidation value of $7.50 per share or $1,500,000)
|
|
|
2,000 |
|
|
|
2,000 |
|
Common
Stock, par value $0.01 per share, 50,000,000 shares authorized, 36,131,981
and 35,563,201 shares issued and outstanding at December 31, 2008 and
2007, respectively
|
|
|
361,320 |
|
|
|
355,632 |
|
Additional
paid-in capital
|
|
|
256,696,849 |
|
|
|
250,240,994 |
|
Unrealized
gain (loss) on available-for-sale securities
|
|
|
126,497 |
|
|
|
(50,202 |
) |
Accumulated
deficit
|
|
|
(180,472,203 |
) |
|
|
(161,332,467 |
) |
|
|
|
|
|
|
|
|
|
Total
shareholders’ equity
|
|
|
76,714,463 |
|
|
|
89,215,957 |
|
|
|
|
|
|
|
|
|
|
TOTAL
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
|
$ |
96,228,505 |
|
|
$ |
105,000,071 |
|
The
accompanying notes are an integral part of these consolidated financial
statements.
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
|
Year
Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
REVENUE:
|
|
|
|
|
|
|
|
|
|
Commercial
revenue
|
|
$ |
5,630,758 |
|
|
$ |
4,428,048 |
|
|
$ |
4,276,250 |
|
Developmental
revenue
|
|
|
5,444,466 |
|
|
|
6,877,859 |
|
|
|
7,645,042 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
revenue
|
|
|
11,075,224 |
|
|
|
11,305,907 |
|
|
|
11,921,292 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING
EXPENSES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost
of chemicals sold
|
|
|
912,094 |
|
|
|
893,276 |
|
|
|
659,507 |
|
Research
and development
|
|
|
22,257,634 |
|
|
|
20,909,262 |
|
|
|
19,562,004 |
|
General
and administrative
|
|
|
10,170,593 |
|
|
|
9,569,381 |
|
|
|
8,902,462 |
|
Royalty
and license expense
|
|
|
397,817 |
|
|
|
305,846 |
|
|
|
687,436 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating expenses
|
|
|
33,738,138 |
|
|
|
31,677,765 |
|
|
|
29,811,409 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(22,662,914 |
) |
|
|
(20,371,858 |
) |
|
|
(17,890,117 |
) |
INTEREST
INCOME
|
|
|
2,607,897 |
|
|
|
3,599,229 |
|
|
|
2,168,933 |
|
INTEREST
EXPENSE
|
|
|
(47,197 |
) |
|
|
(8,192 |
) |
|
|
(10,187 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
LOSS
BEFORE INCOME TAX BENEFIT
|
|
|
(20,102,214 |
) |
|
|
(16,780,821 |
) |
|
|
(15,731,371 |
) |
INCOME
TAX BENEFIT
|
|
|
962,478 |
|
|
|
804,980 |
|
|
|
544,567 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET
LOSS
|
|
$ |
(19,139,736 |
) |
|
$ |
(15,975,841 |
) |
|
$ |
(15,186,804 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
BASIC
AND DILUTED NET LOSS PER COMMON SHARE
|
|
$ |
(0.53 |
) |
|
$ |
(0.47 |
) |
|
$ |
(0.49 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
WEIGHTED
AVERAGE SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON
SHARE
|
|
|
35,932,372 |
|
|
|
33,759,581 |
|
|
|
30,855,297 |
|
The
accompanying notes are an integral part of these consolidated financial
statements.
UNIVERSAL
DISPLAY CORPORATION AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF SHAREHOLDERS’ EQUITY AND COMPREHENSIVE LOSS
|
|
Series
A
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonconvertible
|
|
|
|
|
|
|
|
|
Additional
|
|
|
|
Preferred
Stock
|
|
|
Common
Stock
|
|
|
Paid-in
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE,
JANUARY 1, 2006
|
|
|
200,000 |
|
|
$ |
2,000 |
|
|
|
29,545,471 |
|
|
$ |
295,455 |
|
|
$ |
187,609,407 |
|
Exercise
of common stock options and warrants
|
|
|
— |
|
|
|
— |
|
|
|
1,432,655 |
|
|
|
14,326 |
|
|
|
6,267,442 |
|
Stock-based
employee compensation, net of shares withheld for employee
taxes
|
|
|
— |
|
|
|
— |
|
|
|
123,922 |
|
|
|
1,239 |
|
|
|
1,720,481 |
|
Stock-based
non-employee compensation
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
105,011 |
|
Issuance
of common stock to Board of Directors and Scientific Advisory
Board
|
|
|
— |
|
|
|
— |
|
|
|
73,766 |
|
|
|
738 |
|
|
|
837,062 |
|
Issuance
of common stock, options and warrants in connection with the development
agreements
|
|
|
— |
|
|
|
— |
|
|
|
209,594 |
|
|
|
2,096 |
|
|
|
2,966,578 |
|
Net
loss
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Unrealized
gain on available-for-sale securities
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive
loss
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE,
DECEMBER 31, 2006
|
|
|
200,000 |
|
|
|
2,000 |
|
|
|
31,385,408 |
|
|
|
313,854 |
|
|
|
199,505,981 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance
of common stock through a public offering, net of expenses of
$2,599,977
|
|
|
— |
|
|
|
— |
|
|
|
2,800,000 |
|
|
|
28,000 |
|
|
|
37,972,023 |
|
Exercise
of common stock options and warrants
|
|
|
— |
|
|
|
— |
|
|
|
1,169,648 |
|
|
|
11,696 |
|
|
|
8,528,247 |
|
Stock-based
employee compensation, net of shares withheld for employee
taxes
|
|
|
— |
|
|
|
— |
|
|
|
70,238 |
|
|
|
703 |
|
|
|
2,049,554 |
|
Stock-based
non-employee compensation
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
23,336 |
|
Issuance
of common stock to Board of Directors and Scientific Advisory
Board
|
|
|
— |
|
|
|
— |
|
|
|
37,796 |
|
|
|
378 |
|
|
|
714,364 |
|
Issuance
of common stock in connection with the development and license
agreements
|
|
|
— |
|
|
|
— |
|
|
|
100,111 |
|
|
|
1,001 |
|
|
|
1,447,489 |
|
Net
loss
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Unrealized
gain on available-for-sale securities
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive
loss
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE,
DECEMBER 31, 2007
|
|
|
200,000 |
|
|
|
2,000 |
|
|
|
35,563,201 |
|
|
|
355,632 |
|
|
|
250,240,994 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise
of common stock options and warrants
|
|
|
— |
|
|
|
— |
|
|
|
352,864 |
|
|
|
3,529 |
|
|
|
2,403,631 |
|
Stock-based
employee compensation, net of shares withheld for employee
taxes
|
|
|
— |
|
|
|
— |
|
|
|
86,340 |
|
|
|
863 |
|
|
|
2,085,315 |
|
Stock-based
non-employee compensation
|
|
|
— |
|
|
|
— |
|
|
|
174 |
|
|
|
2 |
|
|
|
6,099 |
|
Issuance
of common stock to Board of Directors and Scientific Advisory
Board
|
|
|
— |
|
|
|
— |
|
|
|
42,932 |
|
|
|
429 |
|
|
|
744,558 |
|
Issuance
of common stock in connection with the development and license
agreements
|
|
|
— |
|
|
|
— |
|
|
|
86,470 |
|
|
|
865 |
|
|
|
1,216,252 |
|
Net
loss
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Unrealized
gain on available-for-sale securities
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive
loss
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE,
DECEMBER 31, 2008
|
|
|
200,000 |
|
|
$ |
2,000 |
|
|
|
36,131,981 |
|
|
$ |
361,320 |
|
|
$ |
256,696,849 |
|
The
accompanying notes are an integral part of these consolidated financial
statements.
UNIVERSAL
DISPLAY CORPORATION AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF SHAREHOLDERS’ EQUITY AND
COMPREHENSIVE
LOSS — (Continued)
|
|
Unrealized
Gain (Loss) on
|
|
|
|
|
|
|
|
|
|
Available-for-Sale
|
|
|
Accumulated
|
|
|
Total
|
|
|
|
Securities
|
|
|
Deficit
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE,
, JANUARY 1, 2006
|
|
$ |
(120,577 |
) |
|
$ |
(130,169,822 |
) |
|
$ |
57,616,463 |
|
Exercise
of common stock options and warrants
|
|
|
— |
|
|
|
— |
|
|
|
6,281,768 |
|
Stock-based
employee compensation, net of shares withheld for employee
taxes
|
|
|
— |
|
|
|
— |
|
|
|
1,721,720 |
|
Stock-based
non-employee compensation
|
|
|
— |
|
|
|
— |
|
|
|
105,011 |
|
Issuance
of common stock to Board of Directors and Scientific Advisory
Board
|
|
|
— |
|
|
|
— |
|
|
|
837,800 |
|
Issuance
of common stock, options and warrants in connection with the development
agreements
|
|
|
— |
|
|
|
— |
|
|
|
2,968,674 |
|
Net
loss
|
|
|
— |
|
|
|
(15,186,804 |
) |
|
|
(15,186,804 |
) |
Unrealized
gain on available-for-sale securities
|
|
|
37,731 |
|
|
|
— |
|
|
|
37,731 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive
loss
|
|
|
— |
|
|
|
— |
|
|
|
(15,149,073 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE,
DECEMBER 31, 2006
|
|
|
(82,846 |
) |
|
|
(145,356,626 |
) |
|
|
54,382,363 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance
of common stock through a public offering, net of expenses of
$2,599,977
|
|
|
— |
|
|
|
— |
|
|
|
38,000,023 |
|
Exercise
of common stock options and warrants
|
|
|
— |
|
|
|
— |
|
|
|
8,539,943 |
|
Stock-based
employee compensation, net of shares withheld for employee
taxes
|
|
|
— |
|
|
|
— |
|
|
|
2,050,257 |
|
Stock-based
non-employee compensation
|
|
|
— |
|
|
|
— |
|
|
|
23,336 |
|
Issuance
of common stock to Board of Directors and Scientific Advisory
Board
|
|
|
— |
|
|
|
— |
|
|
|
714,742 |
|
Issuance
of common stock in connection with the development and license
agreements
|
|
|
— |
|
|
|
— |
|
|
|
1,448,490 |
|
Net
loss
|
|
|
— |
|
|
|
(15,975,841 |
) |
|
|
(15,975,841 |
) |
Unrealized
gain on available-for-sale securities
|
|
|
32,644 |
|
|
|
— |
|
|
|
32,644 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive
loss
|
|
|
— |
|
|
|
— |
|
|
|
(15,943,197 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE,
DECEMBER 31, 2007
|
|
|
(50,202 |
) |
|
|
(161,332,467 |
) |
|
|
89,215,957 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise
of common stock options and warrants
|
|
|
— |
|
|
|
— |
|
|
|
2,407,160 |
|
Stock-based
employee compensation, net of shares withheld for employee
taxes
|
|
|
— |
|
|
|
— |
|
|
|
2,086,178 |
|
Stock-based
non-employee compensation
|
|
|
— |
|
|
|
— |
|
|
|
6,101 |
|
Issuance
of common stock to Board of Directors and Scientific Advisory
Board
|
|
|
— |
|
|
|
— |
|
|
|
744,987 |
|
Issuance
of common stock in connection with the development and license
agreements
|
|
|
— |
|
|
|
— |
|
|
|
1,217,117 |
|
Net
loss
|
|
|
176,699 |
|
|
|
— |
|
|
|
176,699 |
|
Unrealized
gain on available-for-sale securities
|
|
|
— |
|
|
|
(19,139,736 |
) |
|
|
(19,139,736 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive
loss
|
|
|
— |
|
|
|
— |
|
|
|
(18,963,037 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE,
DECEMBER 31, 2008
|
|
$ |
126,497 |
|
|
$ |
(180,472,203 |
) |
|
$ |
76,714,463 |
|
The
accompanying notes are an integral part of these consolidated financial
statements.
UNIVERSAL
DISPLAY CORPORATION AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
|
Year
Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
Net
Loss
|
|
$ |
(19,139,736 |
) |
|
$ |
(15,975,841 |
) |
|
$ |
(15,186,804 |
) |
Non-cash
charges to statement of operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
1,943,184 |
|
|
|
1,774,236 |
|
|
|
1,828,551 |
|
Amortization
of intangibles
|
|
|
1,695,072 |
|
|
|
1,695,072 |
|
|
|
1,695,072 |
|
Amortization
of premium and discount on investments
|
|
|
(1,044,499 |
) |
|
|
(311,613 |
) |
|
|
(158,182 |
) |
Stock-based
employee compensation
|
|
|
3,663,575 |
|
|
|
3,391,394 |
|
|
|
3,028,807 |
|
Stock-based
non-employee compensation
|
|
|
5,110 |
|
|
|
23,336 |
|
|
|
105,011 |
|
Non-cash
expense under Development and License Agreements
|
|
|
1,232,668 |
|
|
|
926,582 |
|
|
|
2,968,074 |
|
Stock-based
compensation to Board of Directors and Scientific Advisory
Board
|
|
|
745,016 |
|
|
|
754,711 |
|
|
|
509,600 |
|
(Increase)
decrease in assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(55,028 |
) |
|
|
(282,153 |
) |
|
|
(169,164 |
) |
Inventory
|
|
|
38,956 |
|
|
|
(10,567 |
) |
|
|
5,833 |
|
Other
current assets
|
|
|
211,023 |
|
|
|
(67,664 |
) |
|
|
(108,521 |
) |
Other
assets
|
|
|
10,000 |
|
|
|
10,000 |
|
|
|
10,000 |
|
Increase
(decrease) in liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts
payable and accrued expenses
|
|
|
621,440 |
|
|
|
(1,816,543 |
) |
|
|
244,976 |
|
Deferred
license fees
|
|
|
(77,864 |
) |
|
|
(511,600 |
) |
|
|
3,188,401 |
|
Deferred
revenue
|
|
|
2,365,919 |
|
|
|
(38,629 |
) |
|
|
(2,078,788 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
cash used in operating activities
|
|
|
(7,785,164 |
) |
|
|
(10,439,279 |
) |
|
|
(4,117,134 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases
of property and equipment
|
|
|
(1,277,098 |
) |
|
|
(1,225,857 |
) |
|
|
(2,349,033 |
) |
Purchases
of investments
|
|
|
(96,859,458 |
) |
|
|
(61,336,182 |
) |
|
|
(24,374,659 |
) |
Proceeds
from sale of investments
|
|
|
98,737,000 |
|
|
|
29,892,000 |
|
|
|
25,589,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
cash provided by (used in) investing activities
|
|
|
600,444 |
|
|
|
(32,670,039 |
) |
|
|
(1,134,692 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
proceeds from issuance of common stock
|
|
|
— |
|
|
|
38,000,023 |
|
|
|
— |
|
Proceeds
from the exercise of common stock options and warrants
|
|
|
2,407,160 |
|
|
|
8,539,943 |
|
|
|
6,281,768 |
|
Payment
of withholding taxes related to stock-based employee
compensation
|
|
|
(771,555 |
) |
|
|
(657,485 |
) |
|
|
(586,658 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
cash provided by financing activities
|
|
|
1,635,605 |
|
|
|
45,882,481 |
|
|
|
5,695,110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(DECREASE)
INCREASE IN CASH AND CASH EQUIVALENTS
|
|
|
(5,549,115 |
) |
|
|
2,773,163 |
|
|
|
443,284 |
|
CASH
AND CASH EQUIVALENTS, BEGINNING OF YEAR
|
|
|
33,870,696 |
|
|
|
31,097,533 |
|
|
|
30,654,249 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH
AND CASH EQUIVALENTS, END OF YEAR
|
|
$ |
28,321,581 |
|
|
$ |
33,870,696 |
|
|
$ |
31,097,533 |
|
The
accompanying notes are an integral part of these consolidated financial
statements.
UNIVERSAL
DISPLAY CORPORATION AND SUBSIDIARIES
Universal
Display Corporation (the “Company”) is engaged in the research, development and
commercialization of organic light emitting diode (“OLED”) technologies and
materials for use in flat panel display, solid-state lighting and other product
applications. The Company’s primary business strategy is to develop and license
its proprietary OLED technologies to product manufacturers for use in these
applications. In support of this objective, the Company also develops new OLED
materials and sells those materials to product manufacturers. Through internal
research and development efforts and relationships with entities such as
Princeton University, the University of Southern California (“USC”), the
University of Michigan (“Michigan”), Motorola, Inc. and PPG Industries, Inc.,
the Company has established a significant portfolio of proprietary OLED
technologies and materials (Notes 3, 5 and 7).
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES:
|
Principles
of Consolidation
The
consolidated financial statements include the accounts of Universal Display
Corporation and its wholly owned subsidiaries, UDC, Inc. and Universal Display
Corporation Hong Kong, Ltd. All intercompany transactions and accounts have been
eliminated.
Management’s
Use of Estimates
The
preparation of financial statements in conformity with U.S. generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. The estimates made are principally in the area of revenue
recognition for license agreements and useful life of acquired technology.
Actual results could differ from those estimates.
Cash,
Cash Equivalents and Short-term Investments
The
Company considers all highly liquid debt instruments purchased with an original
maturity of three months or less to be cash equivalents. The Company classifies
its existing marketable securities as available-for-sale. These securities are
carried at fair market value, with unrealized gains and losses reported in
shareholders’ equity. Gains or losses on securities sold are based on the
specific identification method.
Short-term
investments at December 31, 2008 and 2007 consist of the following:
|
|
Amortized
|
|
|
Unrealized
|
|
|
Aggregate
Fair
|
|
Investment
Classification
|
|
Cost
|
|
|
Gains
|
|
|
(Losses)
|
|
|
Market
Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2008-
|
|
|
|
|
|
|
|
|
|
|
|
|
Certificates
of deposit
|
|
$ |
10,318,000 |
|
|
$ |
35,577 |
|
|
$ |
(3,323 |
) |
|
$ |
10,350,254 |
|
U.S.
Government bonds
|
|
|
38,688,122 |
|
|
|
96,121 |
|
|
|
(1,878 |
) |
|
|
38,782,365 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
49,006,122 |
|
|
$ |
131,698 |
|
|
$ |
(5,201 |
) |
|
$ |
49,132,619 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2007-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate
bonds
|
|
$ |
25,486,974 |
|
|
$ |
— |
|
|
$ |
(22,154 |
) |
|
$ |
25,464,820 |
|
Certificates
of deposit
|
|
|
14,073,000 |
|
|
|
— |
|
|
|
(29,108 |
) |
|
|
14,043,892 |
|
U.S.
Government bonds
|
|
|
9,779,189 |
|
|
|
1,351 |
|
|
|
(291 |
) |
|
|
9,780,249 |
|
Municipal
bonds
|
|
|
500,000 |
|
|
|
— |
|
|
|
— |
|
|
|
500,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
49,839,163 |
|
|
$ |
1,351 |
|
|
$ |
(51,553 |
) |
|
$ |
49,788,961 |
|
All
short-term investments held at December 31, 2008 will mature in
2009.
The
Financial Accounting Standards Board (“FASB”) issued Statement of Financial
Accounting Standards (“SFAS”) SFAS No. 157, Fair Value Measurements
(“SFAS 157”), which clarifies the definition of fair value, establishes a
framework for measuring fair value and expands disclosures on fair value
measurements. SFAS 157 is effective as of an entity’s first fiscal year that
begins after November 15, 2008.
SFAS 157
establishes a valuation hierarchy for disclosure of the inputs to valuations
used to measure fair value. This hierarchy prioritizes the inputs into three
broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active
markets for identical assets or liabilities. Level 2 inputs are quoted prices
for similar assets and liabilities in active markets or inputs that are
observable for the asset or liability, either directly or indirectly through
market corroboration, for substantially the full term of the financial
instrument. Level 3 inputs are unobservable inputs based on management’s own
assumptions used to measure assets and liabilities at fair value. A financial
asset or liability’s classification within the hierarchy is determined based on
the lowest level input that is significant to the fair value
measurement.
The
following table provides the assets and liabilities carried at fair value
measured on a recurring basis as of December 31, 2008:
|
|
|
|
|
Fair
Value Measurements, Using
|
|
|
|
Total
carrying value
|
|
|
Quoted
prices in active markets (Level 1)
|
|
|
Significant
other observable inputs
(Level
2)
|
|
|
Significant
unobservable inputs
(Level
3)
|
|
Investments
|
|
$ |
49,132,619 |
|
|
$ |
49,132,619 |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair
Value of Financial Instruments
Cash and
cash equivalents, accounts receivable, other current assets, and accounts
payable are reflected in the accompanying financial statements at fair value due
to the short-term nature of those instruments.
Property
and Equipment
Property
and equipment are stated at cost and depreciated generally on a straight-line
basis over the estimated useful life of 30 years for building,
15 years for building improvements, and three to seven years for office and
lab equipment and furniture and fixtures. Repair and maintenance costs are
charged to expense as incurred. Additions and betterments are
capitalized.
Inventory
Inventory
consists of chemicals held at the Company’s Ewing, New Jersey facility and is
valued at the lower of cost or market, with cost determined using the specific
identification method.
Acquired
Technology
Acquired
technology consists of license rights and know-how obtained from PD-LD, Inc. and
Motorola, Inc. (Note 5). Acquired technology is amortized on a
straight-line basis over its estimated useful life of
10 years.
Impairment
of Long-Lived Assets
Company
management continually evaluates whether events or changes in circumstances
might indicate that the remaining estimated useful life of long-lived assets may
warrant revision, or that the remaining balance may not be recoverable. When
factors indicate that long-lived assets should be evaluated for possible
impairment, the Company uses an estimate of the related undiscounted cash flows
in measuring whether the long-lived asset should be written down to fair value.
Measurement of the amount of impairment would be based on generally accepted
valuation methodologies, as deemed
appropriate.
As of December 31, 2008, Company management believed that no revision to the
remaining useful lives or write-down of the Company’s long-lived assets was
required. No such revisions were required in 2007 or 2006.
Net
Loss Per Common Share
Basic net
loss per common share is computed by dividing the net loss by the
weighted-average number of shares of common stock outstanding for the period.
Diluted net loss per common share reflects the potential dilution from the
exercise or conversion of securities into common stock. For the years ended
December 31, 2008, 2007 and 2006, the effects of the combined outstanding stock
options and warrants of 4,577,775, 5,172,041 and 6,812,601, respectively, were
excluded from the calculation of diluted EPS as the impact would have been
anti-dilutive.
Revenue
Recognition and Deferred License Fees
Commercial
revenue relates to the incorporation of OLED technologies and materials into the
Company's customers’ commercial products, and includes commercial chemical
revenue, royalty and license revenues, and commercialization assistance
revenue. Developmental revenue relates to OLED technology and
material development activities for which the Company is paid, and includes
contract research revenue, development chemical revenue and technology
development revenue.
Commercial
chemical revenue represents revenues from sales of OLED materials to
manufacturers for the production of commercial products. This revenue is
recognized at the time of shipment, or at time of delivery and passage of title,
depending upon the contractual agreement between the parties.
The
Company has received non-refundable advance license and royalty payments under
certain development and technology evaluation agreements. Certain of these
payments are creditable against future amounts payable under commercial license
agreements that the parties may subsequently enter into and, as such, are
deferred until such license agreements are executed or negotiations have ceased
and Company management determines that there is no appreciable likelihood of
executing a license agreement with the other party. Revenue would then be
recorded over the expected useful life of the relevant licensed technology, if
there is an effective license agreement, or at the time Company management
determines that there is no appreciable likelihood of an executable license
agreement. Advanced payments received under technology development and
evaluation agreements that are not creditable against license fees are deferred
and recognized as technology development revenue over the term of the
agreement. Royalty revenue is recognized when earned and the amount
is fixed and determinable.
Development
chemical revenue represents revenues from sales of OLED materials to product
manufacturers for evaluation and development purposes. Revenue is recognized at
the time of shipment and passage of title. The customer does not have the right
to return the materials.
Contract
research revenue represents reimbursements by government entities for all or a
portion of the research and development costs the Company incurs in relation to
its government contracts. Revenues are recognized proportionally as research and
development costs are incurred, or as defined milestones are
achieved.
Research
and Development
Expenditures
for research and development are charged to operations as incurred. Research and
development expenses consist of the following:
|
|
Year
Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
|
|
|
|
|
Development
and operations in the Company’s facility
|
|
$ |
13,778,398 |
|
|
$ |
13,169,527 |
|
|
$ |
11,891,852 |
|
Patent
prosecution, maintenance and other costs
|
|
|
3,348,851 |
|
|
|
2,548,753 |
|
|
|
2,411,331 |
|
Costs
incurred to Princeton University and USC under the 2006 and 1997 Research
Agreements (Note 3), net of refunded amounts from Princeton
University
|
|
|
1,003,749 |
|
|
|
812,221 |
|
|
|
(551,220 |
) |
PPG
Development and License Agreement (Note 7)
|
|
|
2,055,798 |
|
|
|
2,181,408 |
|
|
|
3,854,969 |
|
Amortization
of intangibles
|
|
|
1,695,072 |
|
|
|
1,695,072 |
|
|
|
1,695,072 |
|
Scientific
Advisory Board compensation
|
|
|
375,766 |
|
|
|
502,281 |
|
|
|
260,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
22,257,634 |
|
|
$ |
20,909,262 |
|
|
$ |
19,562,004 |
|
Patent
Costs
Statement
of Cash Flow Information
The
following non-cash activities occurred:
|
|
Year
Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized
gain on available-for-sale securities
|
|
$ |
176,699 |
|
|
$ |
32,644 |
|
|
$ |
37,731 |
|
Common
stock issued under a Development Agreement that was earned in a previous
period
|
|
|
— |
|
|
|
21,915 |
|
|
|
22,515 |
|
Common
stock issued for royalties that was earned in a previous
period
|
|
|
66,403 |
|
|
|
499,993 |
|
|
|
— |
|
Common
stock issued to Board of Directors and Scientific Advisory Board that was
earned in a previous period
|
|
|
299,968 |
|
|
|
260,000 |
|
|
|
588,200 |
|
Common
Stock issued to employees that was earned in a previous
period
|
|
|
867,510 |
|
|
|
944,115 |
|
|
|
838,854 |
|
Common
stock issued to non-employee that was earned in a previous
period
|
|
|
991 |
|
|
|
— |
|
|
|
— |
|
Income
Taxes
Deferred
tax assets and liabilities are determined based on the difference between the
financial statement and tax bases of assets and liabilities. Deferred tax assets
or liabilities at the end of each period are determined using the tax rate
expected to be in effect when taxes are actually paid or recovered. The Company
accounts for the sale of its net state operating losses on a cash basis;
therefore, it does not record an income tax benefit until the cash is received.
The Company has adopted FASB Interpretation No. 48, Accounting for Uncertainty in Income
Taxes, an Interpretation of SFAS No. 109 (“FIN 48”) effective January 1,
2007, and pursuant to its provisions classifies interest and penalties, if any,
as a component of tax expense.
Share-Based
Payment Awards
The
grant-date fair value of stock options is determined using the Black-Scholes
valuation model. The fair value of share-based awards is recognized as
compensation expense on a straight-line basis over the requisite service period,
net of estimated forfeitures. The Company relies primarily upon
historical experience to estimate expected forfeitures and recognizes
compensation expense on a straight-line basis from the date of the
grant. The Company issues new shares upon the exercise or vesting of
share-based awards.
Recent
Accounting Pronouncements
In
February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial
Assets and Financial Liabilities (“SFAS 159”). SFAS 159
permits entities to measure many financial instruments and certain other items
at fair value on specified election dates. Under SFAS 159, any
unrealized holding gains and losses on items for which the fair value option has
been elected are reported in earnings at each subsequent reporting
date. If elected, the fair value option (1) may be applied
instrument by instrument, with a few exceptions, such as investments otherwise
accounted for by the equity method; (2) is irrevocable (unless a new
election date occurs); and (3) is applied only to entire instruments and
not to portions of instruments. SFAS 159 is effective as of an entity’s first
fiscal year that begins after November 15, 2007 (non-financial instruments
deferred under SFAS 159 to fiscal years beginning after November 15,
2008). The adoption of SFAS 159 did not have any impact on the
Company’s results of operations or financial position.
In June
2007, the FASB approved Emerging Issues Task Force Issue No. 07-03, Accounting for Nonrefundable
Advance Payments for Goods or Services to be Used in Future Research and
Development Activities (“Issue No. 07-03”). Issue No. 07-03
requires that nonrefundable advance payments for future research and development
activities be deferred and capitalized. Such amounts should be recognized as an
expense as goods are delivered or the related services are performed. Issue
No. 07-03 is effective for fiscal years beginning after December 15,
2007. The adoption of Issue No. 07-03 did not have any impact on the
Company’s results of operations or financial position.
In
April 2008, the FASB issued FSP 142-3, Determination of the Useful Life of
Intangible Assets (“FSP 142-3”), which amends the list of factors an
entity should consider in developing renewal or extension assumptions used in
determining the useful life of recognized intangible assets under SFAS
No. 142, Goodwill and
Other Intangible Assets. The new guidance applies to (1) intangible
assets that are acquired individually or with a group of other assets and
(2) intangible assets acquired in both business combinations and asset
acquisitions. Under FSP 142-3, entities estimating the useful life of a
recognized intangible asset must consider their historical experience in
renewing or extending similar arrangements or, in the absence of historical
experience, must consider assumptions that market participants would use about
renewal or extension. This FSP is effective for financial statements issued for
fiscal years beginning after December 15, 2008, and interim periods within
those fiscal years. The Company has not determined the impact that FSP 142-3
will have on its results of operations or financial position.
In June
2008, the Emerging Issues Task Force (“EITF”) issued EITF Issue 07-5, Determining Whether an
Instrument(or Embedded
Feature) Is Indexed to
an Entity's Own Stock ("EITF 07-5"), to address concerns regarding the
meaning of "indexed to an entity's own stock" contained in SFAS 133, Accounting for Derivative
Instruments and Hedging Activities. This issue relates to the
determination of whether a freestanding equity-linked instrument should be
classified as equity or debt. If an instrument is classified as debt, it is
valued at fair value, and this value is remeasured on an ongoing basis, with
changes recorded on the statement of operations in each reporting
period. EITF 07-5 is effective for financial statements for fiscal years
beginning after December 15, 2008. At December 31, 2008, the Company
had warrants to purchase 838,446 shares of common stock outstanding that contain
a “down-round” provision and the fair value of these warrants, based on
utilizing a Black Scholes valuation model, was approximately $2,538,000. The
value of these warrants will be reclassified from equity to a liability on
January 1, 2009.
Correction
of Prior Year Consolidated Financials Amounts
Management
has determined that the shares withheld to cover employee payroll taxes on
stock-based compensation should have been recorded as a cash outflow from
financing activity in the 2007 and 2006 consolidated cash flow
statement. The immaterial error results in a decrease in
net cash used in operating activities and a decrease in net cash provided by
financing activities of $657,485 and $586,658 for the year ended December 31,
2007 and 2006, respectively. This correction did not change any
amounts on the consolidated balance sheet or statement of
operations. Management believes that the effects of the corrections
are not material to the Company’s financial position, results of operations or
liquidity for any period presented.
3.
|
RESEARCH
AND LICENSE AGREEMENTS WITH PRINCETON UNIVERSITY, UNIVERSITY OF SOUTHERN
CALIFORNIA AND THE UNIVERSITY OF
MICHIGAN:
|
The
Company funded OLED technology research at Princeton and, on a subcontractor
basis, at USC, for 10 years under a Research Agreement executed with Princeton
in August 1997 (the “1997 Research Agreement”). The Principal
Investigator conducting work under the 1997 Research Agreement transferred to
Michigan in January 2006. Following this, the 1997 Research Agreement
was allowed to expire on July 31, 2007.
As a
result of the transfer, the Company entered into a new Sponsored Research
Agreement with USC to sponsor OLED technology research at USC and, on a
subcontractor basis, Michigan. This new Research Agreement (the “2006
Research Agreement”) was effective as of May 1, 2006, and has a term of
three years. The 2006 Research Agreement supersedes the 1997 Research
Agreement with respect to all work being performed at USC and
Michigan. Under the 2006 Research Agreement, the Company is obligated
to pay USC up to $4,636,296 for work actually performed during the period from
May 1, 2006 through April 30, 2009. Payments under the 2006
Research Agreement are made to USC on a quarterly basis as actual expenses are
incurred. Through December 31, 2008, the Company had incurred
$1,806,733 in research and development expense under the 2006 Research
Agreement.
On
October 9, 1997, the Company, Princeton and USC entered into an Amended
License Agreement (as amended, the “1997 Amended License Agreement”) under which
Princeton and USC granted the Company worldwide, exclusive license rights, with
rights to sublicense, to make, have made, use, lease and/or sell products and to
practice processes based on patent applications and issued patents arising out
of work performed by Princeton and USC under the 1997 Research
Agreement. Under this agreement, the Company is required to pay
Princeton royalties for licensed products sold by the Company or its
sublicensees. For licensed products sold by the Company, the Company
is required to pay Princeton 3% of the net sales price of these
products. For licensed products sold by the Company’s sublicensees,
the Company is required to pay Princeton 3% of the revenues received by the
Company from these sublicensees. These royalty rates are subject to
renegotiation for products not reasonably conceivable as arising out of the 1997
Research Agreement if Princeton reasonably determines that the royalty rates
payable with respect to these products are not fair and
competitive.
The
Company is obligated under the 1997 Amended License Agreement to pay to
Princeton minimum annual royalties. The minimum royalty payment is
$100,000 per year. The Company incurred $223,901, $163,007 and
$177,436 of royalty expense in connection with the agreement for the years ended
December 31, 2008, 2007 and 2006, respectively.
The
Company also is required under the 1997 Amended License Agreement to use
commercially reasonable efforts to bring the licensed OLED technology to
market. However, this requirement is deemed satisfied if the Company
invests a minimum of $800,000 per year in research, development,
commercialization or patenting efforts respecting the patent rights licensed to
the Company.
In
connection with entering into the 2006 Research Agreement, the Company amended
the 1997 Amended License Agreement to include Michigan as a party to that
agreement effective as of January 1, 2006. Under this amendment,
Princeton, USC and Michigan have granted the Company a worldwide exclusive
license, with rights to sublicense, to make, have made, use, lease and/or sell
products and to practice processes based on patent applications and issued
patents arising out of work performed under the 2006 Research
Agreement. The financial terms of the 1997 Amended License Agreement
were not impacted by this amendment.
4.
|
PROPERTY
AND EQUIPMENT:
|
Property
and equipment consist of the following:
|
|
December
31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
|
|
Land
|
|
$ |
820,000 |
|
|
$ |
820,000 |
|
Building
and improvements
|
|
|
11,151,956 |
|
|
|
11,126,189 |
|
Office
and lab equipment
|
|
|
14,462,838 |
|
|
|
11,502,305 |
|
Furniture
and fixtures
|
|
|
324,773 |
|
|
|
285,573 |
|
Construction-in-progress
|
|
|
2,678 |
|
|
|
1,784,344 |
|
|
|
|
|
|
|
|
|
|
|
|
|
26,762,245 |
|
|
|
25,518,411 |
|
Less:
Accumulated depreciation
|
|
|
(13,902,617 |
) |
|
|
(11,992,697 |
) |
|
|
|
|
|
|
|
|
|
Property
and equipment, net
|
|
$ |
12,859,628 |
|
|
$ |
13,525,714 |
|
Depreciation
expense was $1,943,184, $1,774,236 and $1,828,551 for the years ended
December 31, 2008, 2007 and 2006, respectively.
Acquired
technology consists of acquired license rights for patents and know-how obtained
from PD-LD, Inc. and Motorola, Inc. These intangible assets consist of the
following:
|
|
December
31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
|
|
PD-LD,
Inc.
|
|
$ |
1,481,250 |
|
|
$ |
1,481,250 |
|
Motorola,
Inc.
|
|
|
15,469,468 |
|
|
|
15,469,468 |
|
|
|
|
|
|
|
|
|
|
|
|
|
16,950,718 |
|
|
|
16,950,718 |
|
Less:
Accumulated amortization
|
|
|
(14,021,374 |
) |
|
|
(12,326,302 |
) |
|
|
|
|
|
|
|
|
|
Acquired
technology, net
|
|
$ |
2,929,344 |
|
|
$ |
4,624,416 |
|
On July 19, 2000, the Company, PD-LD, Inc. (“PD-LD”), its
president Dr. Vladimir Ban and the Trustees of Princeton entered into a
Termination, Amendment and License Agreement whereby the Company acquired all
PD-LD’s rights to certain issued and pending OLED technology patents in exchange
for 50,000 shares of the Company’s common stock which was valued at
$1,481,250. Pursuant to this transaction, these patents were included
in the patent rights exclusively licensed to the Company under the 1997 Amended
License Agreement.
On
September 29, 2000, the Company entered into a License Agreement with
Motorola, Inc. (“Motorola”). Pursuant to this agreement, the Company
licensed from Motorola what are now 74 issued U.S. patents and corresponding
foreign
patents relating to OLED technologies. These patents expire in the U.S. between
2012 and 2018. The Company has the sole right to sublicense these patents to
OLED product manufacturers. As consideration for this license, the Company
issued to Motorola 200,000 shares of the Company’s common stock (valued at
$4,412,500), 300,000 shares of the Company’s Series B Convertible Preferred
Stock (valued at $6,618,750) and a warrant to purchase 150,000 shares of the
Company’s common stock at $21.60 per share. The 300,000 shares of the
Series B Convertible Preferred Stock issued were converted into shares of the Company’s common
stock on September 29, 2004. The warrant was recorded at a fair market
value of $2,206,234, based on the Black-Scholes option-pricing model, and was
recorded as a component of the cost of the acquired technology. The
warrant expired on September 29, 2007, without having been
exercised.
The
Company also issued a warrant to an unaffiliated third party to acquire 150,000
shares of the Company’s common stock as a finder’s fee in connection with the
Motorola transaction. The original exercise price of this warrant was
$21.60 per share and the exercise period was seven years. This
warrant was accounted for at its fair value based on the Black-Scholes option
pricing model and $2,206,234 was recorded as a component of the cost of the
acquired technology. Based on anti-dilution adjustments, the number
of warrant shares was adjusted to 191,028 shares, and the exercise price was
adjusted to $16.96 per share. The warrant was exercised on a cashless
basis on August 13, 2007.
In total,
the Company recorded an intangible asset of $15,469,468 for the technology
acquired from Motorola. This includes $25,750 of direct cash
transaction costs. Amortization expense was $1,695,072 for each of
the years ended December 31, 2008, 2007 and 2006. For 2009 amortization
expense will be $1,695,072 and for 2010 it will be $1,234,272.
The
Company is required under the License Agreement to pay Motorola royalties on
gross revenues earned by the Company from its sales of OLED products or
components, or from its OLED technology licensees, whether or not these revenues
relate specifically to inventions claimed in the patent rights licensed from
Motorola. For the two-year period ended December 31, 2006, the
Company issued to Motorola 37,075 shares of the Company’s common stock,
valued at $499,993, and paid Motorola $500,007 in cash to satisfy the minimum
royalty obligation of $1,000,000. The Company is no longer subject to a
minimum royalty obligation under this agreement and for the years ended December
31, 2008 and 2007, the Company recorded royalty expenses of $163,916 and
$132,839, respectively. To satisfy the royalty obligation, the Company issued to
Motorola 12,015 and 3,801 shares of the Company’s common stock, valued at
$81,954 and $66,403 and paid $81,962 and $66,436 in cash,
respectively.
Accrued
expenses consist of the following:
|
|
December
31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
|
|
Compensation
|
|
$ |
3,453,062 |
|
|
$ |
3,087,650 |
|
Royalties
|
|
|
387,817 |
|
|
|
295,846 |
|
Consulting
|
|
|
326,469 |
|
|
|
299,969 |
|
Professional
fees
|
|
|
437,547 |
|
|
|
432,719 |
|
Subcontracts
|
|
|
170,324 |
|
|
|
90,113 |
|
Research
and development agreements
|
|
|
377,786 |
|
|
|
308,497 |
|
Other
|
|
|
143,428 |
|
|
|
63,353 |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
5,296,433 |
|
|
$ |
4,578,147 |
|
7.
|
EQUITY
AND CASH COMPENSATION UNDER THE PPG
AGREEMENTS:
|
On
October 1, 2000, the Company entered into a five-year Development and
License Agreement (“Development Agreement”) and a seven-year Supply Agreement
(“Supply Agreement”) with PPG. Under the Development Agreement, a
team of PPG scientists and engineers assisted the Company in developing its
proprietary OLED materials and supplied the Company with these materials for
evaluation purposes. Under the Supply Agreement, PPG supplied the
Company with its proprietary OLED materials that were intended for resale to
customers for commercial purposes.
On
July 29, 2005, the Company entered into an OLED Materials Supply and
Service Agreement with PPG (the “OLED Materials Agreement”). The OLED
Materials Agreement superseded and replaced in their entireties the Development
Agreement and Supply Agreement effective as of January 1, 2006, and
extended the term of the Company’s relationship with PPG through
December 31, 2008. Under the OLED Materials Agreement, PPG
continues to assist the Company in developing its proprietary OLED materials and
supplying the Company with those materials for evaluation purposes and for
resale to its customers. On January 4, 2008, the term of the OLED
Materials Agreement was extended for an additional three years, through December
31, 2011.
Under the
OLED Materials Agreement, the Company compensates PPG on a cost-plus basis for
the services provided during each calendar quarter. The Company is
required to pay for some of these services in all cash and for other of the
services through the issuance of shares of the Company’s common
stock. Up to 50% of the remaining services are payable, at the
Company’s sole discretion, in cash or shares of the Company’s common stock, with
the balance payable in all cash. The actual number of shares of
common stock issuable to PPG is determined based on the average closing price
for the Company’s common stock during a specified number of days prior to the
end of each calendar half-year period ending on March 31 and September
30. If, however, this average closing price is less than $6.00, the
Company is required to compensate PPG in all cash.
On
April 19, 2006, the Company issued 1,957 shares of common stock to PPG
based on a final accounting for actual costs incurred by PPG under the
Development Agreement for the year ended December 31,
2005. Accordingly, the Company accrued $22,515 of additional research
and development expense as of December 31, 2005, based on the fair value of
these additional shares as of the end of 2005.
In 2008,
2007 and 2006, the Company issued to PPG 82,669, 58,930 and 210,639 shares of
the Company’s common stock, respectively, as consideration for services provided
by PPG under the applicable agreement(s). For these shares, the
Company recorded charges of $1,150,714, $926,582 and $2,619,439 to research and
development expense for 2008, 2007 and 2006, respectively. The
charges were determined based on the fair value of the Company’s common stock as
of the end of each period. The Company also recorded $905,084,
$936,322 and $886,895 to research and development expense for the cash portion
of the work performed by PPG during 2008, 2007 and 2006,
respectively.
In
accordance with the agreements with PPG, the Company is also required to
reimburse PPG for its raw materials and conversion costs for all development
chemicals produced on behalf of the Company. The Company recorded $0,
$318,504 and $0 in research and development expense related to these costs
during 2008, 2007 and 2006, respectively. The remainder of these costs is
included in cost of chemicals sold.
For work
performed through the end of 2006, the Company was required under its agreements
with PPG to grant options to purchase shares of the Company’s common stock to
PPG employees performing certain development services for the Company, in a
manner consistent with that for issuing options to its own employees. Subject to
certain contingencies, these options were to vest one year following the date of
grant and were to remain exercisable for up to 90 days after the individual
PPG employee ceased performing development services for the Company. However, in
connection with the conclusion of the development program on December 31,
2006, the exercise periods for these options were extended. In the case of
certain PPG employees who were hired by the Company as full-time employees in April 2006, the
exercise period was extended to run for so long as they remain employees of the
Company, plus an additional period of up to one year thereafter, just as other
Company employees are treated under the Company’s Equity Compensation Plan. For
those PPG employees not hired by the Company, the exercise period was extended
for three years through December 31, 2009.
On
December 30, 2005 and January 18, 2006, the Company granted to PPG
employees performing development services under the Development Agreement
options to purchase 31,500 and 30,500 shares, respectively, of the
Company’s common stock at exercise prices of $10.51 and $8.14,
respectively. As a result of the Company hiring certain of the PPG
employees in April 2006, the Company accelerated the vesting of 18,500 of the
options granted on December 30, 2005. Accordingly, the Company recorded
$225,882 in research and development costs related to these options in 2006. The
Company also recorded $100,838 in research and development costs for the
remaining 13,000 options during 2006.
The
Company determined the fair value of the options earned during 2006 using the
Black-Scholes option-pricing model with the following assumptions: (1) risk
free interest rate of 4.4 and 5.1%, respectively, (2) no expected dividend
yield, (3) contractual life of 3.25 and 10 years, respectively and
(4) expected volatility of 51% and 77%, respectively.
In lieu
of stock options, and consistent with awards made to the Company’s own
employees, shares of stock were granted to certain PPG employees performing
development services on the Company’s behalf during 2006. On
January 9, 2007, the Company issued 1,500 shares of its common stock as a
bonus to these PPG research and development team members for the year ended
December 31, 2006. Accordingly, the Company accrued $21,915 as
of December 31, 2006 in research and development costs relating to the
issuance. The Company has no obligation to issue options or shares of
stock to any PPG employees in 2007 or thereafter.
The
Company’s Articles of Incorporation authorize it to issue up to 5,000,000 shares
of preferred stock with designations, rights and preferences determined from
time-to-time by the Company’s Board of Directors. Accordingly, the Company’s
Board of Directors is empowered, without shareholder approval, to issue
preferred stock with dividend, liquidation, conversion, voting or other rights
superior to those of shareholders of the Company’s common stock.
In 1995,
the Company issued 200,000 shares of Series A Nonconvertible Preferred
Stock (“Series A”) to American Biomimetics Corporation (“ABC”) pursuant to
a certain Technology Transfer Agreement between the Company and ABC. The
Series A shares have a liquidation value of $7.50 per share.
Series A shareholders, as a single class, have the right to elect two
members of the Company’s Board of Directors. This right has never been
exercised. Holders of the Series A shares are entitled to one vote per
share on matters which shareholders are generally entitled to vote. The
Series A shareholders are not entitled to any dividends. The Series A
shares were valued at $1.75 per share, which was based upon an independent
appraisal.
Effective
as of each of March 31, 2008, June 30, 2008, September 30, 2008, the
Company issued 5,276 shares and, as of December 31, 2008, the Company issued
5,272 shares of fully vested common stock to members of its Board of Directors
as partial payment for services performed for the three-month periods ended on
such dates. The fair value of the shares issued was $369,250, which was recorded
as a compensation charge in general and administrative expense for the year
ended December 31, 2008.
There are
outstanding warrants to purchase 1,611,659 shares of the Company’s common stock
as of December 31, 2008. These warrants are exercisable at a weighted
average exercise price of $14.22, and they expire between 2009 and 2012. For the
years ended December 31, 2008, 2007 and 2006, respectively, 135,415, 685,129 and
1,081,623 warrants were exercised, resulting in proceeds of $1,187,050,
$4,987,903 and $3,718,404, respectively.
In May
2007, the Company sold 2,800,000 shares of its common stock through a public
offering at $14.50 per share. The offering resulted in net proceeds to the
Company of $38,000,023, net of $2,599,977 in associated costs.
In
January 2009, 2008 and 2007, the Company granted a total of 194,955,
105,165 and 124,497 shares of fully vested common stock to employees and
non-employee members of the Scientific Advisory Board for services performed in
2008, 2007 and 2006, respectively. The fair value of the shares
issued was $1,673,352, $1,627,767 and $1,559,283, respectively, for employees
and $299,997, $299,968 and $260,000, respectively, for non-employee members of
the Scientific Advisory Board, which amounts were accrued at December 31,
2008, 2007 and 2006, respectively. In connection with the issuance of
these grants, approximately 63,372, 29,708 and 40,359 shares, with a fair value
of $641,707, $544,845, $589,645 were withheld in satisfaction of employee tax
withholding obligations in 2009, 2008 and 2007, respectively. The stock awards
were recorded as a compensation charge in general and administrative expense for
2008, 2007 and 2006 of $1,162,221, $1,143,792 and $1,135,933, respectively, and
research and development expense of $811,128, $783,944 and $683,350,
respectively. In 2007, the Company issued 500 shares to an employee and $8,750
was charged to research and development expense as the fair value of these
shares.
10.
|
STOCK-BASED
COMPENSATION:
|
Equity
Compensation Plan
In 1995,
the Board of Directors of the Company adopted a Stock Option Plan (the “1995
Plan”), under which options to purchase a maximum of 500,000 shares of the
Company’s common stock were authorized to be granted at prices not less than the
fair market value of the common stock on the date of the grant, as determined by
the Compensation Committee of the Board of Directors. Through
December 31, 2008, the Company’s shareholders have approved increases in the
number of shares reserved for issuance under the 1995 Plan to 7,000,000, and
have extended the term of the 1995 Plan through 2015. The 1995 Plan
was also amended and restated in 2003, and is now called the Equity Compensation
Plan. The Equity Compensation Plan provides for the granting of
incentive and nonqualified stock options, shares of common stock, stock
appreciation rights and performance units to employees, directors and
consultants of the Company. Stock options are exercisable over
periods determined by the Compensation Committee, but for no longer than
10 years from the grant date. At December 31, 2008, there were
1,344,636 shares that remained available to be granted under the Equity
Compensation Plan.
The
following table summarizes the stock option activity during the year ended
December 31, 2008 for all grants under the Equity Compensation
Plan:
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average
|
|
|
|
|
|
|
Exercise
|
|
|
|
Options
|
|
|
Price
|
|
|
|
|
|
|
|
|
Outstanding
at January 1, 2008
|
|
|
3,226,101 |
|
|
$ |
9.77 |
|
Granted
|
|
|
4,000 |
|
|
|
18.34 |
|
Exercised
|
|
|
(263,735 |
) |
|
|
6.16 |
|
Forfeited
|
|
|
– |
|
|
|
– |
|
Cancelled
|
|
|
(250 |
) |
|
|
17.43 |
|
|
|
|
|
|
|
|
|
|
Outstanding
at December 31, 2008
|
|
|
2,966,116 |
|
|
|
10.10 |
|
Vested
and expected to vest
|
|
|
2,964,857 |
|
|
|
10.10 |
|
Exercisable
at December 31, 2008
|
|
|
2,938,116 |
|
|
|
10.08 |
|
The
weighted average grant date fair value of stock options granted in 2008, 2007
and 2006 was $8.80, $8.65 and $10.66, respectively. The fair value of
the stock options granted was estimated using the Black-Scholes option-pricing
model. The Black-Scholes option-pricing model considers assumptions
related to volatility, risk-free interest rate and dividend
yield. Expected volatility was based on the Company’s historical
daily stock price volatility. The risk-free rate was based on average
U.S. Treasury security yields in the quarter of the grant. The
dividend yield was based on historical information. The expected life
was determined using historical information and management
estimates. The following table provides the assumptions used in
determining the fair value of the stock options for the years ended
December 31, 2008, 2007 and 2006, respectively:
|
|
2008
|
|
2007
|
|
2006
|
|
|
|
|
|
|
|
Dividend
yield rate
|
|
0%
|
|
0%
|
|
0%
|
Expected
volatility
|
|
49.4%
|
|
48.1
– 52.5%
|
|
73.4
– 79.9%
|
Risk-free
interest rates
|
|
2.8%
|
|
3.8
– 4.8%
|
|
4.6
– 5.0%
|
Expected
life
|
|
5
Years
|
|
5
Years
|
|
7
Years
|
The
following table summarizes the status of unvested stock options at December 31,
2008, and the weighted-average grant date fair value of these stock options at
December 31, 2008:
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average
|
|
|
|
|
|
|
Grant
Date
|
|
|
|
Options
|
|
|
Fair
Value
|
|
|
|
|
|
|
|
|
Unvested
options at January 1, 2008
|
|
|
52,000 |
|
|
$ |
9.82 |
|
Granted
|
|
|
4,000 |
|
|
|
8.80 |
|
Vested
|
|
|
(28,000 |
) |
|
|
9.75 |
|
Forfeited
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
Unvested
options at December 31, 2008
|
|
|
28,000 |
|
|
$ |
9.69 |
|
A summary
of stock options outstanding and exercisable by price range at December 31,
2008, is as follows:
|
|
|
Outstanding
|
|
|
Exercisable
|
|
|
|
|
Number
of
|
|
|
Weighted-
|
|
|
|
|
|
|
|
|
Number
of
|
|
|
Weighted-
|
|
|
|
|
|
|
|
|
|
|
Options
|
|
|
Average
|
|
|
Weighted-
|
|
|
|
|
|
Options
|
|
|
Average
|
|
|
Weighted-
|
|
|
|
|
|
|
|
Outstanding
|
|
|
Remaining
|
|
|
Average
|
|
|
Aggregate
|
|
|
Outstanding
|
|
|
Remaining
|
|
|
Average
|
|
|
Aggregate
|
|
|
|
|
at
December 31,
|
|
|
Contractual
|
|
|
Exercise
|
|
|
Intrinsic
|
|
|
at
December, 31
|
|
|
Contractual
|
|
|
Exercise
|
|
|
Intrinsic
|
|
Exercise
Price
|
|
|
2008
|
|
|
Life
(Years)
|
|
|
Price
|
|
|
Value
(A)
|
|
|
2008
|
|
|
Life
(Years)
|
|
|
Price
|
|
|
Value
(A)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
3.75–8.14 |
|
|
|
968,630 |
|
|
|
3.94 |
|
|
$ |
6.25 |
|
|
$ |
3,099,432 |
|
|
|
968,630 |
|
|
|
3.94 |
|
|
$ |
6.25 |
|
|
$ |
3,099,432 |
|
|
8.15-9.50 |
|
|
|
611,000 |
|
|
|
2.83 |
|
|
|
8.93 |
|
|
|
321,488 |
|
|
|
604,000 |
|
|
|
2.79 |
|
|
|
8.92 |
|
|
|
319,548 |
|
|
9.51–10.51 |
|
|
|
685,028 |
|
|
|
5.49 |
|
|
|
10.39 |
|
|
|
– |
|
|
|
685,028 |
|
|
|
5.49 |
|
|
|
10.39 |
|
|
|
– |
|
|
10.52–18.13 |
|
|
|
635,458 |
|
|
|
4.63 |
|
|
|
15.34 |
|
|
|
– |
|
|
|
614,458 |
|
|
|
4.54 |
|
|
|
15.39 |
|
|
|
– |
|
|
18.14–24.38 |
|
|
|
66,000 |
|
|
|
1.83 |
|
|
|
24.01 |
|
|
|
– |
|
|
|
66,000 |
|
|
|
1.83 |
|
|
|
24.01 |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
3.75–24.38 |
|
|
|
2,966,116 |
|
|
|
4.17 |
|
|
$ |
10.10 |
|
|
$ |
3,420,920 |
|
|
|
2,938,116 |
|
|
|
4.14 |
|
|
$ |
10.08 |
|
|
$ |
3,418,980 |
|
(A)
|
The
difference between the stock option’s exercise price and the closing price
of the common stock at December 31,
2008.
|
The total
intrinsic value of stock awards exercised during the years ended December 31,
2008, 2007 and 2006 was $1,820,464, $4,607,227 and $2,403,556,
respectively. At December 31, 2008, there was $215,392 of total
unrecognized compensation cost from stock-based compensation arrangements
granted under the Equity Compensation Plan, which cost is related to non-vested
options. The compensation expense is expected to be recognized over a
weighted-average period of approximately one year.
In 2008,
46,286 shares of common stock, valued at $404,976, were tendered to settle the
exercise of 90,000 options.
The
Company has issued restricted stock to employees and non-employee members of the
Scientific Advisory Board with vesting terms of three years. The fair
value is equal to the market price of the Company’s common stock on the date of
grant. Expense for restricted stock is amortized ratably over the vesting period
for the awards issued to employees and using a graded vesting method for the
awards issued to non-employee members of the Scientific Advisory Board. The
following table summarizes the restricted stock activity:
|
|
|
|
|
Weighted-
|
|
|
|
|
|
|
Average
|
|
|
|
Number
of
|
|
|
Grant-Date
|
|
|
|
Shares
|
|
|
Fair
Value
|
|
|
|
|
|
|
|
|
Unvested,
January 1, 2008
|
|
|
124,026 |
|
|
$ |
14.44 |
|
Granted
|
|
|
222,280 |
|
|
|
17.53 |
|
Vested
|
|
|
(172,485 |
) |
|
|
16.45 |
|
Cancelled
|
|
|
(3,500 |
) |
|
|
19.84 |
|
|
|
|
|
|
|
|
|
|
Unvested,
December 31, 2008
|
|
|
170,321 |
|
|
$ |
16.39 |
|
For the
years ended December 31, 2008, 2007 and 2006, the Company recorded as
compensation charges related to all restricted stock awards included in general
and administrative expense of $647,666, $323,377 and $7,090, respectively, and
research and development expense of $445,318, $387,986 and $25,224,
respectively. In connection with the vesting of deferred and restricted stock
awards during the year ended December 31, 2008, 2007 and 2006,
respectively, 13,183, 4,339 and 0 shares, with an aggregate fair value of
$226,710, $67,840 and $0, were withheld in satisfaction of tax withholding
obligations.
In
addition, on January 6, 2009, the Company granted a total of 164,864 shares of
restricted common stock to employees and non-employee members of the Scientific
Advisory Board for services to be rendered. The restricted stock had
a fair value of $1,668,500 on the date of grant and vests over three years from
the date of grant.
11.
|
COMMITMENTS
AND CONTINGENCIES:
|
Commitments
Under the
terms of the 1997 Amended License Agreement with Princeton (Note 3), the
Company is required to pay Princeton minimum royalty payments of
$100,000 per year. To the extent that the royalties otherwise payable to
Princeton under this agreement are not sufficient to meet the minimum amount for
the relevant calendar year, the Company is required to pay Princeton the
difference between the royalties paid and the minimum royalty.
The
Company has agreements with five executive officers which provide for certain
cash and other benefits upon termination of employment of the officer in
connection with a change in control of the Company. The executive is entitled to
a lump-sum cash payment equal to two times the sum of the average annual base
salary and bonus of the officer and immediate vesting of all stock options and
other equity awards that may be outstanding at the date of the change in
control, among other items.
Notice
of Opposition to European Patent No. 0946958
On
December 8, 2006, Cambridge Display Technology, Ltd. (“CDT”), which was acquired
in 2007 by Sumitomo Chemical Company (“Sumitomo”), filed a Notice of Opposition
to European Patent No. 0946958 (the “EP ‘958 patent”). The EP ‘958
patent, which was issued on March 8, 2006, is a European counterpart patent to
U.S. patents 5,844,363, 6,602,540, 6,888,306 and 7,247,073. These
patents relate to the Company’s FOLED technology. They are
exclusively licensed to the Company by Princeton, and under the license
agreement the Company is required to pay all legal costs and fees associated
with this proceeding.
The
European Patent Office (the “EPO”) set a date of May 12, 2007 for the Company to
file a response to the facts and arguments presented by CDT in its Notice of
Opposition. The response was timely filed. The opponents
then filed their reply to the Company’s response on December 7,
2007. The Company has decided that there is no need to file another
response before the oral hearing date is set. The Company is
currently waiting for the EPO to notify it of the date of the oral
hearing.
At this
stage of the proceeding, Company management cannot make any prediction as to the
probable outcome of this opposition. However, based on an analysis of
the evidence presented to date, Company management continues to believe there is
a substantial likelihood that the patent being challenged will be declared
valid, and that all or a significant portion of its claims will be
upheld.
Notices
of Opposition to European Patent No. 1449238
On March
8, 2007, Sumation Company Limited (“Sumation”), a joint venture between Sumitomo
and CDT, filed a first Notice of Opposition to European Patent No. 1449238 (the
“EP ‘238 patent”). The EP ‘238 patent, which was issued on November
2, 2006, is a European counterpart patent, in part, to U.S. patents 6,830,828,
6,902,830, 7,001,536 and 7,291,406, and to pending U.S. patent application
11/879,379, filed on July 16, 2007. These patents and this patent
application relate to
the
Company’s PHOLED technology. They are exclusively licensed to the
Company by Princeton, and under the license agreement the Company is required to
pay all legal costs and fees associated with this proceeding.
Two other
parties filed additional oppositions to the EP ‘238 patent just prior to the
August 2, 2007 expiration date for such filings. On July 24, 2007,
Merck Patent GmbH, of Darmstadt, Germany, filed a second Notice of Opposition to
the EP ‘238 patent, and on July 27, 2007, BASF Aktiengesellschaft, of Mannheim,
Germany, filed a third Notice of Opposition to the EP ‘238
patent. The EPO combined all three oppositions into a single
opposition proceeding.
The EPO
set a January 6, 2008 due date for the Company to file its response to the
opposition. The Company requested a two-month extension to file this
response, and the Company subsequently filed its response in a timely
manner. The Company is currently waiting for the EPO to notify it of
the date of the oral hearing. The Company is also waiting to see
whether the other parties in the opposition file any additional documents, to
which the Company may respond.
At this
stage of the proceeding, Company management cannot make any prediction as to the
probable outcome of the opposition. However, based on an analysis of
the evidence presented to date, Company management continues to believe there is
a substantial likelihood that the patent being challenged will be declared
valid, and that all or a significant portion of its claims will be
upheld.
12.
|
CONCENTRATION
OF RISK:
|
One
non-government customer accounted for approximately 42%, 35% and 14% of
consolidated revenue for the years ended December 31, 2008, 2007 and 2006,
respectively. Accounts receivable from this customer were $657,000 at
December 31, 2008. In addition, one non-government customer also accounted
for approximately 11% of consolidated revenue in 2007 and another non-government
customer also accounted for approximately 24% of consolidated revenue in
2006.
Revenues
derived from contracts with government agencies represented 25%, 41% and 32% of
the consolidated revenue for the years ended December 31, 2008, 2007 and
2006, respectively.
Revenues
from outside of North America represented 72%, 57% and 65% of the consolidated
revenue for the years ended December 31, 2008, 2007 and 2006,
respectively.
All
chemical materials were purchased from one supplier. See Note 7.
|
|
Year
ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
|
|
|
|
|
Current
|
|
$ |
(962,478 |
) |
|
$ |
(804,980 |
) |
|
$ |
(544,567 |
) |
Deferred
|
|
|
(7,962,201 |
) |
|
|
(6,907,000 |
) |
|
|
(8,092,992 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8,924,679 |
) |
|
|
(7,711,980 |
) |
|
|
(8,637,559 |
) |
Increase
in valuation allowance
|
|
|
7,962,201 |
|
|
|
6,907,000 |
|
|
|
8,092,992 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
(962,478 |
) |
|
$ |
(804,980 |
) |
|
$ |
(544,567 |
) |
The
difference between the Company’s federal statutory income tax rate and its
effective income tax rate is due to state income tax benefits, non-deductible
expenses, general business credits and the increase in the valuation
allowance.
As of
December 31, 2008, the Company had net operating loss and credit carry forwards.
The Company’s net operating loss carry forwards differ from the accumulated
deficit principally due to the timing of the recognition of certain
expenses. A portion of the Company’s net operating loss carry
forwards relate to tax deductions from stock-based compensation that would be
accounted for as an increase to additional-paid-in-capital for financial
reporting purposes to the
extent
such future deductions could be utilized by the Company. In accordance with the
Tax Reform Act of 1986, utilization of the Company’s net operating loss and
general business credit carry forwards could be subject to limitations because
of certain ownership changes. The following table summarizes Company
tax loss and tax credit carry forwards at December 31, 2008:
|
|
Related
Tax
|
|
|
Deferred
Tax
|
|
Expiration
|
|
|
Deduction
|
|
|
Asset
|
|
Date
|
|
|
|
|
|
|
|
|
Loss
carry forwards:
|
|
|
|
|
|
|
|
Federal
net operating loss
|
|
$ |
142,960,000 |
|
|
$ |
48,606,000 |
|
2011
to 2028
|
State
net operating loss
|
|
|
97,686,000 |
|
|
|
5,795,000 |
|
2011
to 2028
|
|
|
|
|
|
|
|
|
|
|
Total
loss carry forwards
|
|
$ |
240,646,000 |
|
|
$ |
54,401,000 |
|
|
|
|
|
|
|
|
|
|
|
|
Tax
credit carry forwards:
|
|
|
|
|
|
|
|
|
|
Research
tax credit
|
|
|
n/a |
|
|
$ |
4,012,000 |
|
2018
to 2028
|
State
tax credits
|
|
|
n/a |
|
|
|
1,253,000 |
|
2014
to 2023
|
|
|
|
|
|
|
|
|
|
|
Total
credit carry forwards
|
|
|
n/a |
|
|
$ |
5,265,000 |
|
|
Significant
components of the Company’s deferred tax assets are as follows:
|
|
December
31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
|
|
Gross
deferred tax assets:
|
|
|
|
|
|
|
Net
operating loss carry forwards
|
|
$ |
54,401,000 |
|
|
$ |
46,270,000 |
|
Capitalized
start-up costs
|
|
|
— |
|
|
|
1,961,000 |
|
Capitalized
technology license
|
|
|
3,543,000 |
|
|
|
3,318,000 |
|
Stock
options and warrants
|
|
|
304,000 |
|
|
|
589,000 |
|
Accruals
and reserves
|
|
|
380,000 |
|
|
|
332,000 |
|
Deferred
revenue
|
|
|
5,046,000 |
|
|
|
4,132,000 |
|
Other
|
|
|
354,000 |
|
|
|
466,000 |
|
Tax
credit carry forward
|
|
|
5,265,000 |
|
|
|
4,263,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
69,293,000 |
|
|
|
61,331,000 |
|
Valuation
allowance
|
|
|
(69,293,000 |
) |
|
|
(61,331,000 |
) |
|
|
|
|
|
|
|
|
|
Net
deferred tax asset
|
|
$ |
— |
|
|
$ |
— |
|
During
the years ended December 31, 2008, 2007 and 2006, the Company sold
approximately $12.5 million, $7.5 million and $7.0 million, respectively,
of its net state operating losses and $0, $263,000 and $0 of its research and
development tax credits under the New Jersey Technology Tax Certificate Transfer
Program, and received net proceeds of $962,478, $804,980 and $544,567,
respectively, during these years. The Company recorded the proceeds
as an income tax benefit.
A
valuation allowance was established for all of the deferred tax assets because
the Company has incurred substantial operating losses since inception and
expects to incur additional losses in 2009. At this time, Company management has
concluded that these deferred tax assets will not be realized.
The
Company adopted FIN 48 effective January 1, 2007. No transition adjustment was
recorded as a result of the adoption of FIN 48 and the Company does not have any
liability recorded for uncertain tax positions as of December 31, 2008 and
December 31, 2007. Company management does not anticipate any material change in
the Company’s FIN 48 position in the next twelve months. The Company’s federal
income tax returns for 2005 through 2008 are open tax years and
are
subject to examination by the Internal Revenue Service. State tax jurisdictions
(Pennsylvania, New Jersey, Idaho and California) that remain open to examination
range from 2003 to 2008.
14.
|
DEFINED
CONTRIBUTION PLAN:
|
The
Company maintains the Universal Display Corporation 401(k) Plan (the “Plan”) in
accordance with the provisions of Section 401(k) of the Internal Revenue
Code (the “Code”). The Plan covers substantially all full-time
employees of the Company. Participants may contribute up to 15% of
their total compensation to the Plan, not to exceed the limit as defined in the
Code, with the Company matching 50% of the participant’s contribution, limited
to 6% of the participant’s total compensation. For the years ended
December 31, 2008, 2007 and 2006, the Company contributed $200,956,
$195,697 and $164,050, respectively, to the Plan.
15.
|
QUARTERLY
SUPPLEMENTAL FINANCIAL DATA
(UNAUDITED):
|
Year
ended December 31, 2008:
|
|
Three
Months Ended
|
|
|
|
|
|
|
March
31
|
|
|
June
30
|
|
|
September
30
|
|
|
December
31
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$ |
2,716,819 |
|
|
$ |
2,145,598 |
|
|
$ |
2,625,639 |
|
|
$ |
3,587,168 |
|
|
$ |
11,075,224 |
|
Net
loss
|
|
|
(4,193,385 |
) |
|
|
(5,205,790 |
) |
|
|
(5,302,983 |
) |
|
|
(4,437,578 |
) |
|
|
(19,139,736 |
) |
Basic
and diluted loss per share
|
|
|
(0.12 |
) |
|
|
(0.15 |
) |
|
|
(0.15 |
) |
|
|
(0.11 |
) |
|
|
(0.53 |
) |
Year
ended December 31, 2007:
|
|
Three
Months Ended
|
|
|
|
|
|
|
March
31
|
|
|
June
30
|
|
|
September
30
|
|
|
December
31
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$ |
3,014,630 |
|
|
$ |
2,315,170 |
|
|
$ |
3,077,281 |
|
|
$ |
2,898,826 |
|
|
$ |
11,305,907 |
|
Net
loss
|
|
|
(4,583,801 |
) |
|
|
(5,175,371 |
) |
|
|
(2,960,565 |
) |
|
|
(3,256,104 |
) |
|
|
(15,975,841 |
) |
Basic
and diluted loss per share
|
|
|
(0.15 |
) |
|
|
(0.16 |
) |
|
|
(0.08 |
) |
|
|
(0.08 |
) |
|
|
(0.47 |
) |